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The development of any multicellular organism involves the coordinated 
expression of different genes in complex spatio-temporal patterns. These complex 
patterns of gene expression result from the interplay between multiple transcription 
factors (TFs) and their co-factors, acting on specific cis-regulatory modules to 
activate or repress the affected locus. This study investigates the interaction 
between two essential regulators of myogenesis: the transcription factors Myocyte 
enhancing factor 2 (Mef2) and lame duck (lmd). Mutations in either of these 
transcription factors results in a similar block of fusion phenotype, but the 
molecular basis for this similar phenotype is not yet understood. 
The analysis started with ChIP-on-chip to identify the genomic location 
where each TF binds in vivo. Microarrays were used again to conduct expression 
profiling of loss-of-function mutants, and the combination of these two approaches 
yielded a list of direct target genes of the two TFs. Interestingly, the majority of 
enhancers bound by Lmd are also bound by Mef2 at the same developmental 
timepoint. Likewise, almost 80% of the lmd direct target genes are also direct 
targets of Mef2, revealing an extensive co-regulation between the two TFs. A 
group of shared direct targets was then selected for further study; Lmd and Mef2, 
alone or in combination, were used to drive ectopic expression of these genes, 
resulting in both synergistic and antagonistic interactions. 
The affected enhancer for each target was identified using a variety of 
predictions, and transgenic fly lines were created to demonstrate the capacity of the 
enhancers for correct expression in vivo. These enhancers were also analyzed in the 
mutant background of loss-of-function mutations and revealed specific 
requirements for each transcription factor. Lmd and Mef2 were also tested in vitro 
for their effect on transcription from these enhancers, revealing additive, 
cooperative, and repressive interactions. 
These results indicate that lmd is a temporal and tissue-specific modulator 
of Mef2 activity, acting both as a transcriptional activator and repressor on a sub-
set of the catalog of target genes of Mef2. More generally, it demonstrates a 
scenario of flexibility in the regulatory output of two transcription factors, leading 
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2.1. Regulation of gene expression in development 
 
There are many questions on the mind of a developmental biologist 
contemplating the different arrays of organisms, tissues, cells. The diversity and 
complexity of the processes by which cells grow, divide, communicate, migrate 
and organize themselves into tissues, structures and organs raises questions about 
the coordination between these cells, and the nature of the processes that ultimately 
lead to an organized multicellular organism. However, taking one step back, a 
more fundamental question is: What is it that makes one cell different from another 
in a multicellular organism? This question can be more specifically rephrased as: 
How can the very same genome lead to such a diverse array of phenotypes of cells 
in different tissues? And how are these different readouts achieved in such a 
precise and organized fashion during development? 
The answer to these questions lies in the many different ways to read the 
genome. The processing of information from a gene to the mature protein product 
is by no means an easy or linear process; it is a complex process involving many 
different layers of regulation. Some of these layers represent crucial steps in the 
flow of information, while others may be seen as fine-tuning events leading to the 
refinement of the final readout.  
The readout of the genome can be affected epigenetically by chromatin 
structure remodeling (Turner, 2002), while mRNA splicing and stability in 
combination with the regulation of nuclear export control the composition and 
amount of mature mRNA available for translation in the cytoplasm. The 
processivity of the ribosome regulates translation, and the stability of the protein 
itself defines how much of the final effector is present in the cell. In addition, post-
translational modifications further fine-tune protein function. Before any of these 
steps can happen, regulation of transcription is the first crucial step in the 
regulation of the readout of the genome, common to all known organisms from 
bacteria to complex multicellular organisms. Indeed, transcription is the primary 
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level of control for the expression of most eukaryotic genes (Wray et al., 2003) 
(Lodish et al., 2000). 
Compared to the relative simplicity of the bacterial operon, regulation of 
transcription in eukaryotes is far more complex. The simple design of bacterial 
operons leads to the simultaneous transcription of a set of genes (usually involved 
in a common process) from a common promoter. Eukaryotes on the other hand, 
tend to regulate genes separately, with members of common biological pathways 




Figure 1 - General architecture of a eukaryotic gene locus. 
The transcription machinery starts to assemble at the promotor (red triangle) and is aided by 
transcription factor binding immediately upstream in the upstream promoter proximal elements 
(yellow circle). The transcriptional start site (arrow) is located some 30-50 bp downstream. 
Transcription can be enhanced or repressed by enhancers/silencers (green ellipse) acting up to 
several thousand bp upstream or downstream, or even within introns. 
 
Historically, three different DNA elements have been described for 
eukaryotic gene regulation, based on their distance to the transcriptional start site, 
as well as on interaction with different classes of proteins and functional 
characteristics of the modules (Figure 1). All three elements are cis-regulatory, 
acting on the same strand of DNA, as opposed to trans-acting elements like 
transcription factors (TFs) that can freely diffuse and act on a completely different 
and distant strand of DNA. 
The promoter is the region of DNA to which the RNA polymerase and 
basal transcriptional machinery bind. It is located close (about 50 bp) upstream to 
the transcription start site and usually consists of a TATA box, initiator site or CpG 
island. The promoter proximal elements are elements that influence transcription 
through the binding of transcription factors, and are located about 100-200 bp 
upstream of the start site. They are sometimes considered part of the basal 
promoter (Blackwood and Kadonaga, 1998). Finally, there is a class of elements 
called enhancers due to the fact that even though they are not needed for basal 
INTRODUCTION 16 
 
transcription, they are essential to enhance it. Similar elements can repress 
transcription (silencers). Enhancers/silencers are characterized by their ability to 
influence gene expression regardless of their orientation or relative position to the 
transcriptional start site. They can act over large distances (up to several thousand 
bp) and be located downstream, upstream, and even within introns of a gene 
(Figure 1) (Blackwood and Kadonaga, 1998) (Davidson, 2006).  
These features make the identification of enhancers, also referred to as cis-
regulatory-modules (CRMs), for a specific gene a difficult task. The term module 
emphasizes the fact that in many cases the precise spatio-temporal expression of a 
gene is actually the sum of individual contributions of distinct “modules”. A 
classical example is the Myocyte enhancing factor 2 (Mef2) gene. Mef2 protein is 
expressed in all myogenic cells throughout embryogenesis. Despite this seemingly 
simple pattern, this broad expression is the cumulative result of an impressive array 
of different CRMs spanning about 12 Kb of sequence, each responsible for a 
precise spatio-temporal band of expression in a different subset of mesodermal 
cells (Nguyen and Xu, 1998). Analysis of well-established CRMs shows that they 
typically comprise about 6-15 binding sites of 4-8 different transcription factors 
spanning a region of 50-500 bp of DNA. Thus a CRM is a cluster of TF binding 
sites that functions as a module to drive a specific spatio-temporal pattern in 




2.2. Drosophila melanogaster as a prime model 
organism for the study of Developmental Biology 
 
The fruit fly Drosophila melanogaster has been the subject of extensive 
study for almost a century (Rubin and Lewis, 2000). Drosophila is very well suited 
for the study of development due to its quick embryonic development (≈ 20 hours 
at 25 °C) and rapid generation time of about ten days. Fruit flies are also relatively 
inexpensive to maintain even in high numbers, being robust and tolerant of a wide 
range of environmental conditions. Drosophila is also very amenable to genetic 
studies, as they only have four chromosomes, one of which (the 4th) is very small 
and compact, containing few genes. Effectively, for experimental studies most 
geneticists only have to deal with three chromosomes, simplifying the mapping of 
genes and the ability to decipher their function in vivo. The fact that its genome 
lacks much of the redundancy often found in that of vertebrates has also proven to 
be a key advantage to its usefulness in the genomic era. Besides a sophisticated 
genetic toolkit, a wide range of well-established techniques is available, ranging 
from histological analysis to biochemical approaches, all coupled with a 
meticulously defined morphological mapping of embryonic development 
(Campos-Ortega and Hartenstein, 1997). In addition, the Drosophila research 
community shares a comprehensive pool of accumulated reagents. As a result, 
more knowledge has accumulated during the past 4-5 decades about Drosophila 
melanogaster than about virtually any other multicellular organism. 
The genome of Drosophila melanogaster was sequenced at the turn of the 
millennium (Adams et al., 2000) allowing a new perspective on the study of gene 
function. Many other Drosophila species have since been fully sequenced 
(Richards et al., 2005) (Clark et al., 2007) allowing powerful comparative analysis 
between species. With the recent completion of the human genome, the high 
degree of conservation from flies to humans is now apparent, with ~70% of 




2.3. Overview of Muscle development in Drosophila 
melanogaster 
 
The Drosophila muscle can be divided into three main classes according to 
structural and functional criteria. Somatic (SM) or body wall muscle is analogous 
to vertebrate skeletal muscle, and is present in a stereotypical array of 30 muscles 
per hemisegment used for locomotion and body structure (Figure 2 A). Visceral 
muscle (VM) lines the gut in an analogous way to vertebrate smooth muscle, and 
consists of interior circular rings covered by an exterior layer of longitudinal fibers 
(Figure 2 B). Heart muscle takes the form of the elongated dorsal vessel, and has 
many analogies to vertebrate cardiac muscle (Figure 2 C). 
The different muscle types are derived from a common mesodermal origin 
but have subsequently taken different developmental paths. In brief, the mesoderm 
is specified by an array of transcription factors acting specifically in the ventral 
blastoderm. Cells in this ventral region invaginate into the interior of the embryo, 
dissociate from each other and begin to proliferate and migrate dorsally. The 
different types of muscles are sub-specified both by the action of segmentation 
genes and by signaling from the overlying ectoderm. The dorsal region of the 
mesoderm gives rise to visceral muscle and heart precursors, while the somatic 
muscle arises from cell lying more ventral to the cardiogenic mesoderm.  Once 
specified, the SM myoblasts develop the ability to specifically recognize other 
muscle cells and fuse with each other, creating syncytial myotubes. These 
myotubes terminally differentiate and express the typical proteins of the contractile 
apparatus to become functional muscles. 
 
 
Figure 2 – Somatic, Visceral and Heart, the three major types of muscle in Drosophila larvae. 
Schematic drawing of the three major types of muscle in Drosophila larvae, at stage 17. (A) 
Somatic Muscle. (B) Visceral Muscle. (C) Heart Muscle.  Larvae are depicted with anterior to the 
left and dorsal at the top. Adapted from (Hartenstein, 2006) 
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2.3.1. The mesoderm is specified by signaling leading to 
invagination of a patch of ventral blastoderm 
 
The first steps of Drosophila embryonic development differ from those in 
vertebrates in the fact that the first 13 rounds of nuclear division occur without 
cytokinesis, resulting in a syncytial blastoderm containing many nuclei sharing a 
common cytoplasm. As these divisions take place, the nuclei progressively migrate 
to the periphery of the embryo and form a rim at the edge of the embryo. Next, the 
nuclei are surrounded by in-growing cell membranes and cellularization takes 
place leading to the cellular blastoderm stage, characterized by a single epithelium 
of cells lining the embryo (Gilbert, 2006). The mesoderm originates from a ventral 
patch of cells from this epithelium that invaginate and spread dorsally. 
Simultaneously, they become progressively more sub-specified and eventually give 
rise to all three types of muscle, fat body, gonadal mesoderm and macrophages. 
The specification of this ventral patch is a complex process that can ultimately be 
traced back to the very specification of the embryonic dorso-ventral axis.  
During oogenesis, the dorso-ventral axis of the embryo is established 
through intercellular communication between the oocyte and the surrounding 
somatic follicle cells. When the nucleus of the oocyte is located at an anterior-
dorsal position, it allows the translation of gurken mRNA in this location only. 
gurken (grk) is a homologue of vertebrate EGF (Epidermal Growth Factor), and 
upon secretion from the oocyte binds to an EGF receptor coded by torpedo (top) in 
the follicle cells. This directs these cells to adopt a follicle dorsal fate, and inhibits 
them from expressing pipe (pip). Pipe is therefore synthesized in the ventral 
follicle cells only, and starts a proteolytic cascade in the perivitelline space leading 
to the cleavage of the signaling protein Spätzle specifically on the ventral side of 
the embryo. The cleaved Spätzle fragment is a ligand for the transmembrane 
receptor Toll, ubiquitously expressed in the embryo. Limited diffusion of Spätzle 
(Spz) in the perivitelline space leads to a graded activation of Toll (Tl), with the 
maximum at the ventral side and progressively decreasing dorsally. The gradient of 
Toll activation then directs a gradient activation of the transcription factor dorsal 
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(dl) which will in turn play a key role in the definition of a number of different 
regions along the dorso-ventral axis, among which the presumptive mesoderm. 
Dorsal (NFκ-B ortholog) is usually sequestered in the cytoplasm by Cactus 
(Iκ-B ortholog). Activation of Toll by Spätzle triggers an intracellular signaling 
cascade that results in the phosphorylation and degradation of Cactus, allowing 
Dorsal to move to the nucleus and become active, a pathway that parallels 
strikingly the signaling in vertebrate lymphocytes following the activation of the 
interleukin 1 receptor (part of the Toll-like receptor superfamily) (O'Neill, 2000). 
The gradient of Dorsal nuclear localization/activity sets up the expression of 
different sets of genes at different thresholds, ultimately defining different domains 
along de dorso-ventral axis (Figure 3) (Stathopoulos and Levine, 2002). 
The basic Helix-Loop-Helix (bHLH) transcription factor twist (twi) is one 
of the first genes to be expressed in the presumptive mesoderm (Stathopoulos and 
Levine, 2002). Twist is a direct activator of a large number of other transcription 
factors essential for the proper development of virtually every type of muscle 
(Mef2 (Cripps et al., 1998), tin (Yin et al., 1997), …). Twist resides at the top of a 
cascade of genes regulating mesodermal development and is considered a master 
regulator of the mesoderm. Twist cooperates with its own activator, Dorsal, to 
cooperatively activate the transcription of snail (sna). Snail, itself a transcription 
factor, defines the boundaries of the presumptive mesoderm, delimiting it from the 
neurogenic ectoderm (Ip et al., 1992) by inhibiting neuroectodermal genes (Leptin, 
1991). Dorsal and Twist also activate a novel Wnt family member called wntD, for 
wnt inhibitor of Dorsal. However, as wntD is itself inhibited by Snail in the 
presumptive mesoderm, its expression is limited to the lateral blastoderm. There it 
leads to a diminished nuclear import of Dorsal, helping to sharpen the borders of 











Figure 3 - The blastoderm is subdivided by a gradient of nuclear Dorsal concentration. 
The presumptive mesoderm is specified in the ventral blastoderm by high levels of nuclear Dorsal. 
Dorsal activates Twist and both activate Snail. Snail acts as a repressor of many genes that would 
be activated by Dorsal or Twist and lead to a neural ectoderm fate. At more lateral positions, 
nuclear Dorsal concentration drops, leading to a decrease of Twist, and sharp absence Snail. The 
release of Snail inhibition, allows these cells to transcribe genes that respond to lower levels of 
Dorsal (high affinity sites) that specify the neural ectoderm. The steeper decline in Dorsal nuclear 
localization enhanced by the negative feedback loop of WntD on Dorsal. Direct lines show direct 
activation/repression while broken lines represent genetic interaction. Adapted from (Stathopoulos 
and Levine, 2002) 
 
 
In summary, the blastoderm is subdivided by the nuclear Dorsal gradient 
interacting with members of its downstream transcriptional network, Twist and 
Snail. The target genes respond to the different concentrations of Dorsal through 
the architecture of their enhancers, integrating information from Twist, Snail as 
well as general co-activators/repressors (Stathopoulos and Levine, 2002). Our 
knowledge of the complex interplay between these factors, and the number of 
targets regulated has dramatically increased from two genome wide studies of this 





2.3.2. The mesoderm is subdivided by cues secreted from 
the overlying ectoderm 
After gastrulation, the primitive mesoderm is a uniform layer of cells that 
has proliferated and migrated dorsally from its original ventral origin, spreading on 
each side of the embryo. At this stage, the cells are committed to a mesodermal cell 
fate, but are still pluripotent and therefore must still be sub-specified into the 
different muscle types and remaining mesodermal fates. This cell fate choice 
depends on the relative location of cells within each parasegment, which is 
subdivided into different fields both by the expression of mesodermal transcription 
factors and by the integration of signals from the overlying ectoderm. Each 
parasegment is divided in the anterior-posterior direction into two fields through 
the action of the pair-rule transcription factors even-skipped (eve) and sloppy 
paired (slp) (Figure 4). The eve domain corresponds to the anterior part and slp to 
the posterior. This division of each parasegment into two distinct fields is also 
reflected in the mesodermal expression of two domains of high (slp domain) and 
low (eve domain) twist expression at stage 11 (Riechmann et al., 1997). The 
parasegments are further defined by the action of the segment polarity genes 
wingless (wg) (posterior parasegment) and engrailed (en) and hedgehog (hh) 
(anterior parasegment). To subdivide the mesoderm in the dorsal-ventral direction, 
Decapentaplegic (Dpp), a member of the BMP family is secreted from the dorsal 
ectoderm. Dpp is essential for the specification of all tissue types derived from the 
dorsal mesoderm (Staehling-Hampton et al., 1994) (Frasch, 1995).  
 
 
Figure 4 - The mesoderm is sub-specified both by the 
expression of genes in the mesoderm and by signaling 
from the overlying ectoderm. 
Schematic drawing of the sub-specification of the mesoderm. 
Each segment is divided in the anterior-posterior axis by 
domains of even-skiped (anterior) and sloppy paired 
(posterior). The secreted molecules Wg and Hh act as 
segment polarity genes to further divide these domains. Dpp, 
secreted from the overlying ectoderm patterns the mesoderm 
in the dorso-ventral axis. The different muscle types arise 
from the integration of these signals in specific locations. 
Adapted from (Riechmann et al., 1997). 
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2.3.3. Specification of Founder Cells (FCs) and Fusion 
Competent Myoblasts (FCMs) 
 
One of the remarkable features of skeletal muscle cells is their capacity to 
undergo cell-cell fusion. Final muscle fibers are therefore syncitia, with several 
nuclei sharing a common cytoplasm crossed by the contractile fibers that render 
the muscle functional. In Drosophila, it has long been established that cells 
contributing to the somatic muscle undergo myoblast fusion, whereas heart muscle 
cells do not. More recently it was shown that visceral muscle cells also undergo 
fusion, albeit to a different level than somatic muscle (Martin et al., 2001). One 
important aspect though, is that in Drosophila, myoblast fusion in both somatic 
and visceral muscle is an asymmetrical process. Each muscle fiber is seeded by an 
individual cell, the Founder Cell (FC), which then attracts and fuses with a 
determined number of Fusion Competent Myoblasts (FCM).  
A number of mutants with blocked myoblast fusion continue to develop 
very thin muscles, containing only one nuclei, termed mini-muscles. This 
observation led to the Founder cell hypothesis, which suggested that there are two 
types of somatic muscle cells; one termed the Founder Cell which contains all of 
the necessary information to form a muscle, and a second cell type that was 
thought to be a naïve muscle cell with the capacity to fuse to FCs (termed Fusion 
Competent Myoblast). When myoblast fusion is blocked, FCs still migrate to their 
correct location, form their correct muscle attachment to the ectoderm, attract the 
appropriate motor neurons and express contractile proteins, showing that FCs have 
the necessary information to determine the character of their specific muscle.  
The larval somatic muscle consists of a stereotypical array of 30 
(Riechmann et al., 1997) muscles per hemisegment (A2-A7). Each muscle has 
characteristic properties including its location, size, shape and innervation (Figure 
2 A). Each muscle is seeded by a FC expressing a particular combination of 
identity genes, such as Krüppel (Kr), vestigial (vg), apterous (ap), slouch (slou), 
Toll (Tl), ladybird, Connectin (Con), even-skipped (eve) (Baylies et al., 1998). The 
specific expression of these identity genes, together with the fact that many are 
known transcription factors, led to the hypothesis that these genes could instruct a 
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muscle to choose some of its specific characteristics (Baylies et al., 1998). Indeed, 
for particular cases a correspondence has been show between identity gene loss 
and specific muscle loss or ectopic expression of the identity gene and the partial 
duplication of a specific muscle (Bourgouin et al., 1992) (Keller et al., 1997). It has 
also been shown that forced expression of an identity gene can impart its specific 
characteristics to a different muscle (Ruiz-Gomez et al., 1997).  
 
 
Figure 5 - Progenitor cells are specified via integration of Ras signaling and Delta/Notch 
lateral inhibition. 
Schematic representation of Eve progenitor selection in the dorsal mesoderm. An equivalence 
group of cells expressing l’sc arises in a competence domain created by gradients of Dpp and Wg. 
The Ras/MAPK pathway is activated to intermediate levels in these cells, but cells try to inhibit the 
pathway in a juxtacrine fashion via Delta/Notch lateral inhibition. Finally, only one cell in the 
cluster reaches a high level of Ras signaling, becoming the progenitor cell. Adapted from (Carmena 
et al., 2002). 
 
The specification of a FC is a complex process (Figure 5) that has been 
studied in detail for the dorsal eve-expressing cells (Halfon et al., 2000). In this 
case, a competence domain is created by the combined action of Dpp and Wg in 
the dorsal part of each hemisegment. A group of cells within this competence 
domain start to express the transcription factor lethal of scute (l’sc) and is rendered 
responsive to EGF and FGF signaling. Signaling downstream of FGF/EGF 
receptors activates the Ras/MAPK pathway in this equivalence group leading 
towards the selection of a progenitor cell fate. However, the Ras/MAPK signal is 
inhibited by juxtacrine Delta/Notch lateral signaling within the equivalence group, 
resulting in only one cell being selected as a progenitor cell (Carmena et al., 2002). 
The progenitor cell then divides asymmetrically, yielding either two different FCs 
or a FC and an adult muscle progenitor, or in the case of eve, a FC and a 
pericardial cell (Halfon et al., 2000). The adult muscle progenitor is marked by the 
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persistence of Twist expression and will remain undifferentiated until required 
during metamorphosis of the larva to the adult fly. The remaining cells from the 
equivalence group, where Notch signaling prevails over Ras/MAPK activation, 
become FCMs. 
 
2.3.4. Myotubes are formed by the process of Myoblast 
Fusion between FCs and FCMs 
 
Cell-cell fusion remains the least understood of the three types of 
membrane fusion events (the others being intracellular fusion of organelles and 
virus-cell fusion). Nonetheless, EM studies of the fusion process have revealed a 
defined sequence of events at the ultrastructural level. In a first step, FCMs extend 
filopodia and migrate towards FCs. After this first step of recognition and 
adhesion, paired vesicles of electron-dense margins form along the apposed 
membranes (prefusion-complex). These vesicles then resolve to electron-dense 
plaques, the cells align along their long axes, and finally the apposed membranes 
break down, forming fusion pores and allowing the formation of a multinucleated 
myotube (Doberstein et al., 1997). 
A combination of genetic and biochemical studies have revealed a number 
of key players in the process. The molecules involved can be grouped in three 
broad categories: transmembrane receptors that mediate attraction/recognition, 
intracellular components that integrate the signals from the receptors and finally 
proteins that are capable of modifying the cytoskeleton leading to the process of 
fusion itself. On the transcriptional level, it is interesting to note that only two 
transcription factors have been identified that are essential for fusion of all somatic 
muscle: Myocyte enhancing factor 2 (Mef2), expressed in both FCs and FCMs and 
required for myoblast fusion and muscle differentiation, and lame duck (lmd), 
expressed in FCMs and necessary for FCMs differentiation. Mutation of either 




2.3.4.1. Myoblast attraction and recognition is mediated by 
transmembrane receptors of the IgSF family 
 
The transmembrane receptors dumbfounded/kin of irregular chiasm C 
(duf/kirre) (Ruiz-Gomez et al., 2000), roughest/irregular chiasm C (rst/irreC) 
(Strunkelnberg et al., 2001), sticks and stones (sns) (Bour et al., 2000) and hibris 
(hbs) (Dworak et al., 2001) (Artero et al., 2001) were identified almost 
simultaneously providing a handful of genes involved in the recognition between 
FCs and FCMs. duf and sns were also the first genes shown to be specifically 
expressed in FCs and FCMs respectively, providing a molecular mechanism for the 
founder cell model. duf and its paralog rst encode transmembrane proteins with an 
extracellular domain comprised of five Ig-like domains that share a relatively high 
degree of similarity (Strunkelnberg et al., 2001). The two genes act redundantly 
and only the simultaneous deletion of both genes leads to a complete block of 
fusion. Either gene can rescue the phenotype, and ectopic expression leads to 
attraction of FCMs (Strunkelnberg et al., 2001). sns, which encodes another 
transmembrane protein with extracellular Ig-like domains is expressed only in 
FCMs and is also essential for muscle fusion (Bour et al., 2000). Significantly, in 
both duf+rst double mutants and sns mutants one can find FCM extending 
filopodia, but with seemingly random orientations (Ruiz-Gomez et al., 2000). This 
is in contrast with other fusion mutants which seem to block fusion at a later stage, 
as FCMs are seen extending filopodia towards and making contact with FCs (Chen 
and Olson, 2001) (Chen et al., 2003). Together with evidence that Duf and Sns can 
mediate cell adhesion in cultured Drosophila S2 cells (Dworak et al., 2001), this 
confirms the role of these receptors in the initial recognition and adhesion between 
the two distinct cell populations. Hibris is also expressed in FCMs only but seems 
to act as a negative regulator of Sns, and could provide some fine tuning for the 




2.3.4.2. The “fusion’ signal” is relayed from the membrane to the 
cytoskeleton by a number of signaling pathways 
 
A second group of players are cytosolic proteins that transduce the signals 
from the membrane receptors to the cytoskeleton. Myoblast City (Mbc), a 
Dock180 family (CDM) member, is a cytoplasmic protein long known to be 
crucial to myoblast fusion (Rushton et al., 1995) (Erickson et al., 1997). This 
family has been proposed to form unconventional two-part Guanine nucleotide 
Exchange Factors (GEFs) with ELMO/CED-12 for the small GTPase Rac 
(Brugnera et al., 2002). That has recently been shown to be the case, with the 
identification of the Drosophila ELMO/CED-12 ortholog (Geisbrecht et al., 2008). 
Rac is a small GTPase involved in actin cytoskeleton rearrangements thought to be 
necessary for fusion. Indeed, the Drosophila Rac1 has long been implicated in 
myoblast fusion (Luo et al., 1994), with later analysis uncovering a redundant role 
with Rac2 (Hakeda-Suzuki et al., 2002). The link between Duf and Mbc has been 
found with the identification of the adaptor protein Ants/Rols7. This adaptor 
protein, expressed only in FCs, contains multiple potential protein interaction 
domains (Ankyrin, TRP, Coilled-coil) and was shown to bind to both the 
cytoplasmic domain of Duf and to Mbc in S2 cells. It is localized in vivo to distinct 
foci, and this localization is dependent on the presence of Duf or Rst, providing a 
link between the membrane receptors and actin cytoskeleton rearrangement (Rau et 
al., 2001) (Chen and Olson, 2001) (Menon and Chia, 2001). One intriguing fact is 
that in Ants/Rol7 mutants, a first wave of fusion is able to take place, and 
myofibers with 2-4 nuclei, called muscle precursors, are formed (Rau et al., 2001).  
A second pathway working in parallel and cross-talking with the 
Ants/Rols7 pathway was unveiled with the characterization of loner (Chen et al., 
2003) (also known as schizo (Hummel et al., 1999) ). Loner is also a putative GEF 
with PH and Sec7 domains required for the first fusion event leading to the muscle 
precursor stage, as there is a complete block of fusion in loner mutants. As with 
Ants/Rols7, Loner is localized to distinct foci in a Duf/Rst dependent manner, but 
the Ants/Rol7 and Loner foci overlap only partially, and the localization of one is 
not dependent on the other (Chen et al., 2003). Sec7 domains are usually found in 
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GEFs for the ARF family of small GTPases, and in fact Loner can act as a GEF in 
vitro specifically for ARF6. ARF6 is expressed ubiquitously in the embryo, but a 
dominant negative form expressed in FCs leads to muscle fusion defects. ARF6 
has been connected with the subcellular localization of Rac1, and in loner mutant 
embryos Rac1 seems to be delocalized to the cytoplasm as opposed to distinct loci 
(Chen et al., 2003). Therefore, these two signaling pathways impinge on the 
activation/localization of Rac1 to the sites of fusion, with the Ants/Rol7 pathway 
being crucial for the progression beyond the muscle precursor stage. It is also 
interesting to note, that in visceral muscle, 2-3 and 3-5 nuclei were reported in 
circular and longitudinal fibers respectively (Martin et al., 2001), which could 
correspond to a status similar to precursor cell.  
 
Figure 6 - Model of myoblast 
fusion in Drosophila. 
Initial adhesion is mediated by 
transmembrane protein members 
of the IgSF. Duf is expressed in 
FCs only and interacts with Sns, 
expressed in FCMs only. In FCs, 
the intracellular domain of Duf 
can recruit the adaptor protein 
Ants/Rols7, which in turn 
mediates interaction with Mbc. 
Mbc (interacting with ELMO) is 
a GEF for Rac, activating and 
recruiting it to the membrane. 
Rac can then mediate changes to 
the actin cytoskeleton necessary 
for fusion. A second pathway in 
FCs involves Loner, again a GEF 
this time for ARF6. ARF6 has 
been shown to promote the 
localization of Rac to the 
membrane, an important step for Rac function. In FCMs, WIP recruits WASp to foci of fusion in an 
Sns dependent manner, possibly thought the small adaptor protein Crk. WASp is know to stimulate 
the Arp2/3 complex to start F-actin nucleation. Drosophila Titin (sls) is also involved in structural 
changes during the fusion process. 
 
Two genes have been related to the transition from the precursor cell to the 
completely fused myotube. blown fuse (blow)  (Doberstein et al., 1997) and kette 
(Schroter et al., 2004) are two cytosolic proteins whose mutants arrest fusion after 
the first 3-4 fusion events. blow mutants are unable to do the transition from 
prefusion complex to electron-dense plaques whereas in kette mutants, the 
electron-dense plaques do not resolve into fusion pores, and become abnormally 
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elongated. The fact that the two genes interact genetically during the second fusion 
step makes them good candidates to interact with the Ants/Rols7 pathway at this 
step, leading to transition from the prefusion complex to membrane breakdown 
(Schroter et al., 2004). On the other hand, kette genetically interacts with the 
recently characterized muscle fusion WIP/WASP pathway, necessary for 
progression beyond the precursor cell state (Schafer et al., 2007). WASp (Wiskott-
Aldrich Syndrome protein) is a ubiquitously expressed protein known to activate 
the Arp2/3 complex to modulate F-actin nucleation. It is recruited to the foci of 
fusion by the FCM specific Drosophila WIP (WASp Interacting 
Protein)/Solitary(Sltr)/Verprolin 1(Vrp1). In vitro, WIP can interact with both the 
adptor protein Crk and WASp, and Crk can bind the FCM receptor Sns (Kim et al., 
2007) providing a possible connection in vivo. Accordingly, WIP is localized and 
F-actin enriched to fusion foci in a Sns dependent manner. There is conflicting data 
as to what the exact in vivo function of this F-actin nucleation is, but the pathway 
seems to be necessary for the transition beyond the precursor cell stage (Schafer et 
al., 2007) (Massarwa et al., 2007) (Kim et al., 2007). 
Finally, the large protein Titin – also know as Sallimus (Sls) – long known 
to be necessary for sarcomere function in late differentiation, has meanwhile been 
found to play a role much earlier in myoblast fusion (Zhang et al., 2000).  
 
2.3.4.3. Fusion-Restricted Myogenic-Adhesive Structures (FuRMAS) 
mediate Myoblast Fusion in Drosophila melanogaster 
 
The genetic information described above has recently been supplemented 
with new studies including novel structural data, and a more detailed model of 
fusion has emerged. The transmembrane proteins Sns and Duf were found to be 
organized in a ring-structure at the contact points between FCMs and myotubes, 
with cytoplasmic components as Titin and F-actin forming a plug in the middle 
(Figure 7 A). Interestingly, Blow co-localizes with these actin plugs in FCMs after 
cell adhesion, while Ants/Rols7 is found interacting with Duf in the ring-structure 
in myotubes (Figure 7 B) (Kesper et al., 2007). This structure is involved in both 
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adhesion between myoblasts and the restriction of fusion to the inside of the ring; it 
has been named Fusion-Restricted Myogenic-Adhesive Structure (FuRMAS).  
According to this model, F-actin polymerization and de-polymerization, 
involving the regulators described previously (Section 2.3.4.2), plays an important 
role in the progression of fusion. The branched F-actin plug leads to the 
enlargement of the FuRMAS (Figure 7 B) and electron-dense vesicles accumulate 
at the opposing membranes. As the FuRMAS expands, the FCM is pulled into the 
growing myotube (Figure 7 C) (Onel and Renkawitz-Pohl, 2009). 
 
 
Figure 7 - Fusion-Restricted Myogenic-Adhesive Structures (FuRMAS). 
Taken from (Önel and Renkawitz-Pohl, 2009) 
 
FuRMAS have been compared to similar transient structures such as the 
immunological synapse, podosomes and invadadopodia, The common  bipartite 
architecture of a ring of cell-adhesion molecules and local F-actin branching could 
reflect a common way of restricting spatial and temporal communication between 
cells.  
 
2.3.5. Terminal differentiation of myotubes to functional 
muscle fibers 
 
During the last stages of differentiation, myotubes make contact with 
specific attachment points in the epidermis. Motorneurons are guided towards their 
recipient myotube, and form the functional neuromuscular junctions. In parallel, 
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structural proteins that make up the contractile apparatus are expressed and 
assembled into functional sarcomeres.  
 
2.3.5.1. Migration towards attachment points in the epidermis is 
guided cues between the myotubes and tendon progenitor cells 
 
Myotubes migrate towards and attach to epidermal tendon cell precursors 
as a result of bi-directional interplay between the two cell types. Tendon precursors 
are epidermal cells characterized by the expression of the triple Zinc-Finger TF 
Stripe (Sr), necessary and sufficient to determine tendon cell fate. However, final 
differentiation of tendon cells is dependent on attachment of myotubes providing a 
signal for tendon cell maturation (Volk, 2006). The nature of the cues guiding 
myotubes is not completely clear as yet, but several important components have 
been identified. Slit (Sli) and its receptor Roundabout (Robo) are involved in 
repelling muscles from the ventral midline of the embryo, preventing ventral 
muscles from crossing the ventral CNS. Conversely, later in development, Slit is 
used by segment border cells to attract Robo-expressing Ventral Longitudinal (VL) 
muscles (Kramer et al., 2001). Lateral Transverse (LT) muscles do not express 
Robo, and accordingly are not attracted to segment borders, extending instead in a 
dorso-ventral direction. The correct recognition by LT muscles of their Sr 
expressing tendon counterparts is instead dependent on the RTK Derailed (Drl), 
but the cue originating from these tendon cells has not yet been determined 
(Callahan et al., 1996). After correct attachment, the myotube secretes the 
Neuregulin-like ligand Vein (Vn), activating EGF receptors specifically in the 
tendon precursor and signaling its final maturation. Hemi-adherence junctions are 
formed between extracellular matrix (ECM) and both the tendon cell and the 
myotube resulting in stable attachments capable of withstanding the force of 




2.3.5.2. Axons are guided towards myotubes and form 
neuromuscular junctions (NMJ) 
 
The 30 muscles of each hemisegment (A2-A7) are innervated specifically 
by 35 motorneurons (Nicholson and Keshishian, 2006). While motorneurons can 
initially develop on their own, they require the presence of myotubes to find their 
correct final positioning. At this step, both the growing motorneurons and 
myotubes extend filipodia probing for correct contact. The IgSF member protein 
Sidestep, present on the membrane of all myotubes, is generally required for the 
guidance of motorneurons towards myotubes, but other factor are present in 
specific muscles, [Fascilin III (Fas3), Connectin (Con), Capricious (caps), Netrin-
A (Net-A) or Netrin-B (Net-B)], allowing the identification of specific targets by 
motorneurons (Nicholson and Keshishian, 2006). Toll and Robo were also 
implicated in mediating repulsion of motorneurons. Correct contacts lead to the 
formation of the neuromuscular junction (NMJ), with the assembly of post- and 
presynaptical complexes and the localization of Glutamate receptor (GluR) to the 
synapses. This is in sharp contrast to vertebrates, where acetylcholine is the 
neurotransmitter of choice for neuromuscular junctions, with glutamate used as the 
major excitatory neurotransmitter of the central nervous system. 
 
2.3.5.3. The contractile apparatus is organized into sarcomeres, 
leading to functional myofibers 
 
The main function of muscle is to convert chemical energy into the 
mechanical energy required for contraction. Muscle contraction can be seen as 
highly coordinated and efficient development of the common theme of ATPase 
motor proteins moving along actin filaments (Lodish et al., 2000). Ultrastructural 
information has been obtained from vertebrate and insect muscles, in particular 
from the adult indirect flight muscle (IFM) of Drosophila and the large waterbug 
Lethocerus sp.. The structure and most of the components of contractile apparatus 
show remarkable conservation from insets to vertebrates, where myofibrils are 
organized in repeating units of contraction called sarcomeres (Vigoreaux, 2006). 
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The sarcomeres are formed by an array of thick filaments, consisting mainly of the 
ATPase motor protein Myosin, interspersed with thin actin-based filaments, on 
which the thick Myosin filaments move. The thick filaments consist mainly of 
Myosin, but include other components such as Para-Myosin (PM), mini-
paramyosin (mPm), flightin (fln) (Vigoreaux, 2006) and myofilin (Mf) (Qiu et al., 
2005). The thin filaments are formed mainly by actin, troponin and tropomyosin 
(Vigoreaux, 2006). Very large proteins such as Titin help organize both thick and 





2.4. Comparison with Vertebrate development 
 
The use of model organisms, in one way or another, is as old as biology 
itself. The advantages of using an organism without the constant complications of 
redundancy arising from gene duplications are evident when comparing muscle 
development in Drosophila to that in vertebrates. 
 
2.4.1. The somite is patterned by diffusible signaling 
molecules from nearby structures 
 
As in Drosophila, all muscle in vertebrates is derived from the mesoderm. 
The heart, smooth muscle lining the digestive tract (analogous to visceral muscle) 
and the muscles lining the blood vessels (without equivalence in Drosophila) are 
derived from the Lateral Plate Mesoderm (LPM).  All skeletal muscles (analogous 
to Drosophila somatic muscle) of vertebrates (with the exception of some head 
muscles) arises from the paraxial mesoderm. The paraxial mesoderm is a strip of 
mesodermal cells running in an anterior-posterior orientation on each side of the 
embryo parallel to the main axis formed by the neural tube and the notochord 
(Figure 8). The paraxial mesoderm is then segmented in the anterior-posterior 
direction into a defined number (for every species) of structures called somites. 
Most in vivo studies of vertebrate myogenesis have focused on the subsequent 
patterning of somites (Gilbert, 2006). 
Like the mesoderm of Drosophila, the vertebrate somite receives inputs 
from nearby structures, including the overlying epidermis and notocord. It is 
striking to note that despite the obvious structural differences, the same pathways 
of secreted molecules that pattern the Drosophila mesoderm are used as well to 
pattern the vertebrate somite: Wnt [Wg] signaling from the neural tube and 
overlying epidermis, Sonic hedgehog (Shh) [Hh] signaling from the notochord, and 
Bone Morphogenic Protein 4 (BMP4) [Dpp] from the lateral plate mesoderm. 
Transcription factors of the paired box (PAX) and sine oculis related (SIX) 
families are also expressed in different regions of the somite (Richardson et al., 
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2008) and the interplay of these signaling pathways and regulatory molecules leads 
to the patterning of the somite and activation of master regulators of muscle 
development (section 2.4.2) (Taylor, 2006). The ventral-most region called the 
sclerotome will form cartilage and bone, while the central dorsal dermatome will 
form the dermis. The dorsal medial region (closer to the neural nube) will form the 
epaxial muscles of the back (innervated by dorsal nerves). The dorsal lateral region 
will form the hypaxial muscles and limbs (innervated by ventral nerves). 
 
 
Figure 8 - The vertebrate somite is patterned by secreted signaling molecules of the same 
families as in Drosophila mesoderm patterning.  
Wnt/Wg, Shh/Hh and BMP4/Dpp signaling pathways are used in Drosphila as well as in vertebrate 
mesoderm sub-specification. In vertebrates, they pattern the somites leading to specification of 
Sclerotome (cartilage, bone), dermis, Epaxial (dorsal) and Hypaxial (ventral, limb) muscle. 
 
2.4.2. Muscle development in vertebrates is controlled by 
master regulators of the MyoD family of Muscle 
Regulatory Factors (MRF) 
 
Muscle Regulatory Factors (MRFs) are a family of four basic helix-loop-
helix transcription factors (bHLH) acting as master regulators of vertebrate muscle 
development (MyoD, Myf5, Myogenin and MRF4).  
MyoD was first identified in the mouse fibroblast line 10T1/2 by its ability 
to convert these cells to the myogenic fate (Davis et al., 1987) (Davis et al., 1987). 
This striking effect was the first example of a single gene being able to drive a 
complex program of differentiation, and therefore acting as a master switch 
(Berkes and Tapscott, 2005). Nonetheless, the presence of four closely related 
proteins in the same family required in vivo genetic characterization to determine 
the individual contributions of each gene. There is substantial functional 
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redundancy between MyoD and Myf5, as mutation of either gene causes only mild 
muscle defects (Rudnicki et al., 1992) (Braun et al., 1992), whereas in a double 
mutant setting there is a complete absence of muscle (Rudnicki et al., 1993). 
Myogenin (Myog) can be activated by both MyoD and Myf5 in vitro, and is 
expressed later in development. In Myog mutants, muscle mass is severely 
reduced, with many mononucleate myoblasts but very few differentiated muscle 
fibers (Hasty et al., 1993). Therefore, Myog seems to act downstream of MyoD and 
Myf5 and is required for proper muscle differentiation and fusion. MRF4 has been 
the least studied MRF, and was thought to act only late during differentiation. 
More recently it has been shown to act as well during earlier determination 
(Kassar-Duchossoy et al., 2004). 
MRFs bind to the enhancers of many muscle-specific genes by forming 
heterodimers with the ubiquitously expressed E-box family of bHLH transcription 
factors and binding to E-box motifs (CANNTG). These heterodimers act 
cooperatively with the Mef2 family of TFs, another family of proteins required for 
proper myogenesis. 
As with MyoD, Mef2 was first identified in vertebrate cell culture as a 
factor from C2 myoblasts that could binding to an enhancer of the muscle creatine 
kinase (mck) gene (Gossett et al., 1989). The Mef2 family of transcription factors 
contain an N-terminal MADS-box binding domain, followed by a novel conserved 
Mef2 domain, specific to this family (Olson et al., 1995). Mef2 family members 
form homo- or heterodimers that bind the canonical sequence YTA(W)4TAR that 
is present in virtually every muscle gene (Black and Olson, 1998). Nevertheless, 
Mef2 family members are not able to induce myogenesis of transfected fibroblasts 
on their own, but can instead dramatically increase the myogenic effect of MRF 
family members. Remarkably, this synergistic activation results from direct 
protein-protein interactions between the “myogenic” bHLH of the MRF of an 
MRF/E-Box dimer and both the MADS and Mef2 domains of Mef2. That allows 
either Mef2 or MRF/E-Box to independently bind their respective sequences, and 






Figure 9 - Model of interaction between MRFs and Mef2 on common enhancers. 
 (A) MRF/E-protein heterodimers bind to E-box motifs and recruit Mef2 dimers via direct protein-
protein interaction between the MRF and Mef2. This allows the transactivation domain of Mef2 to 
promote transcription without direct binding of Mef2 to the enhancer. (B) Conversely, Mef2 can 
bind to its site and recruit the MRF/E-protein dimer. (C) On enhancers containing both E-Box and 
Mef2 sites direct interaction between MRF/E-Box dimers and Mef2 dimers leads to synergistic 
activation, potentially facilitating the physical linking of distant enhancers (D). Adapted from 
(Molkentin et al., 1995). 
 
The determination of the exact function of this family in vivo in vertebrates 
has been complicated by the occurrence of four paralogs (Mef2A-D) with 
overlapping expression and redundancy in various muscle tissues. Studying the 
single Mef2 ortholog in Drosophila has therefore contributed significantly to our 
understanding of Mef2 function (Section 2.5).  
In Drosophila the only member of the MRFs family is the gene nautilus 
(nau), a TF with about 90% identity to the other MRFs in its bHLH domain, but 
otherwise quite divergent. However, nau is expressed in a restricted fraction of the 
mesoderm, and seems to act as an identity gene in only a subset of muscle fibers 
(Balagopalan et al., 2001). Instead, a different member of the bHLH family of TFs, 
Twist, performs the role of a functional MRF in Drosophila (Taylor, 2006). Apart 
from its essential role early during gastrulation (section 2.3.1), Twist acts as the 
myogenic switch in Drosophila, sitting at the top of an extensive cascade during 
myogenic specification, and directly activating a number of important genes for 
muscle development, including Mef2 (Cripps et al., 1998). High levels of Twist are 
required for somatic myogenesis (section 2.3.2), and block the formation of other 
mesodermal derivatives. Similar to vertebrate MRFs, ectopic expression of Twist 
in the ectoderm is sufficent to drive these cells into myogenesis (Baylies and Bate, 
1996). In parallel to the vertebrate system, Twist and Mef2 tightly co-regulate a 
great number of muscle genes on common enhancers (Sandmann et al., 2006b), 
tempting speculation on whether Twist could interact with Mef2 in a similar 
cooperative way.  
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2.5. Myocyte enhancing factor 2 (Mef2) is essential 
for myoblast fusion and terminal differentiation in 
Drosophila 
 
2.5.1. Mef2 is expressed in all muscle cells 
 
Following the discovery of the Mef2 family in vertebrate cell culture, a 
single Mef2 gene was identified in Drosophila by screening a cDNA library with a 
probe for the unique MADS-MEF2 sequence (Lilly et al., 1994) (Nguyen et al., 
1994). Both the MADS-box and Mef2 domains of Drosophila Mef2 are highly 
conserved, while the rest of the protein shows little homology to other Mef2 family 
members. In vitro translated Mef2 protein can bind the vertebrate mck enhancer 
and drive expression from this enhancer in CAT assays when transfected in S2 
cells. During development, Mef2 is first detected in the ventral furrow, at cellular 
blastoderm stage 6 (according to (Campos-Ortega and Hartenstein, 1997)) and at 
stage 8 Mef2 is clearly restricted to the mesoderm. At stage 10, as the mesoderm 
segregates into somatopleura (SM precursors) and splanchnopleura (VM and heart 
precursors), Mef2 can be detected in both cell layers, as well as in the cephalic 
mesoderm, precursor of pharyngeal muscle. At stage 12 Mef2 expression starts to 
decline in the VM and heart precursors but can be still be detected in the dorsal 
vessel as well as SM even in late stages of embryonic development (Lilly et al., 
1994) (Nguyen et al., 1994). An antibody against Mef2 protein revealed a nuclear 
localization, consistent with the function of Mef2 as a TF (Lilly et al., 1995) (Bour 
et al., 1995). Mef2 is therefore a mesodermal gene specifically expressed in all 
muscle cell precursors of every muscle type, and not in other mesodermal 
derivatives, such as fat body or pericardial cells. As noted before (section 2.1), this 
broad expression is actually the cumulative result of the action of multiple CRMs 





2.5.2. Mef2 loss-of-function leads to a complete block of 
myoblast fusion and terminal differentiation 
 
Mutation of the single Mef2 gene in Drosophila results in lethality with 
severe muscle defects. There is a complete block of myoblast fusion, the SM fails 
to differentiate and the midgut is bloated, apparently due to the absence of 
differentiated VM. Terminal differentiation is compromised, as judged by the 
almost complete lack of expression of Myosin Heavy Chain (Mhc) in the dorsal 
vessel, SM and VM. These defects do not seem to stem from a block in the 
specification of mesodermal progenitors, as markers of specification of heart and 
VM [tinman (tin), bagpipe (bap) and Fasciclin 3 (Fas 3)] are expressed normally. 
The FC identity genes nau, ap, and slou are also expressed at the right locations, 
but the labeled FCs remain in unorganized clusters, unable to fuse, and syncitia 
cannot be formed. Thus, Mef2 is the only known gene required for terminal 
differentiation in every muscle type to date. 
 
2.5.3. Mef2 regulates several genes involved in different 
aspects of muscle development 
 
Mef2 is genetically downstream of twist and snail, and the activation by 
twist was shown to be direct (Cripps et al., 1998). A comprehensive study of Mef2 
activity throughout development has now shown that Mef2 directly regulates target 
genes at all stages of muscle development (Sandmann et al., 2006b), and the 
integration of twist in the regulation of the same enhancers draws exciting parallels 
to the regulation of MRFs and Mef2 family members of common targets in 
vertebrates. 
 Interestingly, Mef2 can activate itself, and this mechanism of 
autoregulation probably allows Mef2 to reinforce the muscle phenotype throughout 
a myogenesis (Cripps et al., 2004). Mef2 was also shown to directly activate targets 
like Tropomyosin I (Tmn I) (Lin et al., 1996) (Lin and Storti, 1997), β-Tubulin60D 
(βTub60D) (Damm et al., 1998), Muscle LIM protein at 60A (Mlp60A) and Muscle 
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LIM protein at 84B (Mlp84B) (Stronach et al., 1999), and Actin57B (Kelly et al., 
2002). Most of these genes have a structural role, either in the cytoskeleton or as 
part of the contractile apparatus, and can therefore account in part for the defects in 
terminal differentiation seen in Mef2 mutants. However, the broad spatio-temporal 
expression of Mef2 hints at a more general role in myogenesis, from early through 




2.6. lame duck (lmd) a Zn-Finger transcription 
factor essential for FCM specification and myoblast 
fusion  
 
2.6.1. lmd is expressed specifically in FCMs during the 
time of myoblast fusion 
 
lame duck (Duan et al., 2001) (also known as gleeful (Furlong et al., 2001a) 
and minc (Ruiz-Gomez et al., 2002)) is a Zn-Finger transcription factor of the Gli 
superfamily. lmd is expressed between stages 10 and 14, noticeably during the time 
of muscle fusion. It is first detected at late stage 10 in the primordia of the visceral 
mesoderm (VM). This expression continues through stage 11 and lmd is apparently 
expressed in both FCs and FCMs of the VM (Ruiz-Gomez et al., 2002). At this 
stage there is a transition of expression from the VM to the somatic mesoderm. In 
the somatic mesoderm, however, expression is mainly restricted to FCMs, with 
little if any expression in somatic FC as judged by rP298 co-staining. By stage 12 
lmd expression is lost from the VM and continues in the SM until stage 13-14. At 
stage 15 lmd RNA can only be found in the gonadal mesoderm (Ruiz-Gomez et al., 
2002). The expression pattern of Lmd obtained with an antibody raised against the 
N-terminal domain of the protein is similar to the RNA pattern obtained by in-situ 
hybridization of lmd (Duan et al., 2001). It should be noted that lmd is expressed 
only in the types of muscle known to undergo muscle fusion (somatic, visceral) but 
not of the muscle types that do not fuse (heart) (Duan et al., 2001), with the 
gonadal mesoderm being the exception (Ruiz-Gomez et al., 2002). Interestingly, 




2.6.2. lmd loss-of-function results in a lack of FCM 
differentiation and block of fusion. 
 
lmd mutants show a general block of pharyngeal and somatic muscle 
fusion, whereas the VM and heart apparently develop normally (Duan et al., 2001). 
The phenotype can be reasonably rescued with the expression of Lmd driven by 
Twist-Gal4 (Ruiz-Gomez et al., 2002). 
In lmd mutants, the early pan-mesodermal expression of Mef2 is normal, 
indicating that early muscle specification is unaffected, which is in accordance 
with lmd’s relatively late expression pattern. However, later expression of Mef2 in 
somatic muscle is severely reduced. FCs can be detected with the FC-specific 
rP298-lacZ line, and the specification of individual FCs appears unaffected as 
judged by the expression of the identity genes Kr, ladybird and nau. Consistently 
with this normal specification, MHC stains reveal the presence of mononucleated 
mini-muscles. The FCs acquire their specific identity, finding their appropriate 
position, elongating, attaching to the ectoderm and expressing myosin, but there is 
no fusion with any FCMs. On the other hand, the FCM-specific marker sns is not 
expressed in the SM of lmd mutant embryos. Therefore, the reduction of Mef2 in 
the somatic muscle seems to be due to loss of Mef2 staining in the FCM 
population. However, this reduction is not caused by a loss of these cells as 
undifferentiated FCMs can still be detected by their abnormally prolonged twist 
expression. While wild-type FCMs lose twist expression upon differentiation at 
stage 11-12, lmd mutant FCMs do not differentiate and retain twist staining up to 
stage 14. Furthermore, in Notch (N) and Delta (Dl) mutants, where the 
specification of FCMs is unfavored (section 2.3.3) lmd expression is severely 
diminished (Ruiz-Gomez et al., 2002).  Therefore, lmd mutants appear to have a 
defect in the correct differentiation of FCMs. 
The phenotype of lmd mutant embryos differs significantly from those of 
other fusion genes. In  sns, duf+rst, mbc, blow, ants/rols7 mutants, FCMs continue 
to express Mef2 and MHC, indicating that the cells have differentiated but failed to 
fuse. In lmd mutants, segregation of FCs and FCMs occurs, as judged by FC 
development, but the differentiation of FCMs is blocked at an early stage and the 
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cells fail to both reduce twist expression and maintain Mef2 expression. These cells 
do not develop into fully differentiated FCMs, revealing a specific differentiation 
program in this cell type. 
Visceral muscle (VM) appears to be unaffected in lmd mutants, even 
though the TF is expressed there, as judged both by the expression of general 
muscle markers like Mef2 and MHC. Gut constrictions are normal, as is the 
expression of VM specification markers bagpipe (bap) and Fasciclin III (Fas3). 
Interestingly, FCM-specific sns is completely abolished in the SM but not in the 
VM of the lmd mutants, again suggesting that the VM and SM have different 
trancriptional programs regulating myoblast fusion (Ruiz-Gomez et al., 2002). Sns 
is the FCM receptor mediating recognition before fusion (section 2.3.4.1), and the 
lmd loss-of-function phenotype in SM is probably mediated at least in part by the 
SM-specific loss of Sns.  Heart muscle development is also normal as judged by 
morphology, Mef2 and MHC expression (Duan et al., 2001). 
 
2.6.3. lmd is a member of the Gli family of TFs, and can 
directly activate Mef2 
 
lmd encodes a protein with 866 a.a. that contains five C2H2-type zinc 
finger domains. These zinc finger domains share considerable homology to the Gli 
family of transcription factors. The homology is restricted to the Zn-fingers, in 
particular Zn-fingers 3-5, with high divergence in the first two fingers and no 
homology in the remaining protein. The Lmd protein is therefore considered to be  
a member of the Gli superfamily of transcription factors, which also includes the 
Drosophila gene cubitus interruptus (ci) (Duan et al., 2001) (Ruiz-Gomez et al., 
2002).  
Ci/Gli are the main effectors of the Hedgehog signaling pathway in 
Drosophila and in vertebrates and are know to act both as activators and repressors 
of transcription. The protein is proteolyticaly cleaved in the absence of signaling, 
and acts as a transcriptional repressor. Signaling inhibits the cleavage and the 




2.6.4. The activity of Lmd is regulated by distinct 
posttranscriptional mechanisms  
 
In contrast to Mef2, Lmd protein can be found both in the nucleus and in 
the cytoplasm of FCMs. Furthermore, Lmd was shown to activate the transcription 
of Mef2 by directly binding to the IEd5 (Nguyen and Xu, 1998) enhancer, and 
there was a correlation between nuclear localization of Lmd and activation of Mef2 
in vivo: where Lmd is strictly cytoplasmic there is no detectable Mef2 (Duan et al., 
2001). This showed Lmd to be a direct activator of Mef2, but also hinted at a 
dynamic regulation of Lmd’s activity at least in part dependent on its nuclear 
localization.  
Further studies have shown that Lmd’s activity can be modulated by 
distinct posttranscriptional mechanisms (Duan and Nguyen, 2006). A nuclear 
localization sequence (NLS) present in the Zn-Finger domain is responsible for the 
nuclear import of Lmd. An N-teminal “I” domain and a C-terminal “II” domain are 
involved in cytoplasmic retention of the protein. It is not yet clear whether these 
domains act by masking the NLS (directly or indirectly), or/and if they could be 
involved in interaction with the microtubule network leading to cytoplasmic 
retention. In either case, a putative unknown activating factor would suppress these 
two domains, allowing Lmd to move to the nucleus and become active. The 
subcellular localization of Ci was shown to be regulated by microtubule dependent 
and independent mechanisms (Wang and Jiang, 2004), and a similar mechanism 
could potentially be used to regulate Lmd.  
The regulation of activity by localization is crucial for the correct function 
of Lmd. Reintroducing the full length protein leads to extensive rescue of the 
mutant phenotype. Overexpression of the protein throughout the mesoderm with a 
twist-Gal4 driver produces only mild defects, indicating that the excess protein can 
be conveniently regulated by the mechanisms in place. Conversely, exclusively 
nuclear - hence constitutively active - truncated forms cause severe defects when 
over-expressed, and have poor rescue capabilities, indicating posttranscriptional 
regulation of Lmd via the  “I” and “II” regulatory modules is essential.  
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Lmd also contains a putative SH3 domain binding site, as well as a putative 
PKA phosphorylation site. Mutation of either site leads to a hyperactive protein 
without disturbing its intracellular localization. It is tempting to draw parallels with 
the regulation of Ci, where phosphorylation by PKA leads to proteolysis of the 
activating Ci-155 to repressive Ci-75, with the PKA site mutant being a 
hyperactive protein (Price and Kalderon, 1999). However, a cleaved form of Lmd 
could not be detected by Western blot, and increased or decreased PKA function in 
the mesoderm does not seem to cause any obvious muscle defects. Hence it is 
likely that an unknown kinase is responsible for regulation at this PKA site, and it 
might work without promoting cleavage of Lmd (Duan and Nguyen, 2006). 
In summary, Lmd activity is regulated by its nuclear localization and by 
changes at two sites that modulate the protein’s activity independently of nuclear 
localization. This complex regulation, shows some parallels to the regulation of Ci, 
raising the question whether Lmd could also have a dual role as both activator and 




2.7. Synergistic cooperation on common enhancers 
allows complex spatio-temporal regulation   
While Mef2 has been considered a gene essential for terminal 
differentiation and myoblast fusion, its broad spatio-temporal expression 
throughout development suggested a more general role in myogenesis. Looking at 
the array of targets recently identified, it becomes apparent that Mef2 activates 
different batteries of genes in different temporal windows (Sandmann et al., 
2006b). It has been suggested that rising levels of Mef2 could account in part for 
this effect: as development progresses, the concentration of active Mef2 would 
increase and satisfy the higher requirements of late target genes (Elgar et al., 
2008). However, it was also found that Twist is involved in the regulation of early 
targets of Mef2 on common enhancers (Sandmann et al., 2006b). The spatio-
temporal overlap of the two factors reinforces each other, increasing the specificity 
of the regulation.  
Additional interactions have been reported between Mef2 and other factors 
acting on common enhancers. Both GATA4 (Morin et al., 2000) and Hand1 
(Morin et al., 2005) can act synergistically with the Mef2 family to activate 
enhancers functional during vertebrate heart development. In Drosophila muscle 
development, it has recently been found that Mef2 cooperates with vestigial (vg) 
and scalloped (sd) to activate genes in different subsets of developing myoblasts 
(Deng et al., 2009). A very interesting report on the function of holes in muscles 
(him) has shown this gene to be a repressor of Mef2 gene activation by recruiting 
the general repressor Groucho (Gro) (Liotta et al., 2007). All of these interactions 
allow or prevent the broadly expressed Mef2 from activating genes in precise 
spatio-temporal locations. It is likely that other factors are required to explain the 
specificity of Mef2 gene activation in other different myoblast populations.  
The transcription factor lmd has a more restricted expression pattern in 
mid-embryogenesis than that of Mef2. lmd is expressed specifically in FCMs and is 
required for the specification of this population. In addition, both lmd and Mef2 
mutant embryos suffer from a similarly severe block of myoblast fusion, making 
lmd a prime candidate to act as a modulator of Mef2’s activity in the fusion 
competent myoblast population. 
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3. Aim of the project 
 
The aim of this project was to get a better understanding of the connection 
between combined regulation of a common process by two transcription factors 
(resulting in an identical specific phenotype) and combinatorial input these two 
transcription factors binding to shared enhancers. I assessed the contribution of 
each transcription factor on common enhancers using different in vivo and in vitro 
approaches to better understand the logics of target gene regulation.  
The process chosen for analysis, myoblast fusion, is the process by which 
founder cells and fusion competent myoblasts fuse in Drosophila melanogaster 
forming the syncitial myotubes that will then differentiate into larval muscle. This 
process has been shown to integrate the inputs of two transcription factors, Mef2 
and lmd, with the interesting point that loss-of-function mutations in either of them 
leads to a similar complete block in myoblast fusion. More transcription factors 
have been identified whose loss-of-function mutation affects different muscle 
groups (“identity genes”), but lmd and Mef2 are the only known transcription 
factors that affect all muscle fusion, indicating a general role in regulation the 
process. 
The study starts with an analysis of stage-specific expression profiling and 
ChIP-on-chip data for both Mef2 and lmd collected by Thomas Sandmann in the 
Furlong lab. Comparing the target list of the two TFs it was clear that most of the 
targets of lmd where also regulated by Mef2 on a common enhancers. It was also 
striking to see that both Mef2 and lmd seemed to be able to activate and repress the 
expression of genes in this data set. A number of questions highlight the aims of 
this study: 
 What is the individual input of each TF on a common enhancer? 
How do these inputs relate to the final result of enhancer/gene regulation? Do lmd 
and Mef2 act cooperatively of simply additively? Can Lmd or  Mef2 act as direct 
transcriptional repressors?  
 The final aim of this project was to learn more about the nature of 
combinatorial regulation by different transcription factors on common enhancers, 
in the context of a developmental process. 
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1.0x Objective Planapo Leica 
10x ocular (35mm, 2.5x, 4”x5”) Zeiss 
16x/0.50 Plan-Neofluar Objective Zeiss 
20x/0.50 Plan-Neofluar Objective Zeiss 
ABI PRISM 7500 Sequence Detection System Applied Biosystems 
Analytical scales, AE50 Mettler 
Axiophot Light Microscope  Zeiss 
Centrifuges 5415D, 5417C, 5810 Eppendorf 
FireCam 1.1.1 software Leica 
Electrophoresis chamber Mini-Sub Cell GT BioRad 
Electrophoresis chamber Wide Mini-Sub Cell GT BioRad 
Nanodrop Spectrophotometer ND-1000;  Nanodrop Technologies 
Nanodrop 3.1.0 Software  Coleman Tech. Inc. 
Rotary Mixer (Model 34526) Snijder 
Shaker table Gyrotory (Model G2) New Brunswick Scientific 
Shaker table Nutator (220V) Adams 
Speed-Vac Concentrator 5301 Eppendorf 
Stereo Microscope MZ 16 FA Leica 
Stereo Microscope Stemi SV6 Zeiss 
Stereo Microscope Lamps KL 1500 LCD Schott 
Thermal Cycler PTC-200 Multicycler DNA engine MJ Research Peltier 
Thermal Cycler PTC-225 DNA Engine Tetrad MJ Research Peltier 
Water bath Thermomix 5BU B.Braun Biotech Internat. 
Water bath GD100 Grant 
Water bath MP Julabo 
Confocal Microscope Leica SP5  Leica 
Confocal Microscope Software Leica 
VICTOR® Light 1420 Luminescence Counter PerkinElmer 
VICTOR software PerkinElmer 
 




Name Catalog nr. Vendor 
10x UTP-mix (BioPrime CGH Kit) 18095-011 Invitrogen 
Agarose (LMP) 15517-022 Gibco 
Ampicillin A9518 Sigma 
Biorad protein assay 500-0001 Biorad 
Boric acid (99.5%) B7660 Sigma 
Bovine Serum Albumine (BSA, 
fraction V) A-7906 Sigma 
Cellfectene® 10362-010 Invitrogen 
Chloroform C2432 Sigma 
Cy3-dUTP fluorophore PA53022 Amersham Biosciences 
Cy5-dUTP fluorophore PA55022 Amersham Biosciences 
DAB substrate 1718096 Roche 
DEPC treated water 9920 Ambion 
DMSO 8.02912.10 Merck 
deoxynucleoside-5’-triphosphate 
(dNTPs) for PCR  1 277 057 Roche 
DNAse I (RNAse free) 0776785 Roche 
EDTA E6758 Sigma 
Ethanol  Merck 
Ethidium bromide E-1385 Sigma 
Exo-Klenow fragment DNA 
polymerase I  
(40 U/µl, BioPrime CGH Kit)  
18095-011 Invitrogen 
Formamide F5786 Sigma 
Formaldehyde (16%, methanol) 18814 Polyscience Europe 
Glycogen 901393 Roche 
Glycerol 4043-00 J.T.Baker 
Hydrogen peroxide H1009 Sigma 
n-heptane H9629 Sigma 
NP 40 ( = IGEPAL) 13021 Sigma 
Methanol 106009 Merck 
Pepstatin P5318 Sigma 
Pfu DNA-polymerase (native) 600135 Stratagene 
Phenyl methyl sulfonyl fluoride 
(PMSF) P7626 Sigma 
Powerscript reverse transcriptase 639500 Clontech 
Proteinase K 745723 Roche 
2-propanol 1.09634.2500 Merck 
RNA Polymerase SP6 M0207 New England Biolabs 
RNA Polymerase T3 1031163 Roche 
RNA Polymerase T7 881767 Roche 
RNase A 1006693 Qiagen 
RNAse inhibitors 15518-012 Invitrogen 
Sodium acetate 9740 Ambion 
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Sodium chloride 1.06404.5000 Merck 
Sodium dodecyl sulfate L6026 Sigma 
SSC (20x) 9765 Ambion 
Sybr-Green PCR Master Mix 4309155 Applied Biosystems 
Taq-DNA polymerase  EMBL 
T4 DNA-ligase  799099 Roche 
Tris-base T6791 Sigma 
Triton-X-100 T8787 Sigma 
TSA –Plus Fluorescence Palette 
System 
NEL 760 Perkin Elmer 
Tween-20 P-7949 Sigma 
Restriction endonucleases  New England Biolabs 
Western Blocking Reagent 11 921 673 001 Roche 
 
 
4.1.3. Miscellaneous materials 
Name Catalog nr. Vendor 
1 kb-Ladder N3232L New England Biolabs 
100 bp-Ladder N3231L New England Biolabs 
ABIprism 96-well optical reaction plates 4306737 Applied Biosystems 
AeroDuster 100  Servisol 
BioPrime CGH Genomic DNA Labeling 
System 18095-011 Invitrogen 
Brown microcentrifuge tubes (1.5 ml) 1-6180 NeoLab 
Brushes (various sizes) 9.172.050 Buddeberg 
E.coli DH5α, chemocompetent 18265-017 Invitrogen 
Filter Durapore 0.22 µm  Millipore 
Fisher finest premium glass cover slips 
(24x60-1) 12-548-5P Fisher Scientific 
Forceps (110 mm, straight) E-7009 NeoLab 
Glass coplin chars and slide holders  Sigma-Aldrich 
Diamond pen 1-7621 NeoLab 
Hybridisation chambers  Corning 
Microscope glass slides (76x26 mm)  Menzel Glaeser 
MinElute PCR Purification Kit 28066 Qiagen 
MinElute Reaction Clean-up Kit 28204 Qiagen 
Normal Goat Serum (NGS)  Vector Labs 
Parafilm  PM-996 Pechiney 
PCR tubes (0.5 ml, thin walled) 0030 124.502 Eppendorf 
PCR tubes (0.2 ml, thin walled) 0030 124.332 Eppendorf 
Phase-lock heavy gel tubes (2 ml) 0032-005-152 Eppendorf 
Protein A sepharose beads (PAS, CL4B) P9424 Sigma 
QIAprep Spin Miniprep Kit (250) 27106 Qiagen 
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QIAquick PCR purification kit 28104 Qiagen 
QIAquick minelute PCR purification kit 28104 Qiagen 
Safe-Lock Tubes 1.5 ml 28004 Eppendorf 
Safe-Lock Tubes 2.0 ml 0030 120.094 Eppendorf 
Siliconized microcentrifuge tubes (1.6 
ml) 710176 Biozym 




4.1.4.1. Primers for enhancer cloning 
Name Sequence Restriction site 
Act57B-KpnI-F AATGGTACCTCCCCCACCGTAACGAACC Kpn I 
Act57B-SacI-F AATGAGCTCTCCCCCACCGTAACGAACC Sac I 
Act57B-SacI-R AAAGAGCTCAAGTATCGCCGCGTTGGTACTC Sac I 
Act57B-NheI-F AATGCTAGCTCCCCCACCGTAACGAACC Nhe I 
Act57B-NheI-R AAAGCTAGCAAGTATCGCCGCGTTGGTACTC Nhe I 
Act57B-XhoI-R AAACTCGAGAAGTATCGCCGCGTTGGTACTC Xho I 
bTub60D-KpnI-F TAAGGTACCGATGGCTGTGTATCCATGAGATAC Kpn I 
bTub60D-SacI-R ATTGAGCTCTTCAAACGTCAGTTTTGGACG Sac I 
bTub60D-SacI-F TAAGAGCTCGATGGCTGTGTATCCATGAGATAC Sac I 
bTub60D-NheI-R ATTGCTAGCTTCAAACGTCAGTTTTGGACG Nhe I 
bTub60D-NheI-F TAAGCTAGCGATGGCTGTGTATCCATGAGATAC Nhe I 
bTub60D-XhoI-R ATTCTCGAGTTCAAACGTCAGTTTTGGACG Xho I 
blow-KpnI-F AAAGGTACCGGGATGTCGTAATGACAC Kpn I 
blow-SacI-R CGGGAGCTCGGCTTCTAAATAGTATTGTATC Sac I 
blow-SacI-F AAAGAGCTCGGGATGTCGTAATGACAC Sac I 
blow-NheI-R CGGGCTAGCGGCTTCTAAATAGTATTGTATC Nhe I 
blow-NheI-F AAAGCTAGCGGGATGTCGTAATGACAC Nhe I 
blow-XhoI-R CGGCTCGAGGGCTTCTAAATAGTATTGTATC Xho I 
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Name Sequence Restriction site 
CG5080-XhoI-F TAGCTCGAGGCTGGAAAGGGTAGGG Xho I 
CG5080-NheI-R AATGCTAGCTGGATGCAGCCCATG Nhe I 
CG5080-NheI-F CAGGCTAGCGCTGGAAAGGGTAGGG Nhe I 
CG5080-MluI-R AATACGCGTTGGATGCAGCCCATG Mlu I 
CG5080-MluI-F TAGACGCGTGCTGGAAAGGGTAGGG Mlu I 
CG5080-KpnI-R GACGGTACCTGGATGCAGCCCATG Kpn I 
CG9005-KpnI-F TTTGGTACCTGGTGCTCTTCTTCCTCCAC Kpn I 
CG9005-SacI-R AACGAGCTCCATAAATGAAATGTAACGAACTCG Sac I 
CG9005-SacI-F TTTGAGCTCTGGTGCTCTTCTTCCTCCAC Sac I 
CG9005-NheI-R AACGCTAGCCATAAATGAAATGTAACGAACTCG Nhe I 
CG9005-NheI-F TTTGCTAGCTGGTGCTCTTCTTCCTCCAC Nhe I 
CG9005-XhoI-R AACCTCGAGCATAAATGAAATGTAACGAACTCG Xho I 
9416(373)-KpnI-F AAAGGTACCGGCCATTTCAAATGATGATCG Kpn I 
9416(373)-SacI-R AAAGAGCTCCCATATTTATATTCGGCATTTTGG Sac I 
9416(373)-SacI-F AAAGAGCTCGGCCATTTCAAATGATGATCG Sac I 
9416(373)-NheI-R AAAGCTAGCCCATATTTATATTCGGCATTTTGG Nhe I 
9416(373)-NheI-F AAAGCTAGCGGCCATTTCAAATGATGATCG Nhe I 
9416(373)-XhoI-R AAACTCGAGCCATATTTATATTCGGCATTTTGG Xho I 
CG14687(5')NheI-F TAGCTAGCCATGATCCGACGTGGAGAGC Nhe I 
CG14687(5')SalI-R ATAGTCGACCGATGCTGATTCCGGTGAG Sal I 
CG30035-NheI-F AAAGCTAGCCGAATCTTGAACTTCAGTGCC Nhe I 
CG30035-XhoI-R AAACTCGAGCCCACCCGAAAGTTGAATTG Xho I 
gol2.9-KpnI-F AAAGGTACCCAATCTACTGAATCTAACGC Kpn I 
gol2.9-BglII-R AAAAGATCTGAGGTCTACTACCTTTGC Bgl II 
ttk(e)-KpnI-F AAAGGTACCGGAAACGGCGTCGTCG Kpn I 
ttk(e)-SacI-R AAAGAGCTCAAACTTGGATTTTTCCAGTGTGG Sac I 
ttk(e)-SacI-F AAAGAGCTCGGAAACGGCGTCGTCG Sac I 
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Name Sequence Restriction site 
ttk(e)-NheI-R AAAGCTAGCAAACTTGGATTTTTCCAGTGTGG Nhe I 
ttk(e)-NheI-F AAAGCTAGCGGAAACGGCGTCGTCG Nhe I 
ttk(e)-XhoI-R AAACTCGAGAAACTTGGATTTTTCCAGTGTGG Xho I 
ttk(l)-NheI-F AATGCTAGCTATTCAACTTAAAGTCGGTGCAG Nhe I 
ttk(l)-XhoI-R AATCTCGAGTGATCACACGGCACGAAC Xho I 
ttk(l)-KpnI-F AATGGTACCTATTCAACTTAAAGTCGGTGCAG Kpn I 
ttk(l)-SacI-R AATGAGCTCTGATCACACGGCACGAAC Sac I 
ttk(l)-SacI-F AATGAGCTCTATTCAACTTAAAGTCGGTGCAG Sac I 
ttk(l)-NheI-R AATGCTAGCTGATCACACGGCACGAAC Nhe I 
sug-KpnI-F TTTGGTACCTTCGCCTCTCATAATAATGCC Kpn I 
sug-NheI-R AATGCTAGCTCCCATTCCCATTCCCATC Nhe I 
sug-NheI-F TTTGCTAGCTTCGCCTCTCATAATAATGCC Nhe I 
sug-XhoI-R AATCTCGAGTCCCATTCCCATTCCCATC Xho I 
sug-XhoI-F TTTCTCGAGTTCGCCTCTCATAATAATGCC Xho I 
sug-BglII-R AATAGATCTTCCCATTCCCATTCCCATC Bgl II 
 
 















CG5080-qPCR1a-F  AGGGGGTTAGGGTTAGTGGC 
CG5080-qPCR1a-R  ATTAATGGTCCGCAGCGAG 
CG5080-RT3-F  GGGCCGATGTGGATTCG 
CG5080-RT3-R  CTCCGCGATGTGTGACATGT 
CG9005-RT1-F  AATCCCCCTCACTTACCTTTCAA 
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4.1.5. Antibodies 
Antibody Dilution Cat. nr. Source 
Rabbit α-GFP IgG (0.5mg/ml) 
(Immunohistochemistry) 1:300 TP401 
Torrey Pines 
Biolabs 
Donkey α-Rabbit IgG, biotin-coupled 




(Fluorescent insitus)  1207733 Roche 
Anti-Fluor-Peroxidase  
(Fluorescent insitus)  1426346 Roche 
Anti-Fluor- Alkaline Phosphatase 
(Colorimetric)  1426338 Roche 
Anti-Dig- Alkaline Phosphatase 




Name Purpose Source 
pH-stinger Generation of transgenic Drosophila melanogaster GFP-reporter lines 
(Barolo et al., 
2000) 
pAc5.1/V5-hisB Expression of TFs for in vitro luciferase assays Invitrogen 
pGL3-Promotor Start vector for pGL3-hsp70 Promega 
pGL3-hsp70 Cloning of enhancer sequences for luciferase assays or transcriptional regulation This study 
“copia”-Renilla Renilla luciferase transfection control Steve Cohen 
pCRII-TOPO Template for in vitro transcription reactions Invitrogen 




Name Purpose Source 
Vector NTI Visualization of cloning projects, DNA sequence analysis Invitrogen 
Tm4 Microarray normalization and analysis TIGR, USA 
ImageJ Image processing NIH 
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4.1.8. Media, solutions and buffers 
 
Complete SFM 500 ml SFM 
45 ml 200mM L-Glutamine 
5 ml Penicillin Streptomycin (100x) 
 
LB+Amp –medium: 10 g Trypton Peptone 
5 g Bacto-yeast extract 
10 g NaCl 
ad 1 l with H2O 
after autoclaving: 
ad 1 ml 1000x Ampicillin 
 
LB+Amp –plates: 10 g Trypton Peptone 
5 g Bacto-yeast extract 
10 g NaCl 
15 g Agar-Agar 
ad 1 l with H2O 
after cooling off to 50°C: 
add 1 ml 1000x Ampicillin 
 
SOC -medium: 5 g Bacto-yeast extract 
20 g Bacto-Peptone 
20 g Dextrose 
10 mM NaCl 
2,5 mM KCl 
10 mM MgSO4 
ad 1 l with H2O 
 
Standard fly medium: 1 l H2O 
12 g agar 
80g corn powder  
18 g dry yeast 
22 g sirup 
10 g soy powder 
6.2 g propionic acid 
80 g malt extract 
2.4 g nipagin 
 
1kb DNA ladder: #N 3232 L (NEB)  
1000µl of 500 µg/µl 1kb-ladder  
diluted to 1 µg/10µl in 700 µl  
6x Loading Buffer (without xylene cyanol) and 
3300 µl 1x TE-buffer 
used at 1 µg/10µl working stock 
 




# N323L (NEB)  
500 µl of 500 µg/µl 100bp DNA-ladder diluted to 1 
µg/10 µl in 350 µl 6x Loading Buffer (without 
xylene cyanol) and 1650 µl 1x TE-buffer 
use: 0.5 µg/10 µl working stock 
 
1000x Ampicillin: 100 mg/ml, sterile 
 
20x PBS: 175.2 g NaCl 
44.8 g KCl 
46.6 g Na2HPO4 x 12 H2O 
4.2 g KH2PO4 
 
50x TAE: 2 M Tris/glacial acetic acid,  
pH 7.7  
5 mM EDTA in H2O 
 
6x Loading Dye: 30% glycerol  
0.25% bromophenol blue 
0.25% xylene cyanol 
 
DAB Staining solution: 
 
3,3’ Diaminobenzidine (DAB) staining solution 
diluted 1:20 in 3% H2O2 
 
Fixing solution: 125 µl 16% formaldehyde  
(4% final)  




500 µl Fixing solution 
500 µl n-heptane 
 
Methanol/heptane: 50% methanol 
50% n-heptane 
 
Methanol/PBT: 50% methanol 
50% PBT 
 
PBT: 1x PBS 
0.1% Triton-X-100 
 
PBTween 1x PBS 
0.1% Tween-20 
 





+ 0.2% Normal Goat Serum (NGS) 
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A + B solutions  
(Vector Laboratories) 
1:100 in PBT/BSA each;  




10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
 
2x Carbonation Buffer 120 mM Na2CO3, 80 mM NaHCO3 
DEPC H2O, pH 10.2 
 
Hyb-A Buffer 50% Formamide 
5x SSC pH 5.0 
100 µg/ml salmon sperm 
0.1% Tween 20 
50 µl/ml Heparin 
 
Hyb-B Buffer 50% Formamide 
5x SSC pH 5.0 
 
 
4.1.9. Fly lines 
Genotype Source 
 
(Duan et al., 2001) 
 (Bour et al., 1995) 
 (Lilly et al., 1995) 
 (Brand and Perrimon, 1993) 
 (Sandmann et al., 2006b) 
 Previously published as UAS-glf 
(Furlong et al., 2001a) 
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4.2. Methods 
4.2.1. Molecular Biology and Biochemistry  
4.2.1.1. Cloning of constructs to generate transgenic Drosophila 
melanogaster reporter strains 
 
To investigate the regulatory potential of genomic DNA regions transgenic 
Drosophila melanogaster reporter lines were generated. Evaluating conservation of 
non-coding sequences in other Drosophila species allowed further refinement of 
the enriched coordinates.  Fragments within the following coordinates were cloned 
into the pH-stinger vector (Barolo et al., 2000) and germ-line transformed into 
Drosophila melanogaster white- flies: chr2R:16,451,010-16,451,608 (Act57B), 
chr2R:3,096,924-3,097,695 (blow), chr2R:19,817,121-19,817,497 (βTub60D), 
chr3R:6,616,700-6,618,790 (CG14687), chr2R:7,181,666-7,183,332 (CG30035), 
chr2L:1,162,146-1,162,550 (CG5080), chr2R:14,886,256-14,886,651 (CG9416), 
chr2R:20,586,673-20,589,678 (gol), chr2R:8,441,630-8,442,972 (sug) 
chr3R:27,529,670-27,530,400 (ttk). (Coordinates based on D. melanogaster 
genome release 4.2.)  For all constructs but CG5080’s regulatory region, at least 
two independent transgenic lines were obtained and assayed.  
 
4.2.1.2. Cloning of constructs for in vitro luciferase assays  
 
The direct activation of target enhancers by Mef2 and Lmd in vitro was 
tested by luciferase assays. After initial testing of the pGL3-Promotor vector 
(Promega), the expression from the sv40 promotor was found to be insufficient in 
Schneider 2 (S2) cells. The sv40 promotor was cut out (Bgl II / Hind III) and 
replaced with the hsp70 promoter from pH-Stinger (Bgl II / Hind III) increasing 
the activation in S2 cells. At the same time, the enhancers were trimerised in order 
to achieve higher activation. 
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Fragments within the following coordinates were amplified using Pfu DNA 
Polymerase (Stratagene) from genomic DNA and cloned into the pGL3-hsp70 
vector: chr2R:16,451,010-16,451,608 (Act57B), chr2R:3,096,924-3,097,695 
(blow), chr2R:19,817,121-19,817,497 (βTub60D), chr3R:6,616,700-6,618,790 
(CG14687), chr2R:7,181,666-7,183,332 (CG30035), chr2L:1,162,146-1,162,550 
(CG5080), chr2R:14,886,256-14,886,651 (CG9416), chr2R:20,586,673-
20,589,678 (gol), chr2R:8,441,630-8,442,972 (sug) chr3R:27,529,670-27,530,400 
(ttk), (Coordinates based on D. melanogaster genome release 4.2.). 
Mef2 and Lmd 3HA-epitope fusions in pUAST (Sandmann et al., 2006b) 
were digested (EcoRI / XbaI) and cloned into pAC-5.1-V5-hisB (EcoRI / XbaI).  
 
4.2.2. Histological techniques  
4.2.2.1. Colorimetric In situ hybridization 
 
The following ESTs were used to generate digoxigenin or fluorescein-
labeled probes: RE53159 (βTub60D), LD04994 (Act57B), LD34147 (CG5080), 
LP02193 (blow), LD36528 (sug), RE74890 (CG14687), RE28322 (CG9416), 
GH20973 (gol), AT15089 (twi) and RE02607 (wg).  The full-length sns cDNA was 
a kind gift from S. Abmayr.  
Colorimetric in situ hybridizations were done using standard protocols as 
described previously (Furlong et al., 2001a). Briefly, probes were synthesized and 
labeled for 2.5 hours at 37 ºC according to the following reaction: 
Table I – Probe labeling reaction for in situ hybridization 
Volume Reagent 
5 µl PCR product 
2 µl Transcription Buffer 
2 µl Dig or Fluo RNA Labeling Mix 
1 µl RNAse inhibitors 
1 µl RNA Polymerase 
9 µl DEPC H2O 
20 µl Total Volume 
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The DNA template in this reaction was then digested for 15 min at 37 ºC 
with the addition of 2 µl RNAse-free DNAse I, and treated in Carbonation Buffer 
for 20 min at 65 ºC. The probe was subsequently precipitated and re-suspended in 
100 µl of Hyb-A buffer. 
Embryos previously fixed in formaldehyde and stored in ethanol were 
transferred to methanol and then to PBTween by a stepwise decrease in methanol 
content. They were then post-fixed for 20 min in 4% formaldehyde in PBS, and 
then washed in PBTween. A Proteinase K digestion (8 µg/ml in PBS) was 
followed by a second post-fixation and wash cycle. The embryos were then 
transferred to Hyb-B buffer by a stepwise decrease in PBTween content and pre-
hybridized in Hyb-A at 65 ºC for at least 3.5 hrs. At this point the probe was heated 
up to 80 ºC for 10 min, chilled on ice, added to the embryos at 1:50 (in Hyb-A) and 
hybridization was allowed to take place overnight at 65 ºC. 
The probe was washed off the embryos with Hyb-B (3x 30 min followed by 
3x 1 hr washes), and the embryos were transferred to PBTween by a stepwise 
decrease in Hyb-B content. The embryos were then blocked with Western 
Blocking Reagent at 1:5 in PBTween (2x 30 min at RT) and the first antibody was 
incubated overnight at 1:2,000 in PBTween with Western Blocking Reagent. 
The antibody was washed off with PBTween washes (6x 15 min at RT). 
The first TSA reaction was performed according to the manufacturer’s instructions 
at 1:50 in amplification buffer for 5 min. This was immediately followed by 
PBTween washes (6x 20 min at RT). The embryos were then mounted in 80% 
glycerol. In the case of double in situ hybridizations (Section 4.2.2.2), the last 
washing steps were followed by a peroxide inactivation reaction with 3% H2O2 in 
PBTween (15 min at RT). After four 15 min washes with PBTween, the embryos 
were again blocked in Western Blocking reagent and the whole process repeated 
for the second antibody (with the exception of the peroxidase inactivation 
reaction).  
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4.2.2.2. Fluorescent In situ hybridization 
 
Double fluorescent in situ hybridisations were done as described previously 
(Furlong et al., 2001a) (Section 4.2.2.1).  Probes were synthesized as described 
above (Section 4.2.2.1). The probe for GFP was made by amplifying the eGFP 
sequence from the pH-Stinger (primers J207, J208). As a T7-polymerase site was 
included in one primer, the amplified DNA could be utilized directly in the probe-
generation reaction. This probe was used for GFP mRNA-expression detection in 
transgenic animals placed in the mutant background of lmd and Mef2. 
To minimize experimental differences, the embryo fixations and the in situ 
hybridizations were done in parallel and the confocal imaging was performed with 




GFP expression in transgenic animals was detected by 
immunohistochemistry with rabbit α-GFP antibody (Torrey Pines Biolabs) at a 
concentration of 1:300, according to standard protocols. Biotinylated secondary 
antibodies were used in combination with the Vector Elite ABC kit (Vector 
Laboratories). 
 
4.2.3. Quantitative Real-Time Polymerase Chain Reaction 
(qPCR) 
 
Primer pairs were designed flanking putative Mef2 binding sites as well as 
a region of genomic DNA without putative Mef2 sites or expression in the 
mesoderm to be used as a negative control (in the 5’ region of the oskar gene). All 
of these primer pairs amplify a similar sized amplicon (50 bp) with similar CG 
content (50 bp amplicon (GC% 45-55). Reactions were as follows: 
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Table II - qPCR Reaction Mix 
Volume Reagent 
2 µl ChIP or mock eluate 
2.5 µl 2.5 µM primer A 
2.5 µl 2.5 µM primer B 
12.5 µl SYBR green PCR Master  mix 
5.5 µl Water 
25 µl Total Volume 
 
For each primer pair, a standard curve was determined in duplicate using 
serial dilutions from ca. 40 ng/ml sheared genomic DNA (1:10 to 1:10.000 
dilutions). The amplification reactions were performed and recorded on an ABI 
PRISM 7500 real-time PCR system (Applied Biosystems, Foster City, USA) using 
standard settings for absolute quantitation. Dissociation curves were recorded after 
each run to evaluate the amplification of uniform products. The results were 
converted into enrichment ratios by referring to the respective standard curve for 




4.2.4. Cell culture and Luciferase assays 
 
Schneider 2 cells (S2 cells) were sub-cultured in 96-well plates the day 
before transfection. A dense cell culture was diluted with Complete SFM medium 
to a concentration of 1.5 x 106 cells/ml. 100 µl of this suspension (1.5 x 105 cells) 
were aliquoted into each well of a 96-well plate, and cultured for 24 hrs at 25 ºC. 
The cells were then transfected with 0.5 ng of the “Copia-Renilla” transfection 
control vector, 50 ng of the enhancer-pGL3-hsp70 construct, and 1 to 10 ng of 
Lmd-pAc5.1/V5-hisB, Mef2-pAc5.1/V5-hisB, or both together. pAc5.1/V5-hisB 
was added as needed to ensure the total amount of DNA transfected in each well 
was the same (61.5 ng). Transfection was performed with Cellfectene Reagent 
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(Invitrogen) according to instructions by the supplier. The trasfection mixture was 
removed after 24 hrs and the cells were allowed to recover for a further 24 hrs with 
fresh Complete SFM medium. Luminescence as a measure of enhancer activity 
was assessed using the Dual-Luciferase® Reporter Assay System (Promega). The 
cells were lysed in 20 µl Passive Lysis Buffer (PLB) and Firefly and Renilla 
luciferase activities were assessed sequentially using 50 µl of LARII and Stop & 
Glo buffer respectively. The luminescence was read using a VICTOR Light 1420 
Luminescence Counter (PerkinElmer), and the reagents were injected 
automatically. The following program was used: 
 
1. 50 µl of LARII injected 
2. 1.6 s shaking (waiting time) 
3. 5 s luminescence reading (Firefly luciferase) 
4. 50 µl of Stop & Glo buffer injected 
5. 1.6 s shaking (waiting time) 
6. 5 s luminescence reading (Renilla luciferase) 
 
Three independent wells were assayed for every condition. All Firefly 
luciferase luminescence values in Counts Per Second (CPS) were normalized to the 
corresponding Renilla Luciferase CPS values. All values were compared to the 
average result of the negative control (empty pAc5.1-pGL3-hsp70) which was set 
to 1. Therefore, all results indicate a fold change in enhancer activation/repression 
compared to the control, ± Standard Error of the Mean (SEM). 
 
4.2.5. ChIP-on-chip and Expression profiling 
4.2.5.1. Chromatin Immunoprecipitation and DNA Amplification 
Embryo collections and chromatin immunoprecipitations were performed 
as described previously (Sandmann et al., 2006b) (Sandmann et al., 2006a). Two 
antisera were raised against the amino terminus of Lmd and purified from E. coli 
by poly-His tag affinity purification. Four independent staged wild-type embryo 
populations were collected at 6-8 and 8-10 hrs after egg-laying and fixed with 
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formaldehyde. For each time point, chromatin from all four populations was 
precipitated with both antisera as well as the respective preimmunesera, leading to 
a total of 16 reactions (8 mock, 8 anti-Lmd) per time point. DNA amplification, 
labeling and hybridizations were performed as described previously (Sandmann et 
al., 2006b) (Sandmann et al., 2006a) and dye swaps were included to account for 
possible dye biases. 
 
4.2.5.2. Expression Profiling of lmd Loss-of-Function Mutants 
The assayed lmd1 (Duan et al., 2001) line was outcrossed to wild-type flies 
(Canton S) twice to remove any spurious mutants. Six one-hour embryo collections 
were assayed in an expression profiling timecourse (between 5 and 11 hours after 
egg-laying). At each time point, 4 independent populations of lmd mutant and 
stage-matched Canton S embryos were collected and aged. Homozygous mutants 
were selected with an automated embryo sorter (Furlong et al., 2001a) (Furlong et 
al., 2001b). The staging of all collections was verified by formaldehyde fixation of 
a small sample to ensure that wild-type and mutant embryos were tightly stage 
matched. Total RNA was extracted using Trizol (Invitrogen, Carlsbad, US), 
amplified, reverse-transcribed and labelled as described previously (Sandmann et 
al., 2006b). 
 
4.2.5.3. Microarray data analysis 
For expression profiling analysis, mutant and stage-matched control cDNA 
was hybridized directly against each other.  Raw data was normalized using print-
tip LOESS. Differentially expressed genes were identified using Significance 
analysis of microarrays (SAM) (Tusher VG, 2001). Genes with a q < 1% and a fold 
change > 1.6 (log2 > 0.7 or < −0.7) were considered to be differentially regulated.  
Immunoprecipitated DNA from Lmd-specific or mock precipitations was 
hybridized against a total genomic reference DNA sample. Sequences significantly 
enriched by the anti-Lmd-antibodies were identified by comparing rank products 
(Breitling R, 2004) and the false-discovery rate was estimated. Only fragments 
with an FDR < 2% and a fold enrichment > 1.5 (log2 > 0.58 or < −0.58) were 
considered to be significantly enriched (Appendix, 8.1, Table III). 
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Automatic assignment of ChIP-enriched fragments to target genes was 
performed as described previously (Sandmann et al., 2006b). The majority of 
regions co-occupied by Mef2 and Lmd was independently assigned to the same 
target genes using either Mef2-mutant or lmd-mutant expression profiling data. For 
a small number of regions, data from this study indicated a more likely target gene 
than had been assigned previously with Mef2 data alone (Sandmann et al., 2006b); 
in these cases, the updated target prediction was chosen for further analysis. A 
complete list of ChIP-enriched regions, expression profiling results and target 
assignments is available in the Appendix. All raw microarray data is available from 
ArrayExpress (Lmd ChIP (E-TABM-895) and lmd expression profiling (E-TABM-
894).  Lmd- and/or Mef2-bound regions and mutant expression data can be 







5.1. Analysis of lmd expression profiling and ChIP-
on-chip data 
The first step taken to understand the interaction in transcriptional 
regulation between Mef2 and lmd was the identification of the direct target genes 
for each transcription factor. The approach used was twofold. Direct binding to 
genomic regions was assessed by Chromatin Immunoprecipitation (ChIP) followed 
by analysis on genomic tiling arrays (chip), a technique known as ChIP-on-chip. 
This technique reveals the genome location where each of the transcription factors 
bind in vivo, and this binding can then be allocated to specific genes. To 
complement this information, the direction of effect (activation/repression) was 
determined by performing expression profiling in the mutant backgrounds.  
In brief, genes were considered direct targets when they were assigned 
binding by a transcription factor (by ChIP-on-chip) and their expression was 
affected in the mutant background of that same transcription factor. 
All ChIP-on-chip and expression profiling experiments and data collection 
was done by Thomas Sandmann in the Furlong lab for both lmd and Mef2, and the 
data concerning Mef2 has already been analyzed and published (Sandmann et al., 
2006b). 
 
5.1.1. Genomic regions bound by Lmd in vivo 
 
ChIP-on-chip analysis provided an unbiased map of regions bound by Lmd 
in vivo. Lmd-bound DNA was precipitated from stage-matched embryos at two 
consecutive developmental time-points spanning most of the developmental stages 
during which lmd is expressed (stages 10-13) (Figure 10). For each time point, four 
independent chromatin immunoprecipitations were made, each using two different 
antisera raised against Lmd. Hence, eight independent experiments were performed 
per time-point, increasing the sensitivity and specificity of this approach. Potential 
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false targets that could arise from non-specific antibody binding were reduced, as 
genomic regions were considered bound only if they were significantly enriched 
with both antibodies 
The immunoprecipitated DNA was analyzed on microarrays containing 
overlapping 3kb fragments tiling across ~50% of the Drosophila genome 
(Sandmann et al., 2006b). 
 
 
Figure 10 - Schematic overview of lmd and Mef2 function during myogenesis and collected 
data-points. 
Lmd and Mef2 genome binding was assayed at two consecutive 2 hr time-points (orange bars), 
covering the stages of myoblast specification and fusion, the time window when both transcription 
factors are simultaneously expressed. This information was complemented by expression profiling 
of lmd and Mef2 mutant embryos at 4 one hr time points (blue bars). Adapted from (Sandmann et 
al., 2006b). 
 
By using a stringent criteria of a combined fold cutoff (> 1.5 (log2 > 0.58 
OR < -0.58)), and a False Discovery Rate (FDR) (< 2%), Lmd binding was 
detected at 154 unique genomic regions (Appendix, 8.1, Table III). Comparing this 
set of bound sequences with data obtained previously for Mef2 at the same stages 
of development  (fold cutoff > 1.6, q < 0.01) (Sandmann et al., 2006b) (Sandmann 
et al., 2006b) shows that 106 out of 154 (68.8%) Lmd-bound sequences are also 
bound by Mef2 at stages 10-14 (Figure 12 A). The overlap of co-bound regulatory 
elements suggests an extensive co-regulation of target genes by these two 
transcription factors. This is, moreover, a conservative estimate of enhancer co-
occupancy, as regions bound by one or both transcription factors just below the 





5.1.2. Known direct target genes are identified, 
underscoring the accuracy of the ChIP-on-chip results 
Mef2 is at this time the only known direct target of lmd, with the binding 
occurring at the IEd5 enhancer (Duan et al., 2001). sns, the first gene identified with 
specific FCM expression, was shown to be genetically downstream of lmd in the 
SM (but not in the VM) (Duan et al., 2001) (Ruiz-Gomez et al., 2002) and is a very 
likely candidate lmd target gene. Interestingly, the expression of blow in the SM 
has also been shown to be initially restricted to FCMs (Schroter et al., 2006), 
making it a third likely candidate for regulation by Lmd. 
ChIP-on-chip binding was indeed identified in the Mef2 locus, and 
specifically in fragments covering the only identified Lmd binding region to date 
(IEd5 fragment) Figure 11 A). Lmd binding is also detected on a previously 
characterized (Stute, 2004) enhancer of sns (Figure 11 B), confirming that sns is a 
direct target of Lmd. blow is identified as a direct target gene of Lmd as well, and 
binding can be seen in an upstream region previously identified as an enhancer 
(Schroter et al., 2006) (Figure 11 C). 
 
Figure 11 - Positive controls are recovered in the ChIP-on-chip data. 
(A) The known IEd5 enhancer region is recovered in both the Lmd and Mef2 ChIP-on-chip binding 
data. This was the only known Lmd direct target gene, but both the sns (B) and blow (C) locus 
reveal the presence of Lmd and Mef2 binding showing that both genes are actually direct target 
genes of Lmd. ChIP-on-chip fragments (about 3 Kb) are shown as stacks with the early time-point 
(6-8 hours) on top of the late (8-10 hours), for the Lmd (above line) and Mef2 (below line) 
experiments. Fragments labeled in red show binding above the threshold whereas fragments that do 
not meet this criterion are depicted in gray. Exons (gray) and introns (orange) are depicted at the 
bottom. Green arrows illustrate enhancers cloned for this study. 
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Expression of the bHLH transcription factor twist persists longer in lmd 
loss-of-function mutants than in wildtype embryos and direct repression by lmd has 
been proposed to underlie this phenotype (Ruiz-Gomez et al., 2002). Although the 
genomic region containing the twist locus is extensively covered by the 
microarray, no significant Lmd-binding can be detected (data not shown). Even 
though low-level Lmd-binding to the twist region below the detection limit of the 
assay cannot be excluded, this result suggests an indirect regulatory effect instead. 
The recovery of the known Mef2 IEd5 enhancer as well as binding close to 
the suspected targets sns and blow underscores the sensitivity of the ChIP-on-chip 
results. Moreover, a number of Lmd-bound regions overlap additional previously 
characterized regulatory regions, including enhancers of βTub60D (Hinz et al., 
1992), Act57B (Kelly et al., 2002), CG14687 and CG9416 (Sandmann et al., 
2006b). 
5.1.3. Defining direct targets from ChIP-bound regions 
Moving from directly bound genomic regions to the actual implicated 
genes is often a challenge, as regulatory regions in Drosophila can be located at 
varying positions and distances relative to the target gene (section 2.1). Therefore, 
a functional relationship cannot be simply deduced from the proximity of a 
transcription factor binding site to a gene locus. As a starting point, the expression 
of the target gene should be dependent on the presence of the transcription factor in 
vivo, but additional information must also be taken into account. 
Expression profiling data for both lmd and Mef2 was obtained by 
comparing transcription in wt and mutant embryos at six consecutive one-hour 
windows of development (Figure 10, (Sandmann et al., 2006b)).  For the lmd 
dataset, a combined stringent cut off of fold change (> 1.6 (log2 > 0.68 OR < -
0.68) and FDR (q < 0.01) yielded 640 genes with significant gene expression 
differences between wt and lmd mutant embryos, in one or more of the six 
consecutive one-hour windows of the developmental time-course (Appendix, 8.2, 
Table IV). This data was combined with the ChIP-on-chip results for Lmd as well 
as supporting information using an automated scoring approach described earlier 
(Sandmann et al., 2006b), yielding a high-confidence list of 74 direct Lmd target 
genes (Appendix, 8.3, Table V). 
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5.1.4. Extensive co-regulation of target genes by lmd and 
Mef2 via common enhancers 
 
An immediate observation when comparing the direct target genes for lmd 
with the ones previously described for Mef2 is that most of the genes directly 
regulated by lmd are also direct targets of Mef2 (59/74, 79.7%) (Figure 10 B). This 
includes genes involved in myoblast fusion, as sns and blow as well as structural 
genes as Act57B, Act87E or βTub60D. Looking at the data from the perspective of 
the Mef2 direct targets, it is obvious that the number of Mef2 targets co-regulated 
by lmd is only a smaller fraction of the total number of Mef2 target genes (59/203, 
29.1%). This is in accordance to what could be expected considering the much 
broader spatio-temporal expression Mef2: the tight group of lmd co-regulated 
genes can be seen as a defined activity of Mef2 during the more restricted spatio-
temporal expression of lmd, namely in FCMs between stages 10 and 14. 
This stringent set of directly co-regulated genes provides an opportunity to 
examine the details of how input from the same two transcription factors can be 
differently integrated at enhancers both in vivo and in vitro. 
 
 
Figure 12 - Overlap between fragments bound by Lmd and Mef2, as well as direct target 
genes of both TFs.  
 (A) Venn diagram representing the number of fragments bound by Lmd (154) and Mef2 (670). 106 
fragments (68.8 %) are bound by both Lmd and Mef2 at the same time-points. (B) When bound 
fragments are allocated to specific genes it becomes apparent that a great fraction of lmd target 
genes (57/74, 79.7 %) are also targets of Mef2, indicating a high level of co-regulation by Mef2. 
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5.1.5. Lmd and Mef2 CRM occupancy has different effects 
on target gene expression  
 
A list of shared direct target 
genes of these two transcription 
factors raises the important 
question: what is the end result of 
this co-regulation? The expression 
profiling data begins to address this 
by showing the overall 
transcriptional response to loss of 
either transcription factor.  
A comparison between the 
expression profiling data obtained 
with lmd or Mef2 mutant embryos 
using K-means clustering revealed 
seemingly distinct classes of direct 
target genes. A first group of genes 
is down-regulated in both lmd and 
Mef2 mutants (compared to their 
wildtype controls) and includes e.g. 
the structural muscle proteins 
Act57B, Act87E and βTub60D 
(Figure 13, Cluster I). This could be 
seen as the expected or default 
behavior, assuming Lmd is an 
activator of gene expression (as 
seems to be the case with Lmd’s 
regulation of sns) and given the fact 
that Mef2 is a transcriptional 
activator. On the other hand, the 
expression of Mef2 is also strongly 
 
Figure 13 - k-means clustering of lmd and Mef2 
expression data.  
Differential gene expression in lmd and Mef2 loss-of-
function mutants: differences in expression between 
mutant and wt embryos were recorded in a timecourse 
for lmd (left) or Mef2 (right) mutant embryos.  
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reduced in lmd mutant embryos. Therefore, downregulated genes in the lmd mutant 
condition might be dependent on activation by both transcription factors or even on 
Mef2 alone via activation by lmd. 
Surprisingly though, the majority of direct target genes respond differently 
in the two mutant backgrounds, despite occupying a shared enahncer. Indeed, a 
second group of genes including blown fuse (blow), goliath (gol) and tramtrack 
(ttk), show reduced or unchanged levels of expression in the lmd mutant, while 
having increased expression in the Mef2 mutant background. This unexpected 
result could indicate a possible (most likely indirect) repressive effect of Mef2 on 
these genes. 
Finally, a group of genes including CG9416 and CG30035 are 
downregulated in the Mef2 mutants but upregulated in the lmd mutant background. 
This suggests either direct repression by lmd, or an indirect regulatory effect 
instead. 
In conclusion, the overall expression of common target genes as assessed 
by expression profiling yields four seemingly distinct clusters of genes. It should 
be noted that these are most likely not strict classes, but rather reflect an overall 






5.2. lmd and Mef2 regulate target genes in vivo in a 
synergistic or antagonistic manner 
 
A complementary method to examine the regulatory connection between 
lmd and Mef2 and their targets is to ask if these transcription factors are sufficient 
to drive the target gene expression in vivo. This was tested by ectopically 
expressing Lmd and Mef2 in the ectoderm under the control of the engrailed-Gal4 
driver (Brand and Perrimon, 1993), and assaying target gene activation by 
colorimetric in situ hybridization (Figure 14). lmd was previously shown to 
activate Mef2 in the CNS, but not in the remainder of the ectoderm (Furlong et al., 
2001a) (Ruiz-Gomez et al., 2002) (Duan and Nguyen, 2006). This allowed the 
direct contribution of lmd to be assayed independently from Mef2. In addition, the 
factors were also expressed in combination, thus allowing the assessment of their 
combinatorial input.  
Double fluorescent in situ hybridization (FISH) was also performed using 
the same conditions (Figure 15), with wingless (wg) as the second hybridization. 
The engrailed-driven ectopic expression was then easily scored adjacent to the 
wingless domain. 
Several different modes of interaction between Lmd and Mef2 were 
observed in these experiments. In this setting, Lmd is sufficient to activate the 
transcription of CG14687 (Figure 14 & Figure 15 G'), whereas Mef2 alone is not 
(Figure 14 & Figure 15 G''). However, when the two factors are expressed 
simultaneously there is an increase in the expression of these genes, indicating a 
positive interaction between Mef2 and Lmd. Conversely, Act57B and βTub60D are 
activated by Mef2 (Figure 14 & Figure 15 A'', B'') but not Lmd alone (Figure 14 
&Figure 15 A', B'), and again an increase of expression can be seen when the two 
factors are expressed together (Figure 14 & Figure 15 A''', B''').  
CG5080, blow, sug and sns represent an even stronger argument for a 
synergistic effect between these transcription factors. Under these conditions 
neither Lmd (Figure 14 & Figure 15 C', D', E', F') nor Mef2 (Figure 14 &Figure 15 
C'', D'', E'', F'') alone is sufficient to drive ectopic expression of these genes, while 
their combination leads to clear expression in the engrailed domain (Figure 14 & 
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Figure 15 C''', D''', E''', F'''). Interestingly, ubiquitous overexpression of Mef2 using 
a daughterless-Gal4 driver has been reported to ectopically activate CG5080 in the 
head mesoderm (Elgar et al., 2008), adding further evidence to a role for Mef2 as a 
regulator of this locus and hinting at the presence of other tissue-specific co-
activators in other parts of the developing embryo. 
 
 
Figure 14 - Ectopic Expression detected by colorimetric in situ hybridization. 
Lmd and Mef2 were expressed via the UAS/Gal4 system using engrailed-Gal4 as a driver. Ectopic 
gene expression in the ectoderm (red arrows) was detected by in situ hybridization. Expression 
driven by Lmd (prime) and Mef2 (double) prime can be compared with the level of expression 
obtained by expressing both transcription factors simultaneously (triple prime). Red brackets in the 
wildtype column point up to a section of the ectoderm devoid of expression for comparison. Most 
genes are ectopically expressed in the ectoderm by either Lmd or Mef2. When expression is forced 
simultaneously by both Lmd and Mef2 the expression seems often stronger (A''', B''', C''', D''', E''', 
F''', G'''). Interestingly, in the case of CG9416, co-expression of Lmd (H''') seems to repress 






Figure 15 - Ectopic Expression detected by fluorescent in situ hybridization. 
Lmd and Mef2 were expressed via the UAS/Gal4 system using engrailed-Gal4 as a driver, detected 
by double fluorescent in situ hybridization. Ectopic gene expression in the ectoderm (green 
channel) is shown together (within white brackets) with adjacent wingless expression (red channel). 
Expression driven by Lmd (prime) and Mef2 (double) prime can be compared with the level of 
expression obtained by expressing both transcription factors simultaneously (triple prime).  
 
Loss-of-function expression profiling data revealed a number of genes that 
appear to be upregulated in the absence of Lmd (Figure 13, Cluster II). This is an 
intriguing observation that points to the possibility that some genes might actually 
be directly repressed by Lmd. One of these genes, CG9416, was selected to test 
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this hypothesis. Mef2 is sufficient to drive the expression of CG9416 in the 
engrailed domain (Figure 14 & Figure 15 H'') whereas no such expression can be 
seen with Lmd alone (Figure 14 & Figure 15 H'). Interestingly, compared to the 
activation by Mef2 alone, there is a reduction of expression when both 
transcription factors are used together (Figure 14 & Figure 15 H'''), indicating an 
inhibitory effect of Lmd on Mef2 driven activation. Finally in the single case of the 
gene gol neither Lmd nor Mef2, alone or in conjunction, were able to ectopically 
drive expression in the ectoderm. 
In summary, these results reveal the complexity of regulation of theses 
shared target genes. All of the genes with the exception of gol were ectopically 
activated in the ectoderm by either Lmd or Mef2 alone, with a synergistic effect 
being the most common result of the combination of both factors, which indicates 
extensive co-regulation. However, there is considerable flexibility in how 
information is integrated at each individual locus, with one factor or the other 
being predominant for ectopic expression. Furthermore, CG9416 represents an 




5.3. Delimiting enhancers from ChIP bound 
regions for in vivo and in vitro studies 
 
Individual enhancer regions in Drosophila typically range from 0.5 to 1 kb 
in size. However, the ChIP-on-chip resolution was limited by the size of the 
spotted genomic fragments (≈ 3Kb) and frequently one predicted enhancer spanned 
different overlapping fragments, which led to combined fragments of up to 5 Kb in 
length. To better understand the complex direct regulation by Mef2 and lmd, it was 
crucial to analyze the behavior of the actual shared enhancers. As the ChIP 
fragments could theoretically encompass two separate enhancers, the co-bound 
regions were further narrowed down. Briefly, as the chromatin immunoprecipitated 
regions were in the size range of 500 bp, it could be assessed whether Lmd and 
Mef2 co-bind within a 500 bp window. Real time PCR primers were designed 
flanking Mef2 sites within Mef2-bound regions.  These primers were then used to 
amplify Mef2 bound regions from the Lmd immunoprecipitated DNA. If both 
transcription factors are binding within a 500 bp window, then the Mef2 sites 
should be present within the Lmd immunoprecipitated regions, leading to the 
generation of a successful PCR product (Figure 16). The refined enhancer regions 
were then used both for in vitro and in vivo studies in order to allow for a direct 
comparison between all results. 
 
Figure 16 - Enhancers were further refined by qPCR.  
ChIP-on-chip resolution is limited by the relatively large 3 Kb spotted microarray probes. ChIP 
precipitated sequences, at around 500 bp are however much smaller. Once a region was identified 
by ChIP-on-chip, it was assayed by qPCR, with probes scanning the length of the region, and signal 




5.3.1. Scanning the sequences with a Mef2 PWM reveals 
the presence of several putative Mef2 binding sites 
 
First, the bound regions were scanned for putative Mef2 binding sites using 
a Position Weight Matrix (PWM) generated from known Mef2 sites by Michal 
Karzynski in the Furlong lab. It would have been instructive to cross this data with 
the location of putative Lmd sites, but unfortunately there is no consensus site 
available at the moment. Lmd has been shown to bind to a 50 bp fragment - 
IEd5[C/D]* by an Electrophoretic Mobility Binding Assay (EMSA) (Duan et al., 
2001) - but a refined binding site has not been identified 
The Mef2-binding sites were also ranked according to structure-based 
estimations of the affinity of each site (computed by Luis Serrano) to reduce false 
positives and only sites with high affinity were considered.  
 
5.3.2. Conservation of sites in other Drosophila species 
helps to reduce false-positives 
 
A useful method to reduce false-positives, therefore helping to narrow 
down fragments, is to look for conservation of putative binding sites in related 
species. The putative Mef2 binding sites and surrounding regions were analyzed 
using the UCSC Genome browser, comparing with the six closest sequenced 
Drosophila species (looking as far down as Drosophila pseudoobscura) for 
conservation of sequence.  
While this approach has yielded significant results when analyzing 
vertebrate genomes, it poses a challenge in Drosophila melanogaster due to small 
genome size of the species. Smaller genomes contain less non-coding DNA, and so 
generally a larger fraction of this DNA is functional; about 5% of human non-
coding DNA appears to be under evolutionary constraint compared to about 50% 
in D. melanogaster (Peterson et al., 2009). This massive conservation in non-
coding DNA means it is more difficult to find stretches of unconserved DNA 
therefore obscuring the boundaries between functional elements.  
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5.3.3. qPCR shows enrichment of Lmd Chromatin 
Imunoprecipitates in the vicinity of Mef2 sites 
 
Lmd sites are expected to be in the vicinity of the Mef2 sites in co-
regulated fragments, so when more than one conserved Mef2 site was present 
within a large conserved region (see previous section) a supplemental approach 
was used to discern between them. Quantitative real-time polymerase chain 
reaction (qPCR) was performed on Lmd ChIP samples using primers designed to 
flank either side of conserved Mef2 sites (Figure 17). As ChIP fragments are 
around 500 bp long, this allowed confirming Lmd binding in the vicinity of 
conserved Mef2 sites (Figure 16) and thereby delimited the fragments to a size that 
is reasonable to use for in vitro studies. 
 
Figure 17 - Quantitative PCR results show enrichment of Lmd binding in the vicinity of 
different Mef2 binding sites.  
Occasionally, several good quality Mef2 sites present in large bound region could not be discerned 
by either energy of affinity or conservation in related species. In these cases, Lmd binding on top of 
different Mef2 sites was assayed by qPCR, under the rationale that Lmd should bind in the 
proximity of the functional Mef2 site on co-regulated enhancers. Examples are shown with results 
for sites within the same fragment depicted in the same colour and selected Mef2 sites highlighted 
in bold. Occasionally, as in the case of CG14687 and gol, it was not technically possible to discern 





5.4. Characterization of novel enhancers 
 
The newly defined enhancers were cloned in front of a minimal promoter 
and a GFP reporter, and transgenic lines created to analyze the expression driven 
by these enhancers in vivo. This analysis demonstrated that 9 out of 10 of novel 
enhancers lead to expression in the muscle. The cloned fragments for Act57B, 
CG9416, and CG14687 correspond to previously characterized Mef2 enhancers 
that were further refined. As a good example, the enhancer for the gene CG5080 
was reduced to half of its previously defined size. Among the novel enhancers 
further characterized in this study are new enhancers for the genes tramtrack (ttk), 
blown fuse (blow), goliath (gol) and sugarbabe (sug). 
 
 
Figure 18 - Novel tramtrack (ttk) early and late enhancers.  
 (A) Lmd and Mef2 bind coherently to two different regions upstream of the ttk locus. There is 
early binding to a region 9 kb upstream of the gene, as well as late binding immediately upstream of 
the transcriptional start site. ChIP-on-chip fragments (about 3 Kb) are shown as stacks with the 
early time-point (6-8 hours) on top of the late (8-10 hours), for the Lmd (above line) and Mef2 
(below line) experiments. Fragments labeled in red show binding above the threshold whereas 
fragments that do not meet this criterion are depicted in gray. Exons (gray) and introns (orange) are 
depicted at the bottom. (B) Cloned ttk(early) enhancer (top black box, “YourSeq”) showing 
conservation in various species, visualized using the UCSC browser. (C) Stage 10 embryo showing 
the beginning of ttk (early) expression. The expression continues throughout embryogenesis and 
can be seen in the somatic muscle at stage 13 (D). The late fragment also drove expression 
specifically in muscle (not shown). 
 
ChIP-on-chip binding is detected in two regions of the ttk genomic locus, 
with the peculiarity that one region immediately upstream of ttk shows binding by 
both Lmd and Mef2 at the early (6-8 hours) time-points whereas another region 
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further upstream is bound only at the late (8-10) time-points (Figure 18 A). This 
would suggest that two different enhancers are regulated by both lmd and Mef2 at 
different stages of development. Both enhancers were cloned and drive expression 
it the muscle. The ttk enhancer bound in the early time-points [ttk(early)] was used 
throughout this study. It was restricted to 0.7 kb according to the previously 
defined criteria (Section 5.3) including conservation with other Drosophila species 
(Figure 18 B). The enhancer is expressed from stage 10 (Figure 18 C) to the end of 
embryogenesis, and is specific to mesoderm and muscle cells (Figure 18 D). 
An enhancer for the gene blow was also cloned, that partially overlaps a 




Figure 19 - blown fuse (blow) enhancer 
(A) Lmd and Mef2 bind at the late time-point to the same fragment spanning the first and second 
introns of blow. ChIP-on-chip fragments (about 3 Kb) are shown as stacks with the early time-point 
(6-8 hours) on top of the late (8-10 hours), for the Lmd (above line) and Mef2 (below line) 
experiments. Fragments labeled in red show binding above the threshold whereas fragments that do 
not meet this criterion are depicted in gray. Exons (gray) and introns (orange) are depicted at the 
bottom. (B) The blow enhancer to be cloned (top black box, “YourSeq”) was selected from the first 
intron, based on conservation in various species visualized using the UCSC browser. (C) Stage 11 
embryo showing blow enhancer expression in both the somatopleura and splanchnopleura. (D) 
Later expression in the somatic muscle at stage 13-14. 
 
The gene goliath (gol) is representative of the difficulties of defining the 
borders of an enhancer for cloning. Both Lmd and Mef2 bind at both time points to 
the same fragment (Figure 20 A). However, only two Mef2 sites can be identified 
in the fragment. qPCR analysis does not show enrichment for Lmd at either site 
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(Figure 17), and the whole region is overall poorly conserved (Figure 20 B). 
Nevertheless, taking the full 3 Kb region as an unrefined enhancer, the reporter line 
shows specific expression in the muscle between stages 11 (Figure 20 C) and 14  
(Figure 20 D). 
 
 
Figure 20 – Novel goliath (gol) enhancer. 
(A) Lmd and Mef2 bind to the same fragment in the first intron of gol in both the early and late 
time-points. (B) In this case there was minimum conservation as can be seen using the UCSC 
browser, and therefore, the whole 3 Kb fragment was cloned (top black box, “YourSeq”). (C) Stage 
11 embryo showing gol expression in both the somatopleura and splanchnopleura. (D) Later 
expression in the somatic muscle at stage 13-14. 
 
A Mef2-responsive enhancer for CG5080 was identified previously 
(Sandmann et al., 2006b). The enhancer was refined based on a positive 
enrichment for Lmd near the Mef2 site on the 3’, but not on the 5’, section of the 
first intron (Figure 17, CG5080), which is in line with the greater conservation in 
the 3’ region of the enhancer (Figure 21 B). 
Other enhancers previously identified are show in Figure 22. In every case, 
Lmd and Mef2 bind to fragments covering the enhancer at the same time-points, 
with CG14687 showing binding at different time-points (Figure 22 D) but with the 






Figure 21 - Refined CG5080 enhancer. 
A) Lmd and Mef2 bind to the same fragment in the first intron of CG5080 the late time-points (B) 
Conservation down to Drosophila pseudoobscura is larger in the 3’ half or the first intron, and Lmd 
enrichment by qPCR was also detected in that 3’ fragment, but not in the 5’ fragment (Figure 14) 
(top black box, “YourSeq”). (C) Stage 11 embryo showing CG5080 expression at stage 11. (D) 







Figure 22 - Reporter lines previously characterized or refined in this study. 
(A-D) ChIP-on-chip fragments (about 3 Kb) are shown as stacks with the early time-point (6-8 
hours) on top of the late (8-10 hours), for the Lmd (above line) and Mef2 (below line) experiments. 
Fragments labeled in red show binding above the threshold whereas fragments that do not meet this 
criterion are depicted in gray. Exons (gray) and introns (orange) are depicted at the bottom Green 
arrows illustrate the cloned enhancers.  (A’-D”) GFP reporter expression driven by the DNA 







5.5. Loss of lmd and Mef2 differentially affects 
reporter activity in vivo 
 
The GFP reporter lines created in this study were used to assess the 
contribution of lmd and Mef2 to the activity of these enhancers in vivo. Six of these 
lines were placed in the background of two characterized loss-of-function alleles 
for these transcription factors; lmd1 and Mef222.21. It would have been interesting to 
include a condition of loss-of-function of both transcription factors in this analysis. 
Unfortunately, every effort to create a lmd-Mef2 double mutant failed, which in 
itself provides further evidence of the interactive nature of these two transcription 
factors. 
The GFP expression was detected by Fluorescent In Situ Hibridizaton 
(FISH). Homozygous mutant embryos for lmd were identified by FISH for twist, 
based on the fact that lmd mutants maintain broad twist expression beyond stages 
11-12, in contrast to the wildtype situation (Ruiz-Gomez et al., 2002). Mef2 
hetherozygous mutant embryos were identified by the lacZ expression pattern of 
the engrailed-lacZ balancer chromosome; the absence of which being an indicator 
for the homozygous mutant embryos. 
The expression of the βTub60D gene has already been intensively studied 
and shown to be controlled by several independent cis-regulatory modules (Hinz et 
al., 1992) (Damm et al., 1998) (Kremser et al., 1999). One of these enhancers, 
upstream to the βTub60D locus requires Mef2 for full activation (Damm et al., 
1998). In contrast, the intronic βTub60D enhancer used in this study shows 
strongly reduced expression in lmd mutants (Figure 23 A, B), but appears 
unaffected in Mef2 mutant embryos (Figure 24 A, B). The reduction in expression 
of the βTub60D gene in Mef2 mutant embryos detected by expression profiling 
(Figure 13) therefore reflects the combined activity of at least two enhancers: one 
strongly responsive to Mef2 levels and a second one dependent on Lmd (but not 
Mef2) for activation. 
Expression profiling shows a strong reduction in Act57B expression in both 
lmd and Mef2 mutants (Figure 13). The Act57B enhancer shows a clearly reduced 
expression in Mef2 mutant embryos (Figure 23 C, D), in accordance with what has 
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been reported previously (Kelly et al., 2002). This expression is completely 
abolished in lmd mutant embryos (Figure 24 C, D) confirming the role of lmd in 
the activation of Act57B. 
The CG5080 enhancer shows reduction of expression in the Mef2 mutant 
background (Figure 24 E, F), but is only mildly affected by the lack of lmd (Figure 
23 E, F). CG5080 is also downreagulated by both lmd and Mef2 mutants according 
to the expression profiling data (Figure 13) but this particular enhancer seems to be 
affected more predominantly by Mef2. 
In contrast, reporter expression in the somatic muscle driven by the blow 
enhancer is completely abolished in both lmd (Figure 23 G, H) and Mef2 mutant 
embryos (Figure 24 G, H). Additional expression in the hindgut persists in both 
genetic backgrounds, pointing towards additional, tissue-specific input at this 
enhancer. 
The CG14687 enhancer is activated in both somatic and visceral muscle in 
wildtype embryos (Figure 23 I, J, Figure 24 I, J).  Expression in somatic muscle 
requires lmd (Figure 23 J), but is unaffected in Mef2 mutant embryos (Figure 24 J). 
Interestingly, expression in the visceral muscle is independent of both lmd and 
Mef2 expression (Figure 23 J, Figure 24, J), implicating additional factors in the 
activation of this enhancer specifically in this tissue.  Both the homeodomain 
transcription factor bagpipe (bap) and the fork head domain transcription factor 
biniou (bin) are recruited to this enhancer in vivo (Jakobsen et al., 2007) and most 
likely activate gene expression in this tissue.  
Finally, the expression of the gol enhancer is clearly dependent on lmd 
activity (Figure 23 K, L), but remains unaffected on a Mef2 mutant embryo (Figure 
24 K, L). 
In summary, all six muscle enhancers examined show reduced activity in 
one or both mutant conditions, demonstrating that the in vivo occupancy of these 
modules by Mef2 and Lmd has regulatory function.  lmd mutants generally display 
a stronger reduction in enhancer activity than Mef2 mutant embryos. As the 
expression of Mef2 is dependent on lmd, there is a stronger reduction in enhancer 
activity in this genetic background, which reflects and underscores the 





Figure 23 - lmd and Mef2 are differentially required for enhancer activity in vivo. 
In situ hybridization of GFP-reporter mRNA in a wt condition (embryos heterozygous for lmd1) or 
mutant condition (homozygous lmd1 mutant embryos). The same embryos were labeled by in situ 
hybridization for twist mRNA (prime) and shown with an overlay of both signals (double prime). 
Homozygous lmd embryos are recognized by the persistent broad twist expression after stages 11-





Figure 24 - lmd and Mef2 are differentially required for enhancer activity in vivo. 
In situ hybridization of GFP-reporter mRNA in a wt condition (embryos heterozygous for Mef222.21)  
or mutant condition (homozygous Mef222.21 mutant embryos). The same embryos were labeled by in 
situ hybridization for lacZ (balancer chromosome) mRNA (prime) and shown with an overlay of 




5.6. lmd co-regulates enhancers with Mef2 in a 
cooperative, additive or inhibitory manner 
 
The complex regulation of different genes by lmd and Mef2 required an 
analysis aimed at understanding the interplay between these transcription factors 
regulation at the level of individual enhancers. The enhancers were analyzed in 
vitro by luciferase assays, providing a quantitative response to increments in the 
activity of Lmd and Mef2 on these individual enhancers. 
Drosophila Schneider 2 (S2) cells were chosen, due to the extensive 
knowledge available on this cell line, and to the fact that they do not express any 
endogenous lmd or Mef2 (Sims et al., 2006). Lmd and Mef2 were sub-cloned from 
HA-tagged versions created from from full-length ESTs (LD47926 and GH24154, 
respectively), and placed in the pAc5.1/V5-hisB vector (Invitrogen). The 
enhancers were sub-cloned into an expression vector, upstream of a minimal 
promoter and the firefly luciferase gene. After initial tests using the pGL3 vector 
(Promega) revealed a signal level too close to background noise, the sv40 promoter 
was replaced with a hsp70 minimal promotor from pH-Stinger (Barolo et al., 
2000), resulting in a satisfactory signal level. Some enhancers were still trimerized 
in order to obtain a more robust signal. A copia-Renilla luciferase vector was used 
as a transfection control, and the normalized values were calculated as the fold 
increase over the negative control (empty pAc5.1/V5-hisB vector) ± Standard 




5.6.1. lmd can act as a transcriptional repressor 
 
One of the most intriguing questions raised by both the expression profiling 
and ectopic expression data was whether lmd could act directly as a transcriptional 
repressor. Evidence for this role came from the set of genes whose overall 
expression seemed to be enhanced in lmd mutants (Figure 13). CG9416 and 
CG30035 where selected as examples from this set of genes, with the former 
already showing additional evidence of repression by Lmd, namely repression of 
Mef2-driven ectopic expression (Figure 14 & Figure 15 H'', H'''). 
  
 
Figure 25 - Lmd can repress expression activated by Mef2 in vitro. 
Cells were co-transfected with expression plasmids for Renilla luciferase (transfection control), 
Firefly luciferase reporter constructs for CG9416 (A) or CG30035 (B) and different concentrations 
of expression plasmids encoding Lmd or Mef2 (as shown). (A) CG9416 expression does not change 
when transfecting 1 or 10 ng of Lmd (blue bars), while the enhancer responds dramatically to 
increasing amounts of Mef2 (green bars). There is no detectable effect when combining (purple 
bars) activation by 1 ng of Mef2 with 1 ng of Lmd (dotted line), but the effect is pronounced with 
10 ng of Lmd (solid line): activation by Mef2 is repressed from 49.8 to 6.1 fold. (B) The CG30035 
enhancer responds in a similar fashion: repression by Lmd is visible by the suppression of Mef2-
driven activation (1 ng) from 15.0 fold to 10.2 (dotted line) or 2.7 fold (solid line). Values represent 
fold change ± SEM, n=3. Student’s t-test (unpaired, two-tailed), (*) p<0.05, (**) p<0.01, (***) 
p<0.001). 
 
The CG9416 enhancer showed no significant change in expression when 
transfected with either 1 or 10 ng of Lmd alone (Figure 25 A, blue bars). The 
design of this system produces a diminutive plateau of expression due to the hsp70 
minimal promoter, and for this reason it is very difficult to observe any reduction 
in this level on any condition. On the other hand, the enhancer responded steadily 
to increasing levels of Mef2: 49.8 fold with 1 ng and 151.3 fold in response to a 10 
ng transfection of Mef2 cDNA (green bars). The strong activation of about 50 fold 
in response to 1 ng of Mef2 was used to access the effect of Lmd interacting with 
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the ability of Mef2 to activate this enhancer (purple bars). A co-transfection of 1 ng 
of Lmd was not enough to change this activation (dotted line), but the co-
transfection of 10 ng of Lmd resulted in a pronounced decrease of Mef2 activity 
from 49.8 to 6.1 fold (solid bracket). This represents the first direct evidence that 
Lmd can directly repress Mef2-mediated activation on common enhancers. 
The CG30035 enhancer was cloned to provide a second example to study 
repression by lmd. As in the case of CG9416, Lmd alone was not able to 
significantly alter the activity of this enhancer (Figure 25 B, blue bars), while Mef2 
was able to activate transcription (green bars). In this case, co-transfection of even 
1 ng of Lmd (purple bars) led to a decrease in the activity of 1 ng Mef2 (dotted 
bracket), confirming a significant repression from 15.0 to 2.7 fold. 
It is very significant that from more than a dozen enhancers tested by this 
assay only the two genes suspected of being repressed by Lmd actually showed 
this behavior. A number of other genes (gol, ttk, CG14687) show a slight up-
regulation in Mef2 mutant embryos according to the expression profiling data 
(Figure 13) and were tested correspondingly to check whether Mef2 could act as a 
direct repressor in a way similar to Lmd. However, Mef2 could not repress 
activation mediated by lmd under any experimental condition (data not shown). 
In summary, these are the first examples of direct repression by Lmd, and 
the overall upregulation of a group of genes in the Mef2 mutant background is 






5.6.2. lmd and Mef2 can act additively to activate target 
genes  
 
Most of the genes tested 
were ectopically expressed by either 
Lmd or Mef2, with a stronger 
activation often resulting from the 
combined action of both 
transcription factors (Figure 14 & 
Figure 15). The cloned enhancers 
were similarly shown to depend on 
a different level of one or both 
transcription factors for their in vivo 
expression (Figure 23, Figure 24).  
Nevertheless, the question of 
whether this activation is simply 
additive or cooperative cannot be 
answered by in situ hybridization. 
We therefore addressed this 
question in vitro using the 
quantitative nature of the luciferase 
assays. 
The CG14687 enhancer 
(Figure 26 A) could be activated to 
modest levels by increasing 
amounts of both Lmd (blue bars) 
and Mef2 (green bars). When 
different amounts of Lmd were co-transfected with 1 ng of Mef2 (purple bars), the 
resulting activation was simply a sum of the activation of each transcription factor 
by itself. For instance, a 2.4 fold activation by 1 ng of Mef2 is supplemented by a 
3.6 fold activation by 10 ng of Lmd, leading to an additive result of a 5.0 fold 
activation (solid bracket). A similar situation was seen for gol (Figure 26 C), even 
 
Figure 26 - Additive activation of targets in vitro 
between Lmd and Mef2.  
Cells were co-transfected with expression plasmids 
for Renilla luciferase (transfection control), Firefly 
luciferase reporter constructs for CG14687 (A), 
CG5080 (B) or gol (C) and different concentrations 
of expression plasmids encoding Lmd or Mef2 (as 
shown). In all cases, there is an additive increase in 
the activation obtained from each transcription 
factor separately. Values represent fold change ± 
SEM, n=4.  Student’s t-test (unpaired, two-tailed), 
(*) p<0.05, (**) p<0.01, (***) p<0.001). 
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though the very modest levels of activation render some of the comparisons less 
significant.  
CG5080 (Figure 26 B) is another case of additive interaction between Lmd 
and Mef2. In this case, a strong activation of around 30 fold was observed in 
response to 1 ng of Mef2, which increased to ~40 fold when co-transfected with 10 
ng of Lmd (which by itself induces a 10 fold activation of expression). 
This additive behaviour suggests that Lmd and Mef2 exert their function 
independently from each other, possibly at remote binding sites and without 




5.6.3. Lmd and Mef2 can act cooperatively to activate 
target genes 
 
When studying transcription 
factors with such an extensive 
overlap in their target genes and 
associated enhancers (79.7 % of the 
targets of lmd are also Mef2 targets) 
and looking at the strong interaction 
between them observed for example 
on the ectopic expression of blow 
and βTub60D (Figure 14 & Figure 
15), one can suspect instances of a 
more complex cooperative 
interaction at some enhancers. 
For example, the ttk 
enhancer (Figure 27 A) is extremely 
responsive to Lmd (blue bars) and 
modestly responsive to Mef2 (green 
bars). Interestingly, when co-
transfecting 1 ng of Mef2 and 10 ng 
of Lmd (purple bars), the resulting 
31.1 fold activation is clearly 
greater than the sum of the 
individual (1.7 & 8.9 fold) 
activations (solid line), indicating a 
strong cooperative interaction 
between Lmd and Mef2. This 
cooperative effect is seen at still lower levels of transcription in the case of the 
blow enhancer (Figure 27 B). Even the low concentration of 1 ng of Lmd, 
insignificant on its own (blue bars) can boost the activation of 1 ng of Mef2 (green 
bar) from 2.8 fold to 8.4 fold when co-trasnsfected (dotted bracket). This effect is 
 
Figure 27 - Cooperative response.  
Cells were co-transfected with expression plasmids 
for Renilla luciferase (transfection control), Firefly 
luciferase reporter constructs for ttk (A), blow (B) 
or βTub60D (C) and different concentrations of 
expression plasmids encoding Lmd or Mef2 (as 
shown). In all cases, the enhancer activation by the 
addition of both Lmd (blue bars) and Mef2 (green 
bars) together is greater than the combined sum of 
affects of both transcription factors added 
separately (purple bars, dotted and full lines), 
indicating a cooperative effect between Lmd and 
Mef2.  Values represent fold change ± SEM, n=4  
Student’s t-test (unpaired, two-tailed), (*) p<0.05, 
(**) p<0.01, (***) p<0.001). 
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re-confirmed with 10 ng of Lmd (going from ~2.5 fold with each transcription 
factor separately to 14.2 fold when both are combined, solid bracket). The same 
robust effect can be seen with the βTub60D enhancer (Figure 27 C). 
 
Overall, lmd and Mef2 activate common enhancers either additively or 
cooperatively. This behaviour is expected to be dependent on the particular 
enhancer architecture.  Unfortunately, the absence of a Lmd consensus binding site 
makes it difficult to test this hypothesis. Interestingly, lmd is also capable of acting 





The development of multicellular organisms involves the harmonious 
development of different tissues. Diverse tissues are made from specific cell types 
that reflect the coordinated activation and repression of particular genes. 
Traditional genetic studies have revealed key regulators of many processes, 
including transcription factors involved in myogenesis, such as Mef2 and lmd. It is 
clear that unveiling the catalog of genes regulated by essential transcription factors 
is key to understand development, but there is a further layer of complexity. To 
achieve a molecular understanding of the regulatory networks controlling cellular 
decision-making, it is essential to understand how inputs from different regulators 
are being integrated at the level of shared enhancers. It is this interaction of TFs 
that ultimately gives rise to the defined patterns of gene expression that shape 
development. 
 
6.1. A systematic genomic approach identifies 
direct target genes of lmd 
 
This study has used a genomic approach to systematically identify the 
direct target genes of lmd, an important myogenic regulator, of which only one 
direct target was previously known. As expected, the list of newly identified direct 
targets includes genes involved in myoblast fusion, such as sns and blow, and also 
structural genes such as Act57B, Act87E or βTub60D, suggesting a more prominent 
role of lmd in differentiation than was previously thought. Even more interestingly, 
comparing this list with the one previously generated for Mef2 shows that lmd 
regulates the majority of its targets in conjunction with Mef2. While in a few 
instances (e.g. ladybird-early, PAK-kinase or short stop, data not shown) the two 
transcription factors target the same locus through different enhancers, the majority 
of targets were regulated via common enhancers. Moreover, analyzing the two 
different time points used for the ChIP-on-chip experiments shows a frequent 
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correlation in the timing of transcription factor binding. The tramtrack locus, for 
instance, contains both an exclusively early-bound and an exclusively late-bound 
enhancer. The early enhancer, used extensively for this study, is bound by both 
factors at stages 10-11 (6-8 h) but not later (Figure 18 A), whereas a second 
enhancer is bound at stages 12-13 (8-10 h) but not earlier. Additionally, the blow 
(Figure 19 A) and CG5080 (Figure 21 A) enhancers are co-bound at stages 12-13 
(8-10 h) but not earlier.  
 
6.2. The integration of diverse techniques provides 
information from different perspectives 
 
Using a diverse range of methods to approach the same problem from 
different perspectives is one of the hallmarks of scientific endeavor. The rational is 
that any particular technique is prone to some degree of error and artifacts, and one 
can be better assured of the validity of an observation by combining data taken 
from different viewpoints. However, different techniques do read out different 
aspects of the problem under study and some degree of interpreting is required to 
assemble the whole picture.  
This study was initiated with ChIP-on-chip, providing a genome-wide 
overview of the occupancy of two TFs that bind to common genomic regions. 
While this technique highlights sites bound in vivo, it provides no indication of the 
identity of the targeted gene or on the change in its transcriptional state as a result 
of the transcription factor’s occupancy. The binding data had to be integrated with 
expression profiling in mutant backgrounds of the same TFs, to obtain a stringent 
list of direct targets and respective transcriptional effects. Analysis of the behavior 
of the direct target genes led to the identification of distinct modes of regulation by 
the TFs, and at this point, examples representing these modes of behavior were 
selected for further study. The TFs were tested for their ability to ectopically 
express their target genes in the ectoderm. A positive result in this experiment 
shows that a factor is sufficient to activate gene expression, yet a negative result is 
more difficult to interpret, taking into account the possibility of differences in 
chromatin structure or the absence of required co-factors in the ectopic location, 
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and even the general artifacts resulting from associations of proteins not normally 
expressed together. Considering the additional complexity of having different 
independent enhancers with different modes of regulation in the same locus (e.g. 
βTub60D, ttk), the study moved to the characterization of individual responsive 
enhancers. These enhancers were assessed both in vivo, comparing the expression 
of transgenic reporters in a wildtype and mutant background, and in vitro with the 
expression of reporters driven by the TFs in cell culture. Overall, it is expected that 
some discrepancies might arise from the use of such diverse techniques, but some 
results that do not appear immediately obvious are in many cases extremely 
indicative.  
 
6.3. Combinatorial binding on shared enhancers 
leads to additive, cooperative or repressive effects 
 
Act57B is ectopically expressed in the ectoderm by Mef2 (Figure 14 Figure 
15 B''), but not by lmd alone (Figure 14 Figure 15 B'). On the other hand, reporter 
expression is only slightly reduced in Mef2 mutants (Figure 24 D), while being 
completely lost in lmd mutants (Figure 23  D), which also have significant lower 
levels of Mef2. A recent study showed that the initiation of Act57B expression at 
stage 11 requires Mef2. However, this expression could not be prematurely 
initiated by artificially increasing the levels of Mef2 at this early stage (Elgar et al., 
2008). These results can be better understood taking into account that the 
combined action of Lmd and Mef2 is required for expression at this stage. 
Therefore, the presence of Mef2 alone is not sufficient to activate transcription, 
while being capable of maintaining the expression of Act57B at later stages.  
A good example of an additive interaction between lmd and Mef2 is the 
gene CG5080. The expression of this gene is downregulated in both mutants 
(Figure 13, Cluster I), but the individual contribution of each TF to the activation is 
difficult to discern. The fact that none of the TFs is sufficient to ectopically express 
the gene (Figure 14 & Figure 15, C', C'), while their combined action is (Figure 14 
& Figure 15, C'''), indicates that neither factor is predominant over the other in 
activating the gene. The fact that there is a single regulatory region in the locus 
DISCUSSION 101 
 
where the two factors co-bind (Figure 21 A) means that there is probably only one 
enhancer where the factors can interact, and simplifies the integration of 
information from this enhancer to the basal promoter of the gene. Indeed, the 
transgenic reporter line is similarly affected, but not abrogated, in both mutant 
backgrounds (Figure 23 F and Figure 24 F), and the quantitative in vitro data 
shows a simple additive effect in the activation of the enhancer by lmd and Mef2. 
In conclusion, lmd and Mef2 bind to the same enhancer and activate CG5080 in a 
non-cooperative way. Their individual contributions, which separately are not 
sufficient to ectopically express the gene, is uncovered in the respective mutant 
backgrounds as a decrease in the expression of the reporter. 
The blow enhancer, on the other hand, is a good example of cooperative 
activation by lmd and Mef2. Expression profiling shows a mild reduction of 
expression in Mef2 mutants in the late time points (Figure 13) that is markedly 
more substantial in lmd mutants (in which Mef2 levels are also compromised). It is 
also clear that neither Lmd (Figure 14 & Figure 15 C') nor Mef2 (Figure 14 & 
Figure 15 C'') are sufficient to ectopically express blow in the ectoderm, unless 
their activity is combined (Figure 14 & Figure 15 C'''). The enhancer requires both 
Lmd (Figure 23 H) and Mef2 (Figure 24 H) for expression, and is activated co-
operatively by the two factors in vitro (Figure 27 B). Altogether, this cooperative 
activation of blow can be seen as a classic “AND gate” condition, where absence 
of, or low input from, either TF compromises activation. Only when there is robust 
input and co-operation from both TFs is the full activation achieved. 
 
6.4. lmd as a transcriptional repressor 
 
The ability of lmd to directly repress genes activated by Mef2 is one of the 
most intriguing aspects of the co-regulation between the two transcription factors. 
A substantial portion of co-regulated genes is dependent on Mef2 for overall 
activation, but seems to be repressed by lmd (Figure 13, Cluster II). CG9416, one 
of the genes previously identified as a Mef2 target (Sandmann et al., 2006b) was 
immediately selected to further investigate this behavior, and has indeed 
confirmed, by every method used, the repressive potential of lmd. First, whilst 
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Mef2 is capable of driving ectopic expression of CG9416 in the ectoderm, co-
expression of lmd leads to a reduction in these expression levels (Figure 14 & 
Figure 15 C-C'''). Directly analyzing the enhancer confirms the repression and 
provides a quantitative readout of this effect. Simultaneous transfection of lmd 
represses the CG9416 enhancer, reversing the activation by Mef2 to almost basal 
levels in a concentration dependent manner (Figure 25 A). To confirm this effect, 
the group of genes with the same overall expression change was re-visited, and a 
second example, CG30035, was selected for analysis. The size of the enhancer was 
refined and prompt in vitro analysis revealed a quantitative behavior mirroring that 
observed for CG9416: Lmd again inhibits activation by Mef2 in a concentration 
dependent manner (Figure 25 B). A second independent example of this restricted 
behavior confirms the ability of lmd to act as a transcriptional repressor, and opens 
up multiple questions regarding the mechanism of this behavior. 
 
 Lmd is a member of the Gli superfamily of transcription factors (Section 
2.6.3), known to act both as activators and repressors of transcription: the full 
protein activates transcription but can be proteolyticaly cleaved into a repressor 
from. While it is immediately tempting to envision such a mechanism of action for 
Lmd as well, there are some issues to consider beforehand. First, it should be noted 
that Lmd is quite a distant member of this family, and that Ci is the true 
Drosophila ortholog of the vertebrate Gli proteins. The homology observed 
between Lmd and other Gli superfamily members does not extend beyond the Zn-
finger domain, and in particular fingers 3-5 (Duan et al., 2001). Importantly, the 
remainder of the protein contains a number of regulated motifs that affect Lmd’s 
subcellular localization and function, features that could be relevant in 
distinguishing Lmd from other Gli superfamily members. To complicate things 
further, it has not been possible to detect a cleaved form of Lmd to date (Duan and 
Nguyen, 2006). 
 
This study demonstrates that Lmd can act as both an activator and a 
repressor in the same tissues at the same stage of development. Gli superfamily 
members, in contrast, respond to external signaling (Hedgehog) by switching from 
repression to activation in the whole cell. This switch mechanism, and for the same 
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reason any of the general modifications in protein function described for Lmd 
(Duan and Nguyen, 2006) are difficult to reconcile with the dual function of Lmd 
at different loci within the same cells and tissues, as is any mechanism of binding 
to Mef2 and sequestering the protein in the cytoplasm. 
 
There are other examples of a transcription factor with the dual function of 
activation and repression, acting in a sequence-dependent manner in the same cells. 
One example is lozenge (lz), a member of the Runx family of transcriptional 
regulators (Canon and Banerjee, 2003). Lz is an activator that can also repress 
expression by binding regulatory sequences and recruiting the general repressor 
Groucho. However, unlike Harry-family proteins that bind Groucho in a stable 
manner through the conserved tetrapeptide motif WRPW (Jimenez et al., 1997), 
the interaction between Lz and Groucho is mediated through the Runx-family 
motif WRPY (Canon and Banerjee, 2003). This later interaction is unstable, and 
requires the binding of the extra adaptor Cut to stabilize repression. Cut binds to 
DNA sequences adjacent to the Lz binding sites, and directly binds Groucho and 
Lz, stabilizing the complex. In this system, lz acts as an activator that can also 
directly repress expression on enhancers that are co-bound by a cofactor (Cut), by 
recruiting a general repressor (Groucho) (Canon and Banerjee, 2003). It should be 
noted, that this interesting model could only be elucidated by analyzing the 
genomic sequences in the vicinity of consensus Runx binding sites. 
 
In the case of Lmd however, and given the fact that no consensus Lmd 
binding site has been identified, a more general hypothesis must be considered. 
Lmd could exert a dominant inhibitory influence over a transcriptional activator, 
either by locally quenching the activity of Mef2 or through direct repression of the 
locus, similar to transcriptional repressors described in other developmental 
networks (Gray et al., 1995), (Gray and Levine, 1996). In any case, the 
identification of a consensus Lmd binding site would allow to further distinguish 
between the different possibilities by allowing the analysis of the surrounding 




In summary, this study has revealed a large number of novel direct targets 
of lmd, a vast majority of which are co-regulated by Mef2. One of the very first 
observations regarding the activity of lmd was that it was an activator of Mef2. 
However, the severe lmd muscle phenotype is not due merely to the lack of Mef2, 
as reintroducing Mef2 in a lmd background is not sufficient to rescue muscle 
differentiation (Ruiz-Gomez et al., 2002). The data provided in this study provides 
a molecular understanding for why this is the case: lmd modulates the activity of 
Mef2 in a context-dependent fashion, allowing for additive, cooperative or 
repressive interactions in the same cells. Thereby both factors must act 
concomitantly on common enhancers to regulate the developmental program in 
muscle at these stages of development. The mechanism of how their input is 
integrated to finally give rise to either additive or cooperative activation, or even 




8. Appendix  
 
8.1. Non-Overlapping regions bound by Lmd 
 
Table III - Non-overlapping regions obtained by merging all significantly enriched sequences. 
Genome coordinates refer to Drosophila melanogaster genome ver. 5 
 
Merged enriched sequence ID(s) Chrom. Start End Total length 
D880_3_h7 X 13476129 13479662 3533 
D906_1_c1/D906_1_d1/D906_1_e8 X 15164266 15169328 5062 
D1191_4_f11 X 15692317 15695702 3385 
D893_5_g2 X 16166237 16169372 3135 
D904_3_d7/D904_2_a11 X 19323264 19328069 4805 
D905_4_d2/D905_2_g8 X 19509152 19515045 5893 
D843_2_e8/D275_1_g8/D843_2_b4 2L 592328 597682 5354 
D845_1_g4 2L 1160403 1163603 3200 
D847_2_c5 2L 2169778 2172949 3171 
D847_1_g12/D847_1_h11/D847_1_g
4/D847_1_g8 
2L 2207469 2214721 7252 
D1012_2_h1 2L 2750582 2753348 2766 
D1012_2_h3 2L 2830271 2833602 3331 
D1093_4_g9 2L 3409648 3412719 3071 
D263_1_b6 2L 3802652 3805184 2532 
D1088_5_f2/D1088_4_f1 2L 4994370 4999527 5157 
D118_3_h5/D118_3_d7/D118_3_f8 2L 5976548 5983317 6769 
D195_5_h9 2L 6868357 6871835 3478 
D605_6_h3 2L 8104070 8106816 2746 
D1018_1_g1 2L 8947934 8951093 3159 
D1019_4_e5 2L 9160647 9163256 2609 
D336_1_h12/D336_1_h7 2L 9173444 9178048 4604 
D1019_4_b1 2L 9194603 9198375 3772 
D574_1_e5 2L 9565732 9568940 3208 
D571_4_f10 2L 9781599 9785424 3825 
D1020_5_e1 2L 9918493 9922181 3688 
D569_2_g9/D569_6_e10 2L 10964012 10970684 6672 
D307_1_a9/D307_3_a1 2L 11224674 11230482 5808 
D330_4_e3/D330_4_f9 2L 11804678 11808736 4058 
D1137_1_a10 2L 12083640 12086257 2617 
D865_1_b10/D865_1_f1 2L 12482373 12485903 3530 
D539_1_f7 2L 18078231 18081716 3485 
D327_5_f8/D327_2_e2 2L 18137047 18142291 5244 
D543_1_h9 2L 18439322 18442346 3024 
D1035_1_c8 2L 19057828 19061395 3567 
D421_5_c1 2L 19130459 19133927 3468 
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Merged enriched sequence ID(s) Chrom. Start End Total length 
D421_4_d1/D421_2_f12 2L 19152627 19156593 3966 
D534_2_h2 2L 19419631 19423076 3445 
D537_3_c3/D537_4_a6 2L 20461320 20467620 6300 
D537_3_e1 2L 20472546 20475451 2905 
D529_2_e9 2L 20806912 20809941 3029 
D532_6_a11 2L 21815979 21819371 3392 
D532_9_b3 2L 21884985 21887676 2691 
D533_2_d4/D1171_1_e9/D533_4_h9 2L 22006608 22015305 8697 
D1043_1_c5 2R 1591809 1594556 2747 
D1043_1_c4 2R 1629542 1632607 3065 
D916_1_f3 2R 1663764 1666633 2869 
D916_1_a8 2R 1742648 1745613 2965 
D1144_1_d7 2R 2084464 2087669 3205 
D620_2_f3/D620_2_f12 2R 2110150 2114114 3964 
D921_2_g11 2R 3095224 3098606 3382 
D578_7_d12 2R 3685720 3689195 3475 
D580_4_f8/D580_7_h8 2R 4157328 4162837 5509 
D581_6_d6 2R 4306593 4310326 3733 
D582_1_f1 2R 4374401 4377431 3030 
D582_1_h8 2R 4424062 4426759 2697 
D585_6_e2 2R 4914169 4916610 2441 
D443_3_e5/D443_3_e12 2R 5057907 5061560 3653 
D600_2_e4/D599_4_h8 2R 5440854 5445049 4195 
D601_1_f1 2R 5611885 5614537 2652 
D627_1_b10 2R 5932678 5935578 2900 
D1049_1_g2 2R 6050432 6053440 3008 
D1049_2_g4 2R 6129963 6133493 3530 
D628_2_c12 2R 6153065 6156237 3172 
D1050_1_c5 2R 6322303 6326142 3839 
D590_8_a7/D1156_2_f7/D590_4_d7 2R 7119133 7124324 5191 
D590_8_g4 2R 7145035 7147706 2671 
D590_5_a10 2R 7151675 7154633 2958 
D1156_2_e7 2R 7180865 7183742 2877 
D595_6_a8 2R 7967900 7970685 2785 
D595_8_e1/D595_6_h7 2R 8101694 8106719 5025 
D412_2_c7 2R 8275771 8278491 2720 
D587_1_h10 2R 8440520 8444253 3733 
D587_1_e8 2R 8531476 8534265 2789 
D413_3_a11 2R 8738267 8741827 3560 
D474_9_b8 2R 8962362 8966136 3774 
D598_2_h3 2R 9078814 9082044 3230 
D598_2_e8 2R 9099446 9102059 2613 
D598_2_d6 2R 9169498 9172117 2619 
D448_1_e11 2R 9366097 9369853 3756 
D615_1_e2 2R 9389527 9392879 3352 
D616_1_g12 2R 9556940 9560149 3209 
D1052_8_g3 2R 10476910 10480184 3274 
D933_1_g7 2R 11779450 11782030 2580 
D933_1_c3 2R 11819843 11822615 2772 
D435_15_b11 2R 12778247 12781477 3230 
D665_1_a7/D665_1_h10 2R 13229524 13233678 4154 
D937_5_b12 2R 13869627 13872893 3266 
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Merged enriched sequence ID(s) Chrom. Start End Total length 
D939_1_a4 2R 14786294 14789208 2914 
D940_1_e12 2R 14885388 14888474 3086 
D178_3_a2 2R 15144361 15147969 3608 
D179_3_f12/D943_1_d9 2R 15617913 15622538 4625 
D943_1_a3 2R 15625121 15627887 2766 
D1055_2_d6/D651_2_b4 2R 16450050 16453029 2979 
D651_2_f7 2R 16503763 16506941 3178 
D946_1_d5 2R 16707679 16710441 2762 
D186_3_f2 2R 17010236 17013344 3108 
D436_13_h7 2R 17890438 17894406 3968 
D950_1_d11 2R 18017428 18020445 3017 
D950_1_a3 2R 18076379 18079830 3451 
D953_2_c2 2R 18398794 18401401 2607 
D635_2_c2 2R 19173661 19176660 2999 
D956_1_a5 2R 19815670 19818422 2752 
D432_4_d12/D432_3_c5 2R 20320270 20323642 3372 
D431_1_c3 2R 20449921 20452927 3006 
D642_1_h2 2R 20586696 20589629 2933 
CG17181-2-PCR/CG17181-1-PCR 3L 572793 576793 4000 
D1081_6_g4 3R 143200 146222 3022 
D965_3_e1 3R 183867 187506 3639 
D653_1_b5 3R 256888 259616 2728 
D653_2_b11/D653_1_c9 3R 277161 281688 4527 
D670_7_e7 3R 1089484 1091992 2508 
D672_1_h11 3R 1496776 1499733 2957 
D1184_3_h4 3R 2173688 2177210 3522 
D967_4_a7 3R 4879804 4883201 3397 
D834_5_e2 3R 5356583 5360429 3846 
D711_1_e12 3R 6421273 6424345 3072 
D972_2_c9/D973_1_b10 3R 6616897 6621015 4118 
D972_2_e12/D972_1_e3 3R 6650983 6655300 4317 
D679_1_d12 3R 7177783 7180510 2727 
D696_2_a11 3R 7677016 7679506 2490 
D709_3_a8 3R 7711419 7714844 3425 
D696_1_c10 3R 7744998 7747298 2300 
D696_2_f2 3R 7783916 7786716 2800 
D976_5_g10 3R 8104679 8107804 3125 
D979_1_g5/D979_2_b8 3R 9252216 9255920 3704 
D688_5_b4 3R 9637723 9640933 3210 
D689_1_f8 3R 9808951 9811856 2905 
D1195_1_e6 3R 10239057 10241865 2808 
D705_2_e2/D705_1_d4 3R 11110216 11115624 5408 
D700_2_c12 3R 11731656 11735569 3913 
D700_1_b11 3R 11862544 11864667 2123 
D987_2_f7 3R 14517987 14520669 2682 
D728_2_h9 3R 14674329 14676644 2315 
D732_1_b8 3R 15659891 15662868 2977 
D992_2_a9 3R 16079123 16082431 3308 
D743_2_h9 3R 17113053 17115780 2727 
D1189_1_g6/D1189_1_f4/D1189_1_
c3 
3R 17258156 17262118 3962 
D747_1_a6 3R 17430823 17433563 2740 
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Merged enriched sequence ID(s) Chrom. Start End Total length 
D751_4_f11 3R 18192657 18195579 2922 
D757_1_a2 3R 18861125 18863639 2514 
D757_1_b10 3R 18867662 18870482 2820 
D767_1_d11 3R 21008759 21011340 2581 
D773_1_f7 3R 21787297 21790669 3372 
D1061_1_g9 3R 21821255 21824309 3054 
D1061_2_c12/D1061_2_d9 3R 21833392 21839172 5780 
D1061_2_d12 3R 21850899 21854331 3432 
D794_1_d8 3R 25106535 25109594 3059 
D798_1_h7 3R 25719613 25722367 2754 
D802_1_b3 3R 26356268 26358853 2585 
D803_2_e10 3R 26620544 26624503 3959 
D810_1_d7 3R 27514649 27516778 2129 
D810_2_g9 3R 27528694 27532134 3440 
D810_1_d6 3R 27536479 27539356 2877 
D1186_3_b8 4 526918 530249 3331 
 
8.2. Expression profiling of lmd 
Table IV - Expression profiling of lmd. 
Differentially expressed genes with fold change > 1.6 (corresponds to log2 = 0.68) 
and FDR<1% at one or more time-points). Median values of four independent 
repeats (log2). 
 
FBgn Symbol 5-6 h 6-7 h 7-8 h 8-9 h 9-10 h 10-11 h 
FBgn0020766 Aats-phe -0.46 -0.50 -0.20 -0.76 -1.39 -1.25 
FBgn0014454 Acp1 -0.94 -1.25 -0.55 -0.60 -0.30 -0.17 
FBgn0000044 Act57B -0.88 -0.60 -0.74 -0.96 -1.04 -0.22 
FBgn0000046 Act87E -0.20 -0.15 -0.02 -0.77 -0.77 -0.17 
FBgn0000667 Actn 0.13 0.33 0.17 0.15 0.12 0.78 
FBgn0036752 Adgf-A 0.35 0.85 0.16 0.04 -0.06 -0.59 
FBgn0000055 Adh -0.52 -0.26 -0.19 0.41 0.98 1.29 
FBgn0046812 AGO2 0.41 0.85 0.90 0.35 0.26 0.57 
FBgn0000064 Ald -0.02 0.65 0.59 1.02 0.68 1.13 
FBgn0015569 alpha-Est10 1.13 0.50 0.37 0.76 0.69 1.89 
FBgn0003885 alphaTub84D -0.32 -0.12 0.34 -0.34 -0.76 -0.48 
FBgn0003886 alphaTub85E -0.45 -0.42 0.28 -0.20 -0.76 -0.29 
FBgn0000075 amd -0.53 -0.08 0.06 -0.15 0.18 0.70 
FBgn0033366 Ance-4 0.14 0.45 0.38 0.76 0.54 0.83 
FBgn0035076 Ance-5 0.06 0.00 -0.06 0.18 0.29 0.81 
FBgn0026150 ApepP -0.76 -1.42 -0.50 -0.28 -0.28 -0.15 
FBgn0000116 Argk -0.69 0.15 -0.26 -1.61 -1.75 -2.56 
FBgn0038369 Arpc3A -0.21 0.11 -0.12 -0.36 -0.70 -0.43 
FBgn0000120 Arr1 -0.47 0.59 2.25 0.12 -0.35 1.11 
FBgn0000140 asp -0.41 -0.73 -0.63 -0.59 -0.69 -0.33 
FBgn0000147 aur 0.24 -0.18 -0.56 -0.68 -0.87 -0.79 
FBgn0004587 B52 -0.82 -0.99 0.44 -0.70 -1.01 -0.32 
FBgn0025463 Bap60 -0.58 0.02 0.52 -0.29 -0.76 -0.37 
FBgn0014127 barr 0.10 -0.15 -0.27 -0.49 -0.68 -0.48 
FBgn0000165 Bc -0.13 0.73 0.39 0.87 0.82 0.64 
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FBgn Symbol 5-6 h 6-7 h 7-8 h 8-9 h 9-10 h 10-11 h 
FBgn0063765 BcDNA:AT03385 0.37 0.82 0.61 1.21 0.82 0.67 
FBgn0063292 BcDNA:AT28829 -0.57 -0.59 -0.60 -1.09 -0.36 -1.20 
FBgn0063249 BcDNA:GH14618 -0.84 -1.29 -1.47 -1.54 -1.26 -1.93 
FBgn0047290 BcDNA:GM02002 -0.06 -0.43 -1.00 -0.82 -0.56 -0.69 
FBgn0063019 BcDNA:RE43210 -0.17 -0.31 -0.74 -0.55 -0.38 -0.41 
FBgn0047095 BcDNA:RE54004 -0.20 -0.39 -0.56 -0.39 -0.24 -0.72 
FBgn0063664 BcDNA:RH07382 -0.65 -0.35 -0.56 -0.65 -0.81 -1.06 
FBgn0063660 BcDNA:RH25742 -0.81 -0.41 -0.61 -0.72 -0.84 -1.13 
FBgn0063653 BcDNA:RH61266 0.93 0.90 0.83 0.20 1.15 0.13 
FBgn0045760 BcDNA:SD02026 -1.81 -1.73 -1.45 -1.36 -0.88 -1.35 
FBgn0046991 BcDNA:SD03311 2.03 1.49 1.24 1.34 1.08 1.20 
FBgn0061365 BcDNA:SD08734 1.24 1.18 1.08 0.91 0.77 0.58 
FBgn0008635 betaCop 0.09 0.52 0.70 -0.06 -0.20 0.10 
FBgn0010395 betaInt-nu -0.18 -0.19 -0.53 -0.54 -0.46 -1.20 
FBgn0003888 betaTub60D -0.39 0.22 -0.16 -0.55 -0.40 -1.33 
FBgn0003890 betaTub97EF 0.14 0.04 0.21 -0.19 -0.74 -0.33 
FBgn0027348 bgm 0.10 0.63 0.92 0.90 0.68 0.37 
FBgn0002638 Bj1 -0.07 0.09 0.41 -0.35 -0.91 -0.78 
FBgn0000216 Brd 0.03 -0.48 -0.91 -1.48 -1.63 -1.34 
FBgn0025458 Bub1 -0.08 -0.28 -0.27 -0.44 -0.96 -0.53 
FBgn0021742 C901 -0.06 -0.11 -0.07 -0.01 0.24 0.70 
FBgn0000250 cact -0.47 -0.69 -0.23 -0.02 -0.17 0.03 
FBgn0030741 CalpC 0.45 0.52 0.58 0.24 0.20 0.79 
FBgn0010014 CanB -0.11 0.01 -0.13 0.14 0.65 0.91 
FBgn0015614 CanB2 -0.22 -0.10 -0.11 0.39 0.55 0.93 
FBgn0026257 cav -0.27 -0.48 -0.55 -0.65 -0.81 -0.87 
FBgn0004106 cdc2 -0.11 -0.21 -0.25 -0.38 -0.75 -0.72 
FBgn0027491 Cdk5alpha 0.01 0.24 0.03 1.12 0.82 0.72 
FBgn0015618 Cdk8 -0.36 -0.69 -0.53 -0.29 -0.38 -0.24 
FBgn0000277 CecA2 0.41 0.66 0.49 0.90 0.69 0.87 
FBgn0038028 CG10035 -0.78 -1.50 -0.83 -1.26 -1.91 -0.85 
FBgn0033942 CG10112 -2.07 -1.10 -0.29 1.19 1.16 2.20 
FBgn0036353 CG10171 0.15 0.30 0.37 0.68 0.76 1.13 
FBgn0033968 CG10200 0.09 0.08 0.07 0.74 0.69 1.14 
FBgn0037439 CG10286 0.04 -0.15 -0.11 -0.64 -0.87 -0.91 
FBgn0031868 CG10354 1.15 1.46 1.19 0.97 0.68 1.31 
FBgn0036549 CG10516 0.30 0.58 0.53 0.68 0.62 0.84 
FBgn0037044 CG10585 -0.06 0.07 -0.08 -0.18 0.42 1.46 
FBgn0035621 CG10591 -1.18 1.21 1.25 1.88 1.81 1.47 
FBgn0045761 CG10618 0.01 0.20 0.09 0.54 0.54 1.16 
FBgn0032726 CG10621 0.99 1.04 1.28 0.43 0.14 0.27 
FBgn0036290 CG10638 -0.39 -0.58 -0.69 -0.61 -0.38 -0.62 
FBgn0046302 CG10650 0.02 0.10 0.06 0.95 0.73 1.19 
FBgn0032833 CG10664 -0.90 -0.57 0.71 -0.06 -0.81 -0.72 
FBgn0032754 CG10700 -0.36 -0.25 0.24 -0.01 0.33 -0.68 
FBgn0033821 CG10799 0.01 -0.08 -0.03 0.04 0.21 0.71 
FBgn0027930 CG1102 0.43 0.67 0.51 0.66 0.73 0.73 
FBgn0030094 CG11042 0.99 0.97 1.06 0.53 0.18 0.63 
FBgn0030511 CG11158 -0.01 -0.15 -0.23 -0.43 -0.31 -1.15 
FBgn0039800 CG11314 0.66 0.56 0.78 0.76 0.65 0.74 
FBgn0035542 CG11347 -0.52 0.11 0.36 0.37 -0.17 0.70 
FBgn0034200 CG11395 0.01 0.17 -0.08 0.34 0.39 0.70 
FBgn0037165 CG11437 -0.11 1.02 0.97 1.36 1.14 0.56 
FBgn0040623 CG11500 -0.64 -0.79 -0.60 -0.57 -0.49 -0.66 
FBgn0039859 CG11539 -1.37 -1.51 -1.51 -2.21 -1.07 -2.35 
FBgn0036194 CG11652 0.42 -1.27 -0.62 -0.10 -0.77 -0.63 
FBgn0040551 CG11686 -0.36 0.07 -0.14 0.97 0.98 0.72 
FBgn0037239 CG11739 -0.36 0.73 0.29 0.88 0.63 0.77 
FBgn0030294 CG11750 0.83 0.90 0.82 0.46 0.25 0.41 
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FBgn Symbol 5-6 h 6-7 h 7-8 h 8-9 h 9-10 h 10-11 h 
FBgn0037611 CG11755 -0.39 -0.68 -0.59 -0.73 -0.85 -0.68 
FBgn0037615 CG11760 -0.21 -0.32 -0.22 -0.39 -0.60 -0.87 
FBgn0039264 CG11786 -0.27 -0.10 -0.14 0.63 0.98 1.60 
FBgn0033519 CG11825 1.53 -1.62 -1.00 -1.36 -1.66 -1.00 
FBgn0039332 CG11910 -0.04 0.16 0.03 0.93 0.94 1.46 
FBgn0035464 CG12006 0.11 -0.21 -0.37 -0.84 -1.22 -1.09 
FBgn0035430 CG12009 -0.02 -0.03 0.00 0.24 0.26 0.89 
FBgn0038220 CG12207 -0.25 -0.51 -0.09 -0.75 -0.74 -0.78 
FBgn0038002 CG12256 -0.05 -0.01 -0.09 0.15 0.09 0.75 
FBgn0038489 CG12265 0.13 -0.30 -0.32 -0.53 -0.91 -0.88 
FBgn0040808 CG12487 -0.09 -0.71 -0.47 -1.41 -1.33 -1.59 
FBgn0036872 CG12519 -0.32 -0.45 -0.19 -0.22 -0.17 0.84 
FBgn0040666 CG12848 0.33 0.51 0.79 0.31 0.46 0.37 
FBgn0033945 CG12868 0.10 0.92 0.55 1.21 0.92 0.74 
FBgn0033521 CG12896 1.71 -0.25 0.66 0.02 0.15 0.89 
FBgn0033554 CG12938 -0.12 -0.36 -0.36 -0.60 -0.83 -0.93 
FBgn0030771 CG13011 1.05 0.30 -0.03 -1.14 -0.85 -1.58 
FBgn0040794 CG13056 0.99 1.61 1.77 2.12 2.09 2.30 
FBgn0032789 CG13083 0.59 0.38 0.52 1.20 1.15 2.47 
FBgn0033721 CG13159 -2.20 0.84 0.44 0.90 0.85 0.52 
FBgn0033608 CG13220 -0.10 -0.02 0.49 -0.09 -0.55 -0.69 
FBgn0035930 CG13307 0.04 0.06 0.04 0.32 0.27 0.69 
FBgn0033855 CG13333 -0.19 0.04 0.42 -0.38 -0.81 -0.64 
FBgn0029531 CG13362 -0.23 0.28 0.53 1.06 0.97 0.77 
FBgn0030559 CG13404 -0.87 -1.08 -1.13 -0.96 -0.84 -0.89 
FBgn0038901 CG13419 -0.01 0.03 0.04 0.22 0.32 0.91 
FBgn0039795 CG1342 -0.28 0.26 0.11 1.25 0.79 1.68 
FBgn0034514 CG13427 -0.66 -0.47 -0.38 -0.76 -1.03 -1.30 
FBgn0036503 CG13454 0.10 -0.51 -0.79 -1.22 -0.83 -0.69 
FBgn0040809 CG13465 -0.11 -0.74 -0.37 -1.39 -1.57 -1.59 
FBgn0034760 CG13512 -0.36 -0.35 -0.17 -0.28 0.08 -0.77 
FBgn0030151 CG1354 0.27 0.47 0.71 0.11 -0.12 0.04 
FBgn0040660 CG13551 -0.78 -0.78 0.08 -0.06 -0.22 -0.03 
FBgn0034928 CG13562 0.10 0.03 -0.03 0.23 0.25 0.80 
FBgn0039176 CG13610 0.27 -0.27 -0.42 -0.58 -0.84 -0.79 
FBgn0039200 CG13616 -0.01 0.29 0.03 0.63 0.94 0.70 
FBgn0040600 CG13631 -0.09 -0.05 0.09 0.37 0.31 2.09 
FBgn0036773 CG13698 -0.28 0.18 0.15 0.78 0.84 0.65 
FBgn0035578 CG13707 0.03 0.05 0.05 0.34 0.37 0.95 
FBgn0033341 CG13746 -0.41 -0.40 0.48 -0.34 -0.70 -0.55 
FBgn0031897 CG13784 -0.39 -0.77 -0.65 -0.22 -0.11 0.18 
FBgn0035325 CG13806 -0.24 -0.07 -0.02 0.53 0.50 1.13 
FBgn0035313 CG13810 1.43 1.10 0.37 0.55 0.52 1.05 
FBgn0036956 CG13813 -0.13 -0.07 0.01 0.41 0.65 1.13 
FBgn0039041 CG13838 -0.04 0.11 -0.19 -0.57 -0.63 -1.12 
FBgn0038971 CG13845 0.97 0.51 0.28 0.76 0.66 0.80 
FBgn0035173 CG13907 0.62 0.64 0.68 0.40 0.43 0.80 
FBgn0035209 CG13914 0.07 -0.10 -0.20 -0.73 -0.96 -1.08 
FBgn0025712 CG13920 0.08 1.05 1.05 0.61 0.04 -0.01 
FBgn0030277 CG1394 -0.13 -0.08 0.08 0.15 0.34 1.26 
FBgn0031807 CG13981 -0.19 0.23 0.13 1.11 1.00 1.62 
FBgn0031792 CG13983 0.00 0.07 0.09 0.73 0.62 1.32 
FBgn0036359 CG14105 0.09 0.02 0.10 0.52 0.46 0.99 
FBgn0036351 CG14107 -0.02 0.08 -0.28 0.31 0.91 1.75 
FBgn0036352 CG14110 -0.71 0.63 0.61 1.84 1.77 1.58 
FBgn0036193 CG14135 -1.17 -1.37 -0.72 -0.43 -0.86 -0.82 
FBgn0035994 CG14179 1.04 1.15 0.88 0.65 0.24 0.43 
FBgn0031037 CG14207 1.11 1.12 0.89 0.27 0.20 0.04 
FBgn0032022 CG14275 0.53 1.98 0.80 -0.23 -0.26 0.14 
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FBgn Symbol 5-6 h 6-7 h 7-8 h 8-9 h 9-10 h 10-11 h 
FBgn0039620 CG1443 0.05 0.03 -0.04 0.22 0.33 1.03 
FBgn0033046 CG14470 0.00 -0.02 0.13 0.39 0.43 0.85 
FBgn0034228 CG14479 0.08 0.93 0.62 0.26 -0.01 -0.14 
FBgn0034281 CG14490 0.03 -0.01 -0.11 -0.40 -0.18 -0.71 
FBgn0039611 CG14528 0.03 0.08 0.01 0.32 0.35 0.68 
FBgn0040398 CG14629 0.89 1.84 0.97 1.20 1.02 0.84 
FBgn0037835 CG14687 0.61 0.71 -0.30 -0.95 -0.86 -1.31 
FBgn0037819 CG14688 -0.51 -1.21 -0.88 -1.27 -1.35 -0.70 
FBgn0033275 CG14756 -0.47 0.28 0.29 0.97 0.86 0.37 
FBgn0026871 CG14781 -1.03 -0.52 0.43 -0.80 -0.79 0.00 
FBgn0035750 CG14826 0.09 0.26 0.09 0.35 0.41 0.80 
FBgn0032362 CG14928 -0.19 -0.07 -0.01 0.35 0.31 1.34 
FBgn0035428 CG14960 0.04 0.17 0.05 0.98 0.95 1.24 
FBgn0034430 CG15119 -0.11 -0.15 0.26 -0.32 -0.68 -0.74 
FBgn0030322 CG15220 -0.25 -0.39 0.16 -0.65 -1.02 -1.13 
FBgn0029681 CG15239 -0.04 0.00 0.02 0.31 0.11 0.98 
FBgn0030040 CG15347 -0.57 0.49 0.41 1.00 0.77 0.74 
FBgn0040930 CG15352 -0.07 0.06 -0.06 -0.26 -0.36 -0.73 
FBgn0031549 CG15415 -0.53 -0.78 -0.88 -0.70 -0.85 -0.58 
FBgn0031610 CG15436 0.00 -0.20 -0.33 -0.58 -0.53 -0.80 
FBgn0032489 CG15480 -0.64 -0.81 -1.04 -0.84 -1.20 -0.89 
FBgn0034168 CG15614 -0.05 0.84 0.88 0.61 -0.02 -0.22 
FBgn0031635 CG15626 -0.55 -0.29 0.19 -0.34 -0.65 -0.73 
FBgn0031627 CG15630 0.11 0.03 0.05 0.15 0.32 0.76 
FBgn0030309 CG1572 0.02 -0.25 -0.35 0.20 0.53 0.70 
FBgn0031910 CG15818 0.03 0.00 0.11 0.36 0.42 1.17 
FBgn0032136 CG15828 0.53 0.45 0.63 0.48 0.47 0.91 
FBgn0038132 CG15887 -0.33 -0.24 -0.22 0.31 0.31 1.57 
FBgn0033182 CG1621 -0.15 -0.47 -0.06 -0.23 -0.65 -0.69 
FBgn0033453 CG1667 -1.10 -1.06 -0.78 -0.78 -0.58 -0.31 
FBgn0039897 CG1674 -0.21 -0.34 -0.50 0.02 -0.24 -0.88 
FBgn0029768 CG16752 0.32 0.54 0.66 0.46 0.75 0.20 
FBgn0035348 CG16758 0.04 0.36 0.55 0.73 0.57 0.21 
FBgn0029659 CG16782 0.00 -0.02 -0.12 -0.17 -0.28 -0.95 
FBgn0039574 CG16918 0.08 0.32 0.72 1.13 1.23 1.62 
FBgn0040732 CG16926 1.84 1.46 0.53 0.88 0.47 0.62 
FBgn0025621 CG16989 0.69 0.86 0.70 0.06 0.08 0.22 
FBgn0031117 CG1702 -0.20 0.04 0.06 0.22 0.40 0.80 
FBgn0036546 CG17033 -0.40 -0.31 0.42 -0.53 -0.82 -0.58 
FBgn0039051 CG17109 -0.08 -0.08 0.10 0.30 0.25 0.84 
FBgn0039045 CG17119 -0.10 0.14 0.17 0.30 0.31 0.71 
FBgn0035144 CG17181 -0.25 0.72 0.41 -1.03 -1.04 -0.86 
FBgn0027500 CG17286 0.30 0.15 0.04 -0.49 -0.81 -0.59 
FBgn0039915 CG1732 0.11 0.01 0.12 0.30 0.42 0.86 
FBgn0032713 CG17323 -0.09 0.81 0.82 0.75 0.40 0.41 
FBgn0035640 CG17498 -0.57 -0.53 -0.08 -0.63 -0.98 -0.95 
FBgn0034352 CG17669 1.36 1.01 0.71 1.20 0.72 0.79 
FBgn0038718 CG17752 -1.31 -1.47 -1.30 -1.61 -0.90 -1.49 
FBgn0037433 CG17919 0.09 0.07 0.05 0.36 0.57 0.93 
FBgn0030365 CG1796 -0.92 -0.93 -0.35 -0.89 -0.89 -0.93 
FBgn0032189 CG18145 -0.20 -0.60 -0.60 -0.35 -0.76 -0.31 
FBgn0035725 CG18156 0.35 -0.41 -0.51 -0.47 -0.74 -0.90 
FBgn0033836 CG18278 -1.13 -0.64 -0.52 -0.84 -0.63 -0.72 
FBgn0036873 CG18294 -0.43 -0.28 -0.29 -0.23 -0.12 1.15 
FBgn0034382 CG18609 0.05 0.06 0.19 0.22 0.24 0.86 
FBgn0040964 CG18661 -1.12 -1.16 -1.19 -1.37 -1.17 -1.49 
FBgn0040599 CG18669 0.06 0.02 0.10 0.08 0.23 0.69 
FBgn0035398 CG1869 -0.21 0.11 -0.01 0.53 0.66 0.75 
FBgn0042185 CG18769 -0.34 -0.41 -0.21 -0.87 -0.58 -1.05 
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FBgn Symbol 5-6 h 6-7 h 7-8 h 8-9 h 9-10 h 10-11 h 
FBgn0039869 CG1890 -0.31 -0.26 0.02 -0.13 -0.44 -0.72 
FBgn0037468 CG1943 -1.05 -0.90 0.33 -0.76 -1.35 -0.93 
FBgn0039886 CG2003 0.00 0.24 0.05 0.41 0.53 0.80 
FBgn0039664 CG2006 -0.43 -0.40 -0.06 -0.50 -0.52 -0.73 
FBgn0037289 CG2016 0.02 -0.06 0.03 0.37 0.44 1.09 
FBgn0033205 CG2064 0.24 0.76 0.46 0.56 0.31 0.79 
FBgn0039873 CG2191 1.02 -0.67 -0.92 -0.53 -0.95 -0.66 
FBgn0029990 CG2233 -0.53 -0.38 -0.31 0.66 0.71 0.58 
FBgn0029994 CG2254 0.69 1.90 1.72 1.95 1.72 2.23 
FBgn0039665 CG2310 -0.32 0.07 0.33 -0.18 -0.84 -0.57 
FBgn0032969 CG2528 0.05 -0.18 -0.76 -0.51 -0.15 -0.33 
FBgn0030394 CG2560 0.10 -0.02 0.15 0.44 0.67 1.06 
FBgn0037478 CG2656 -0.43 -0.54 -0.70 -0.58 -0.60 -0.47 
FBgn0035090 CG2736 0.00 0.01 -0.08 0.25 0.41 0.87 
FBgn0037534 CG2781 -0.08 -0.04 -0.21 0.30 1.00 0.83 
FBgn0031263 CG2789 -0.87 -0.40 -0.22 -0.42 -0.52 -1.00 
FBgn0030186 CG2962 -0.98 -0.76 0.14 0.77 1.52 2.80 
FBgn0050069 CG30069 -0.01 0.01 -0.02 0.95 1.40 0.91 
FBgn0050148 CG30148 0.03 0.13 0.14 0.96 0.88 2.05 
FBgn0050384 CG30384 -0.37 0.23 -0.08 0.64 0.65 1.01 
FBgn0050392 CG30392 1.03 1.12 0.78 0.75 0.69 0.56 
FBgn0050437 CG30437 -0.14 -0.12 -0.11 0.15 0.72 0.91 
FBgn0050492 CG30492 1.08 0.79 0.55 0.68 0.59 0.87 
FBgn0050502 CG30502 0.14 0.21 0.00 0.61 0.78 0.73 
FBgn0029807 CG3108 0.01 -0.20 -0.34 0.10 0.82 1.37 
FBgn0051300 CG31300 -0.13 0.25 0.21 0.68 0.99 0.26 
FBgn0051323 CG31323 0.04 -0.02 -0.11 0.18 0.40 0.80 
FBgn0038198 CG3153 -0.21 -0.05 0.03 0.90 0.81 1.46 
FBgn0051997 CG31997 -0.08 -0.13 -0.18 0.86 1.14 1.54 
FBgn0051999 CG31999 -0.08 -0.06 -0.30 -0.28 -0.31 -1.04 
FBgn0045770 CG32063 0.17 0.92 0.61 0.70 0.54 1.02 
FBgn0034569 CG3221 -0.40 -0.35 -0.78 -0.78 -0.61 -0.46 
FBgn0031434 CG3227 -0.25 -0.49 -0.45 -0.53 -0.76 -0.69 
FBgn0052369 CG32369 -0.02 -0.19 -0.17 -0.46 -0.43 -0.81 
FBgn0052412 CG32412 -0.02 0.11 0.02 0.33 0.19 0.83 
FBgn0031629 CG3244 -0.93 -0.37 -0.30 0.60 1.48 0.93 
FBgn0052649 CG32649 -0.32 -0.05 -0.02 0.05 0.24 0.70 
FBgn0052756 CG32756 0.10 -0.03 -0.15 -0.30 -0.40 -0.68 
FBgn0053006 CG33006 0.16 0.94 0.68 0.16 -0.05 -0.05 
FBgn0053056 CG33056 -0.05 0.04 0.03 0.56 0.41 0.90 
FBgn0053143 CG33143 0.13 0.74 0.26 -1.15 -1.07 -0.99 
FBgn0040609 CG3348 -0.17 -0.08 0.17 -0.28 -0.87 -1.51 
FBgn0034792 CG3499 0.81 0.78 0.81 0.23 0.05 0.37 
FBgn0038250 CG3505 -0.25 0.05 0.04 0.55 0.41 1.33 
FBgn0038467 CG3590 0.47 0.50 0.72 0.41 0.14 0.24 
FBgn0031418 CG3609 -0.74 0.21 0.43 0.66 0.64 0.75 
FBgn0040397 CG3655 0.92 1.18 0.60 0.41 0.63 1.13 
FBgn0027521 CG3679 -0.54 -0.53 -0.70 -0.97 -1.02 -1.14 
FBgn0040349 CG3699 0.51 -0.11 0.08 0.44 0.55 0.68 
FBgn0034951 CG3860 -0.07 0.21 0.10 0.40 0.34 0.69 
FBgn0038292 CG3987 -0.03 0.14 0.00 0.71 0.93 0.73 
FBgn0037801 CG3999 0.50 -0.65 -0.13 0.64 0.72 1.10 
FBgn0038017 CG4115 -1.10 0.14 0.08 1.55 1.40 2.36 
FBgn0030745 CG4239 0.00 -0.05 -0.08 -0.13 -0.11 -0.79 
FBgn0034761 CG4250 -0.07 -0.13 -0.23 -0.45 -0.44 -0.98 
FBgn0014092 CG4278 -0.53 -0.15 -0.16 -0.42 -0.45 -0.70 
FBgn0025632 CG4313 -0.15 0.14 0.46 1.23 0.83 0.55 
FBgn0030452 CG4330 0.38 0.69 0.69 0.19 0.07 0.19 
FBgn0039075 CG4393 0.10 0.19 0.25 0.58 0.51 0.72 
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FBgn Symbol 5-6 h 6-7 h 7-8 h 8-9 h 9-10 h 10-11 h 
FBgn0039073 CG4408 -1.21 -1.45 -0.63 -0.73 -0.53 -0.98 
FBgn0034128 CG4409 1.80 1.38 0.91 0.99 0.74 0.89 
FBgn0040984 CG4440 -0.33 -0.69 -0.39 -1.19 -1.67 -1.77 
FBgn0032105 CG4454 -0.84 -0.79 0.10 -0.63 -1.09 -0.82 
FBgn0029838 CG4666 -0.45 -0.24 -0.34 0.55 1.13 1.44 
FBgn0033815 CG4676 0.18 -0.30 -0.43 -0.72 -0.84 -0.70 
FBgn0037992 CG4702 -0.17 0.05 0.03 1.73 1.36 2.44 
FBgn0039024 CG4721 0.00 -0.03 -0.05 0.19 0.30 0.73 
FBgn0043456 CG4747 1.04 1.52 1.20 0.18 0.07 0.46 
FBgn0027600 CG4778 0.03 0.12 0.20 0.40 0.31 0.74 
FBgn0032618 CG4826 0.04 0.15 0.00 0.31 0.20 0.86 
FBgn0030803 CG4880 -0.63 -0.81 -0.44 -0.77 -0.70 -0.72 
FBgn0036616 CG4893 0.15 -0.17 -0.12 0.17 0.74 0.78 
FBgn0034145 CG5065 -0.11 0.29 0.19 0.63 0.71 0.43 
FBgn0031320 CG5126 -0.43 -0.34 -0.22 -0.47 -0.61 -0.76 
FBgn0035957 CG5144 -0.52 -0.21 -0.13 -0.51 -0.60 -0.96 
FBgn0038476 CG5175 -0.40 -0.58 -0.66 -0.70 -1.11 -0.89 
FBgn0031908 CG5177 -0.42 -0.36 -0.85 -0.38 -0.44 -1.77 
FBgn0034365 CG5335 -0.16 0.42 0.21 0.88 0.99 0.52 
FBgn0032242 CG5355 -0.39 -0.83 -0.68 -0.32 -0.41 -0.07 
FBgn0032213 CG5390 -0.11 0.44 0.09 0.64 0.48 1.45 
FBgn0039521 CG5402 -0.13 -0.04 0.05 0.52 1.00 0.78 
FBgn0032436 CG5418 0.00 0.10 -0.07 0.18 0.30 0.79 
FBgn0034887 CG5428 0.23 0.29 0.09 0.30 0.24 0.83 
FBgn0034888 CG5431 -0.06 -0.06 -0.18 0.48 0.53 1.00 
FBgn0038384 CG5470 -0.06 -0.17 0.06 0.32 0.52 0.91 
FBgn0034364 CG5493 -0.22 0.81 -0.25 -1.24 -0.47 0.13 
FBgn0027565 CG5498 -0.79 -0.78 -0.73 -0.50 -0.45 -0.27 
FBgn0039560 CG5514 0.51 0.73 0.83 0.51 0.34 0.57 
FBgn0034158 CG5522 0.18 -0.61 -0.86 -0.16 -0.34 -0.10 
FBgn0034902 CG5532 -0.79 -0.71 0.13 -0.27 -0.60 -0.71 
FBgn0035639 CG5537 -0.23 0.00 0.34 -0.48 -0.74 -0.65 
FBgn0034914 CG5554 -1.49 -0.95 -0.18 -1.06 -1.26 -1.10 
FBgn0032200 CG5676 -0.28 -0.66 -0.31 -0.42 -0.44 -0.71 
FBgn0039172 CG5677 -0.01 -0.03 -0.03 0.27 0.27 1.13 
FBgn0032197 CG5694 -0.02 -0.14 -0.13 0.35 0.29 1.26 
FBgn0034310 CG5733 -0.38 -0.86 -0.78 -0.66 -0.94 -0.64 
FBgn0034299 CG5757 -0.19 -0.40 -0.29 -0.46 -0.43 -0.75 
FBgn0039198 CG5768 -0.09 0.05 0.09 0.53 0.54 1.41 
FBgn0034290 CG5773 1.84 1.55 1.16 1.24 0.99 0.98 
FBgn0038516 CG5840 0.42 0.16 0.28 0.41 0.62 0.81 
FBgn0038511 CG5873 -0.10 0.20 0.33 0.52 0.76 1.08 
FBgn0039379 CG5886 0.08 0.12 -0.13 -0.48 -0.56 -0.93 
FBgn0039139 CG5933 -0.37 -0.85 -0.46 -0.20 -0.41 0.00 
FBgn0031913 CG5958 1.21 1.58 1.09 0.57 0.42 0.74 
FBgn0038056 CG5961 -0.35 -0.72 -0.66 -0.89 -0.50 -0.78 
FBgn0038676 CG6026 -0.08 0.06 -0.01 0.25 0.35 1.58 
FBgn0036182 CG6084 -0.26 -0.10 -0.04 0.45 0.86 1.79 
FBgn0036542 CG6112 -0.03 -0.38 -0.61 -0.99 -0.52 -0.96 
FBgn0038407 CG6126 0.36 0.87 0.42 0.43 0.30 0.38 
FBgn0032252 CG6232 -0.12 -0.04 -0.15 0.17 0.21 0.80 
FBgn0038071 CG6234 -0.43 -0.76 -0.24 0.04 -0.45 0.01 
FBgn0034276 CG6385 -0.08 -0.05 -0.04 0.46 0.54 1.12 
FBgn0027889 CG6386 -0.15 -0.27 -0.04 -0.84 -0.76 -0.72 
FBgn0032287 CG6415 -0.03 -0.07 0.15 0.70 0.41 0.76 
FBgn0034162 CG6426 -0.05 -0.05 0.03 0.24 0.34 0.79 
FBgn0039213 CG6668 0.13 0.36 0.70 0.26 0.14 0.25 
FBgn0033887 CG6704 0.06 -0.05 -0.04 0.38 0.31 1.24 
FBgn0032394 CG6746 -0.04 -0.34 -0.32 0.09 0.08 0.68 
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FBgn0032292 CG6750 0.40 0.63 0.86 0.48 0.19 0.16 
FBgn0036031 CG6761 0.06 -0.09 -0.04 0.07 0.24 0.68 
FBgn0032400 CG6770 -0.36 -0.20 -0.05 0.90 0.82 0.16 
FBgn0037913 CG6783 -0.29 0.74 0.66 0.71 0.53 0.56 
FBgn0032399 CG6785 -0.19 -0.03 0.09 0.25 0.23 1.06 
FBgn0030882 CG6835 -0.39 -0.33 -0.09 NA -0.39 -0.77 
FBgn0036815 CG6874 0.22 -0.27 -0.44 -0.50 -0.62 -0.78 
FBgn0030955 CG6891 1.83 2.04 1.54 1.63 1.41 1.48 
FBgn0036800 CG6897 -0.02 -0.69 -0.77 -0.55 -0.78 -0.54 
FBgn0030958 CG6900 0.56 1.29 0.89 1.48 1.29 1.29 
FBgn0036261 CG6906 -0.30 -0.16 -0.04 0.30 0.45 0.78 
FBgn0037956 CG6959 0.31 0.97 0.85 0.75 0.30 0.37 
FBgn0039008 CG6972 -0.19 -0.13 -0.25 -0.20 -0.55 -1.26 
FBgn0036945 CG6981 -0.46 0.32 0.22 1.29 0.73 0.40 
FBgn0038972 CG7054 -0.76 -0.93 -0.26 -0.66 -0.33 -0.25 
FBgn0031961 CG7102 -0.25 -0.53 -0.92 -0.55 -0.62 -0.50 
FBgn0031947 CG7154 -0.32 -0.47 -0.87 -0.57 -0.53 -0.56 
FBgn0038574 CG7212 -0.29 -0.72 -0.63 -0.63 -0.72 -0.57 
FBgn0031971 CG7224 0.17 -1.11 -0.31 -0.84 -1.58 -2.26 
FBgn0031970 CG7227 -0.09 0.02 0.03 1.03 0.94 1.29 
FBgn0032286 CG7300 0.07 -0.06 0.17 0.35 0.64 0.98 
FBgn0031977 CG7380 0.00 -0.34 -0.34 -0.52 -0.63 -0.78 
FBgn0036927 CG7433 -1.04 -0.72 -0.47 0.20 0.12 0.75 
FBgn0038533 CG7523 -0.20 -0.29 -0.22 -0.40 -0.75 -0.98 
FBgn0035798 CG7526 -0.18 -0.12 -0.23 -0.03 -0.15 -0.73 
FBgn0036738 CG7542 -0.09 -0.15 -0.12 -0.34 -0.18 -0.80 
FBgn0038610 CG7675 -0.74 0.77 0.48 1.35 1.36 0.68 
FBgn0033633 CG7759 0.01 0.09 -0.17 -0.37 -0.60 -1.12 
FBgn0032021 CG7781 -0.07 0.10 -0.08 0.12 0.31 0.68 
FBgn0039704 CG7802 0.17 0.95 0.86 0.74 0.30 1.11 
FBgn0039736 CG7912 -0.25 -0.72 -0.67 -1.03 -0.70 -1.03 
FBgn0037607 CG8036 -0.35 0.74 1.06 0.59 0.42 0.58 
FBgn0034011 CG8160 -0.09 -0.01 -0.07 -0.01 0.41 0.81 
FBgn0030864 CG8173 0.07 -0.21 -0.03 -0.66 -0.79 -0.78 
FBgn0033367 CG8193 0.25 0.85 0.96 0.28 -0.39 -0.15 
FBgn0030683 CG8239 -0.03 -0.38 -0.43 0.17 -0.08 0.78 
FBgn0037718 CG8286 0.58 0.78 0.28 0.51 0.42 0.54 
FBgn0034143 CG8303 -0.14 -0.07 -0.12 0.17 0.23 0.97 
FBgn0034142 CG8306 0.42 0.31 -0.19 0.39 0.48 0.74 
FBgn0037723 CG8327 0.73 0.45 0.27 0.70 0.62 0.76 
FBgn0037634 CG8359 -0.06 -0.48 -0.66 -0.92 -0.59 -0.82 
FBgn0037664 CG8420 -0.22 0.02 0.35 1.21 0.68 0.91 
FBgn0037670 CG8436 0.08 -0.29 -0.48 -0.62 -0.88 -0.79 
FBgn0033917 CG8503 -0.07 0.19 0.01 -0.51 -0.72 -1.20 
FBgn0037759 CG8526 -0.44 -0.77 -0.62 -0.51 -0.48 -0.33 
FBgn0035773 CG8580 -0.11 -0.21 -0.08 -0.55 -0.75 -0.71 
FBgn0033921 CG8589 -0.53 -0.92 -0.74 -0.65 -0.46 -0.43 
FBgn0033271 CG8708 -0.05 0.09 0.21 0.60 0.49 0.69 
FBgn0033764 CG8776 0.44 0.61 0.73 1.24 0.80 0.85 
FBgn0028955 CG8788 -0.41 -0.43 0.33 -0.07 -0.62 -0.75 
FBgn0031663 CG8891 -1.44 -0.83 -0.31 0.04 0.21 0.24 
FBgn0031886 CG8902 -0.08 -0.41 -0.50 -0.70 -0.70 -0.70 
FBgn0035199 CG9134 -0.19 -0.14 -0.10 0.35 0.55 0.88 
FBgn0035194 CG9187 -0.10 -0.02 -0.09 -0.69 -0.73 -1.05 
FBgn0038180 CG9307 0.01 0.06 0.07 0.43 0.53 0.73 
FBgn0032879 CG9317 -0.28 0.05 1.06 -0.10 -0.31 0.42 
FBgn0032895 CG9335 -0.01 0.08 -0.02 0.43 0.52 0.79 
FBgn0032897 CG9336 -0.10 1.23 0.62 1.16 0.88 0.89 
FBgn0032899 CG9338 -0.07 0.97 0.82 1.21 0.87 0.81 
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FBgn0035094 CG9380 0.28 0.14 -0.13 0.91 0.67 1.09 
FBgn0037063 CG9391 0.03 -0.04 0.04 0.61 0.48 0.68 
FBgn0037715 CG9399 -0.36 -0.62 -0.19 -0.71 -0.79 -0.59 
FBgn0034438 CG9416 0.09 0.67 0.66 1.08 0.68 0.96 
FBgn0037730 CG9444 0.29 0.24 0.19 0.41 0.35 0.75 
FBgn0036875 CG9449 1.80 1.41 0.60 1.05 0.88 0.60 
FBgn0033115 CG9460 0.01 0.04 0.08 0.45 0.37 0.70 
FBgn0030587 CG9522 -0.07 -0.01 -0.14 0.19 0.33 1.18 
FBgn0032087 CG9568 -0.34 -0.15 -0.33 0.13 0.91 1.22 
FBgn0036433 CG9628 -0.46 0.92 0.36 0.78 0.35 0.23 
FBgn0036857 CG9629 1.20 0.94 0.19 0.68 0.72 1.05 
FBgn0031483 CG9641 -0.11 -0.16 -0.23 -0.71 -0.68 -0.98 
FBgn0031515 CG9664 1.11 0.77 0.13 0.52 0.27 0.43 
FBgn0030159 CG9689 -0.72 0.24 0.30 1.23 1.00 0.92 
FBgn0036661 CG9705 -0.23 -0.53 -0.30 -0.65 -0.37 -0.77 
FBgn0037669 CG9740 0.03 -0.42 -0.39 -0.57 -0.73 -0.71 
FBgn0038149 CG9796 -1.00 0.71 0.64 0.65 0.40 -0.14 
FBgn0037637 CG9836 0.67 0.61 0.77 0.46 0.21 0.16 
FBgn0031453 CG9894 -0.39 -0.40 0.78 -0.65 -0.90 -0.10 
FBgn0030755 CG9906 0.59 0.97 0.96 0.36 0.37 0.49 
FBgn0035726 CG9953 -0.66 -0.93 -0.58 -0.51 -0.67 -0.46 
FBgn0023395 Chd3 0.20 -0.19 -0.53 -0.42 -0.61 -0.70 
FBgn0035499 Chd64 -0.47 0.39 0.12 1.07 0.79 0.80 
FBgn0000337 cn 1.14 0.16 -0.25 -0.93 -1.05 -0.60 
FBgn0015622 Cnx99A 0.56 1.02 1.17 0.35 0.56 0.65 
FBgn0063757 CR32366 0.01 -0.19 -0.25 -0.50 -0.55 -0.88 
FBgn0047242 CR32646 -0.18 0.95 0.76 0.89 0.83 0.36 
FBgn0053327 CR33327 -0.22 -0.13 0.21 0.81 0.78 0.50 
FBgn0000405 CycB -0.04 0.11 0.11 -0.50 -0.97 -1.15 
FBgn0015625 CycB3 -0.45 -0.52 -0.48 -0.99 -1.45 -1.38 
FBgn0053503 Cyp12d1-d 0.46 0.01 -0.38 -0.77 -0.25 -0.73 
FBgn0038095 Cyp304a1 0.13 0.16 -0.13 0.53 0.55 2.01 
FBgn0035618 Cyp307a1 -1.15 -1.05 -0.15 -0.15 -0.33 0.04 
FBgn0037601 Cyp313b1 -0.08 -0.05 -0.01 0.20 0.27 0.86 
FBgn0010019 Cyp4g1 -0.66 -0.31 -0.15 0.54 0.68 1.85 
FBgn0033304 Cyp6a13 0.04 0.06 0.02 0.25 0.39 1.10 
FBgn0033978 Cyp6a23 0.03 0.22 0.29 0.73 0.58 0.90 
FBgn0013772 Cyp6a8 0.77 1.33 0.87 0.66 -0.12 0.27 
FBgn0015040 Cyp9c1 0.04 0.04 0.07 0.32 0.49 1.03 
FBgn0038037 Cyp9f2 0.04 0.57 0.31 1.13 0.92 0.74 
FBgn0038034 Cyp9f3Psi 0.04 0.11 0.13 0.85 0.58 0.60 
FBgn0035141 Cypl -0.80 -0.69 0.09 -0.34 -0.50 -0.38 
FBgn0000406 Cyt-b5-r -0.17 -0.44 -0.66 -0.84 -0.80 -0.41 
FBgn0010316 dap 0.60 0.71 0.23 -0.32 -0.88 -0.49 
FBgn0028381 decay -0.08 0.02 0.06 0.44 0.68 0.75 
FBgn0035964 Dhpr -0.13 -0.20 0.14 0.06 0.16 0.74 
FBgn0000449 dib -0.49 -0.70 -0.77 -0.63 -0.76 -0.46 
FBgn0000454 Dip-B -0.47 -0.34 -0.07 0.42 0.47 0.71 
FBgn0039802 dj-1beta -1.23 -0.67 -0.03 -0.82 -0.71 -1.07 
FBgn0022338 dnk -0.14 -0.20 0.22 -0.29 -0.60 -0.76 
FBgn0020306 dom 0.21 0.74 0.66 0.04 -0.04 0.14 
FBgn0015929 dpa -0.28 -0.14 0.68 -0.30 -0.82 -0.57 
FBgn0002183 dre4 -0.52 -0.64 -0.10 -0.61 -0.64 -0.72 
FBgn0035434 dro5 -0.96 -1.98 -1.54 -2.93 -2.83 -3.28 
FBgn0010381 Drs -0.34 -0.78 -0.76 -1.42 -1.41 -1.86 
FBgn0011764 Dsp1 -0.45 -0.18 -0.37 -0.81 -0.92 -1.11 
FBgn0028737 Ef1beta -0.94 -0.84 -0.03 -0.53 -1.01 -0.82 
FBgn0003731 Egfr 0.76 0.78 0.68 0.53 0.36 0.97 
FBgn0040227 eIF-3p66 -0.37 -0.20 0.59 0.01 -0.79 -0.24 
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FBgn0000565 Eip71CD -0.02 -0.22 -0.07 -0.41 -0.75 -0.82 
FBgn0000570 elav -0.21 0.02 -0.07 -0.55 -0.43 -0.75 
FBgn0010435 emp -0.01 0.14 0.03 0.41 0.61 0.72 
FBgn0034433 endoB 0.48 0.85 0.58 1.16 0.90 1.25 
FBgn0000579 Eno -0.01 0.04 0.08 -0.09 -0.83 -1.12 
FBgn0013953 Esp 0.09 -0.46 -0.51 -0.10 -0.68 -0.68 
FBgn0000636 Fas3 0.00 1.01 1.14 0.72 0.12 0.09 
FBgn0026721 fat-spondin -0.13 0.58 0.64 0.68 0.55 0.75 
FBgn0032820 fbp -0.56 0.24 0.21 0.75 0.43 0.02 
FBgn0033079 Fmo-2 0.12 -0.12 -0.22 0.07 0.28 1.03 
FBgn0040222 fne -0.12 0.56 0.34 0.71 0.41 0.26 
FBgn0025373 Fpps 0.09 -0.58 -0.77 -0.20 -0.78 -0.60 
FBgn0016081 fry -0.28 -0.49 -0.61 -0.70 -0.79 -0.50 
FBgn0036485 FucTA 0.13 0.18 0.11 0.44 0.45 0.70 
FBgn0001086 fzy -0.02 -0.32 -0.38 -0.48 -0.85 -0.67 
FBgn0010223 Galpha73B 0.26 0.23 0.06 0.62 0.40 0.74 
FBgn0028968 gammaCop 0.70 0.75 0.88 0.58 0.47 0.55 
FBgn0026077 Gasp -0.69 0.36 -0.05 1.24 1.25 1.61 
FBgn0004868 Gdi 0.18 0.28 0.69 0.25 -0.02 -0.09 
FBgn0033081 geminin 0.25 0.16 0.30 -0.46 -0.70 -0.70 
FBgn0027341 Gfat1 -0.38 0.03 -0.09 0.71 1.38 1.29 
FBgn0027657 glob1 1.33 1.39 0.69 1.25 1.47 1.49 
FBgn0001114 Glt -0.21 -0.13 0.03 0.99 0.72 1.81 
FBgn0034603 Glycogenin -0.18 -0.02 -0.03 -0.54 -0.28 -0.84 
FBgn0004919 gol -0.29 0.02 -0.59 -1.05 -0.89 -0.88 
FBgn0039520 Gr98a 1.84 2.19 2.08 2.11 2.07 2.74 
FBgn0001148 gsb -0.27 -0.83 -0.72 -0.82 -1.14 -0.80 
FBgn0010041 GstD5 -0.03 0.35 0.46 0.84 0.69 1.16 
FBgn0034335 GstE1 0.02 0.10 0.49 0.85 0.81 1.19 
FBgn0010391 Gtp-bp 0.20 0.46 0.70 0.34 0.06 0.23 
FBgn0004461 gwl -0.32 -0.43 -0.62 -0.42 -0.76 -0.40 
FBgn0001174 halo -1.10 -0.79 -0.39 -0.45 -0.51 -0.27 
FBgn0040211 hgo -0.09 0.00 -0.05 0.07 0.24 0.83 
FBgn0030900 Him 0.39 0.64 1.13 0.98 0.89 0.81 
FBgn0061209 His2B:CG17949 2.10 2.85 2.66 3.19 3.52 3.57 
FBgn0002609 HLHm3 0.88 0.92 0.46 -0.13 -0.24 -0.32 
FBgn0002631 HLHm5 -0.22 -0.68 -0.55 -0.79 -0.34 -0.63 
FBgn0002734 HLHmdelta 0.13 -0.56 -0.86 -0.93 -0.97 -0.87 
FBgn0002735 HLHmgamma -0.17 -0.53 -0.56 -0.67 -0.95 -0.81 
FBgn0004362 HmgD 0.05 0.03 0.28 -0.19 -0.46 -0.83 
FBgn0010611 Hmgs 0.33 0.67 0.52 0.54 0.77 1.49 
FBgn0001208 Hn -0.03 0.19 -0.03 0.90 1.04 1.48 
FBgn0030082 HP1b -0.60 -0.54 0.10 -0.57 -0.70 -0.82 
FBgn0001217 Hsc70-2 -1.11 -0.87 -0.67 -0.51 -0.42 -0.53 
FBgn0001219 Hsc70-4 -0.34 0.25 2.15 -0.08 -0.44 1.16 
FBgn0001223 Hsp22 -2.77 -1.22 -0.23 -0.71 -1.14 -0.31 
FBgn0001224 Hsp23 -1.43 -1.27 -0.48 -1.07 -0.92 -0.24 
FBgn0001226 Hsp27 -1.19 -0.83 -0.17 -0.29 -0.36 -0.59 
FBgn0013275 Hsp70Aa -2.08 -1.41 -0.37 -0.70 -0.90 0.05 
FBgn0024227 ial 0.08 0.16 0.20 -0.49 -0.86 -0.60 
FBgn0019972 Ice -0.47 -0.24 0.36 -0.39 -0.93 -0.52 
FBgn0020415 Idgf2 -0.23 -0.30 -0.02 0.82 0.78 1.49 
FBgn0001250 if 0.56 0.72 0.75 0.74 0.67 0.64 
FBgn0033835 IM10 -0.18 -0.05 -0.04 0.09 0.37 0.71 
FBgn0001254 ImpE2 -0.60 -0.26 -0.02 0.73 0.99 1.19 
FBgn0001256 ImpL1 -0.57 -0.14 -0.18 1.53 1.49 1.60 
FBgn0001257 ImpL2 -0.50 -0.75 -0.08 -0.72 -1.56 -1.24 
FBgn0001258 ImpL3 0.07 -0.06 0.05 -0.50 -0.93 -1.30 
FBgn0011603 ine 0.05 -0.02 0.02 0.10 0.21 0.96 
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FBgn Symbol 5-6 h 6-7 h 7-8 h 8-9 h 9-10 h 10-11 h 
FBgn0025885 Inos -0.03 -0.31 -0.06 -0.86 -0.85 -0.61 
FBgn0001276 ix -0.14 -0.38 -0.53 -0.47 -0.70 -0.58 
FBgn0028841 jhamt -0.08 -0.20 -0.36 -1.18 -1.66 -3.28 
FBgn0010053 Jheh1 0.02 0.11 0.08 0.76 0.42 0.82 
FBgn0034406 Jheh3 -0.45 0.11 0.10 0.87 0.76 0.63 
FBgn0028425 JhI-21 -0.11 -0.26 -0.51 -0.44 -0.50 -0.68 
FBgn0028424 JhI-26 0.12 0.26 0.29 0.69 0.52 0.18 
FBgn0015396 jumu 0.31 -0.19 -0.55 -0.38 -0.71 -0.50 
FBgn0028370 kek3 0.07 -0.70 -0.18 -0.63 -0.77 -1.33 
FBgn0004378 Klp61F 0.11 -0.16 -0.74 -0.57 -0.73 -0.49 
FBgn0028342 l(1)G0230 -0.80 -0.92 -0.57 -0.19 -0.36 -0.36 
FBgn0002561 l(1)sc -0.11 -0.51 -0.53 -0.73 -0.73 -0.49 
FBgn0010488 l(2)01424 0.11 0.74 0.58 0.23 0.19 0.29 
FBgn0010622 l(2)06496 -1.12 -0.61 -0.12 -0.54 -0.72 -0.60 
FBgn0010786 l(3)02640 0.91 0.86 0.69 0.78 0.48 1.01 
FBgn0002526 LanA 0.73 0.76 0.97 0.35 0.14 0.48 
FBgn0002527 LanB1 0.66 0.80 0.78 0.62 0.38 0.47 
FBgn0016032 lbm -0.18 0.42 0.30 1.03 0.73 0.71 
FBgn0041203 LIMK1 0.36 0.69 0.80 0.58 0.89 0.17 
FBgn0039039 lmd 0.19 0.93 0.52 -0.29 -0.27 -0.54 
FBgn0039114 Lsd-1 0.08 0.49 0.39 0.54 0.34 0.87 
FBgn0010602 lwr -0.63 -0.53 0.27 -0.49 -0.79 -0.56 
FBgn0004425 LysB 1.20 0.95 0.59 0.78 0.51 0.34 
FBgn0002629 m4 -0.36 -0.73 -0.53 -0.98 -0.79 -0.96 
FBgn0002632 m6 -0.12 1.20 0.91 1.61 1.50 1.18 
FBgn0010342 Map60 0.18 -0.05 0.06 -0.55 -0.69 -0.39 
FBgn0017577 Mcm5 -0.41 -0.69 -0.34 -0.68 -1.17 -0.82 
FBgn0043069 MESK4 0.23 0.57 0.78 1.03 0.84 0.84 
FBgn0004228 mex1 -0.04 0.43 0.31 1.35 1.10 1.10 
FBgn0011643 Mlp60A -0.90 -1.10 -1.48 -0.35 -0.40 -0.80 
FBgn0026409 Mpcp -0.93 -0.46 0.28 -0.22 -1.07 -0.89 
FBgn0030556 mRNA-capping-
enzyme 
0.08 0.01 0.01 0.31 0.25 1.10 
FBgn0039555 mRpS22 -0.16 -0.34 0.14 -0.39 -0.57 -0.84 
FBgn0035534 mRpS6 -0.25 -0.51 -0.43 -0.47 -0.44 -0.90 
FBgn0027949 msb1l -0.04 -0.31 0.24 -0.75 -1.04 -0.82 
FBgn0002775 msl-3 -1.30 -1.11 -0.37 -0.62 -0.35 -0.98 
FBgn0002868 MtnA -0.28 -0.08 0.09 0.89 1.08 1.18 
FBgn0010246 Myo61F -0.03 0.24 0.08 0.69 0.79 0.78 
FBgn0017565 Nacalpha -0.49 -0.10 0.67 -0.24 -0.70 -0.53 
FBgn0002924 ncd 0.06 -0.05 0.25 -0.47 -0.69 -0.71 
FBgn0002931 net -1.09 -0.31 -0.34 -0.50 -0.59 -1.10 
FBgn0002939 ninaD 0.02 0.05 -0.21 -0.62 -0.50 -1.13 
FBgn0016685 Nlp -0.15 -0.20 0.13 -0.74 -0.58 -0.66 
FBgn0005771 noc -0.38 -0.32 -0.52 -0.62 -0.73 -0.90 
FBgn0032946 nrv3 0.41 0.53 0.36 0.50 0.96 0.67 
FBgn0029147 NtR 0.58 0.84 0.40 0.52 0.48 0.48 
FBgn0036640 nxf2 0.03 -0.55 -0.93 -1.10 -1.05 -1.07 
FBgn0034468 Obp56a -0.27 0.10 0.50 1.16 1.07 0.95 
FBgn0039678 Obp99a 0.20 0.32 0.14 -0.37 -0.42 -0.87 
FBgn0040296 Ocho -0.32 -0.63 -0.42 -0.75 -1.08 -0.83 
FBgn0033901 O-fut1 -0.65 -0.99 -0.80 -0.23 -0.67 -0.32 
FBgn0002997 ome -0.07 0.01 0.00 0.66 0.66 0.96 
FBgn0015271 Orc5 -0.34 -0.84 -0.55 -0.30 -0.82 -0.54 
FBgn0019952 Orct 0.56 0.78 0.63 0.73 0.53 0.53 
FBgn0040279 Osi14 -0.26 -0.11 -0.23 0.18 0.45 1.17 
FBgn0037424 Osi15 -1.08 -0.23 -0.61 0.73 0.86 2.16 
FBgn0037429 Osi19 -0.29 -0.03 -0.10 0.03 0.62 1.98 
FBgn0027527 Osi6 -0.48 -0.55 -0.45 1.04 1.04 1.83 
APPENDIX 118 
 
FBgn Symbol 5-6 h 6-7 h 7-8 h 8-9 h 9-10 h 10-11 h 
FBgn0037414 Osi7 -0.55 -0.14 -0.22 0.54 0.29 1.57 
FBgn0037416 Osi9 -0.10 0.07 -0.13 0.04 0.22 1.26 
FBgn0060296 pain -0.08 -0.02 -0.02 0.20 0.32 0.76 
FBgn0020389 Paps -0.17 0.34 0.80 0.41 0.20 -0.04 
FBgn0011692 pav -0.11 -0.53 -0.93 -1.14 -1.08 -1.14 
FBgn0004401 Pep -0.78 -0.29 0.55 -0.49 -0.92 0.36 
FBgn0040959 Peritrophin-15a 1.01 0.37 0.73 0.72 1.34 -0.04 
FBgn0036529 pgant8 0.24 0.30 0.18 0.26 0.55 0.99 
FBgn0003076 Pgm -0.53 -0.29 -0.55 -0.82 -0.74 -1.09 
FBgn0039779 PH4alphaSG2 -0.03 0.14 -0.11 -0.29 -0.44 -0.78 
FBgn0016054 phr6-4 -0.09 -0.25 -0.29 -0.55 -0.61 -0.70 
FBgn0003087 pim 0.00 -0.43 -0.52 -0.64 -0.91 -1.31 
FBgn0003114 plu -0.77 -0.85 -0.22 -0.59 -0.26 -0.88 
FBgn0003124 polo 0.25 0.08 -0.39 -0.65 -0.76 -0.99 
FBgn0014269 prod -0.16 -0.04 0.27 -0.59 -0.68 -0.60 
FBgn0015282 Pros26.4 0.90 0.78 0.78 0.51 0.37 0.61 
FBgn0033520 Prx2540-1 1.76 -0.17 0.70 -0.01 0.13 0.90 
FBgn0033518 Prx2540-2 1.78 -0.18 0.66 0.17 0.15 1.01 
FBgn0003187 qua -0.13 0.14 -0.04 0.55 0.52 0.93 
FBgn0033881 RacGAP50C 0.23 -0.18 -0.50 -0.57 -1.05 -0.78 
FBgn0024194 rasp -0.32 -0.64 -0.75 -0.86 -0.94 -1.00 
FBgn0010256 Rbp2 -1.00 -0.51 -0.66 -1.37 -0.92 -1.15 
FBgn0017551 Rca1 -0.03 -0.21 0.09 -0.42 -0.72 -0.66 
FBgn0016724 RfaBp 0.81 1.06 0.85 0.68 0.44 0.62 
FBgn0032244 RfC3 -0.29 -0.76 -0.40 -0.51 -0.76 -0.40 
FBgn0010173 RpA-70 0.13 -0.25 -0.06 -0.30 -0.72 -0.48 
FBgn0003276 RpII140 -0.20 -0.60 -0.38 -0.35 -0.68 -0.39 
FBgn0022981 rpk -0.47 -0.70 -0.85 -0.90 -0.69 -0.93 
FBgn0015288 RpL22 0.52 0.89 0.84 0.34 -0.04 0.24 
FBgn0003279 RpL4 -0.93 -0.54 0.93 -0.34 -1.04 -0.68 
FBgn0031035 RpS10b -0.44 -0.39 0.73 -0.14 -0.60 0.01 
FBgn0038277 RpS5b -0.79 -0.98 0.15 -0.74 -1.15 -1.29 
FBgn0003292 rt -0.03 -0.03 0.11 0.42 0.42 0.77 
FBgn0037672 sage 0.69 0.80 0.01 -0.65 -0.61 -0.36 
FBgn0003313 sala -0.29 -0.52 -0.32 -0.57 -0.54 -0.83 
FBgn0035471 Sc2 -0.39 0.04 0.27 0.84 0.54 0.57 
FBgn0025682 scf 0.34 0.66 0.70 0.30 0.40 0.53 
FBgn0037889 scpr-A -0.08 -0.24 -0.74 -1.13 -1.04 -1.27 
FBgn0037888 scpr-B 0.06 -0.13 -0.46 -0.93 -0.77 -0.85 
FBgn0037879 scpr-C -0.07 -0.20 -0.73 -1.65 -1.21 -1.70 
FBgn0004243 scra -0.25 0.22 0.29 -0.40 -0.74 -0.60 
FBgn0026361 sep5 -0.32 -0.99 -0.65 -0.72 -0.80 -0.68 
FBgn0014879 Set -0.15 -0.08 0.09 -0.38 -0.74 -0.76 
FBgn0035772 Sh3beta 0.80 1.31 1.07 0.97 1.16 1.02 
FBgn0003411 sisA 0.16 -0.04 0.01 -0.82 -1.01 -0.41 
FBgn0010083 SmB -0.70 -0.42 0.54 -0.46 -1.05 -0.81 
FBgn0027783 SMC2 0.11 -0.21 -0.53 -0.40 -0.74 -0.42 
FBgn0016983 smid 0.02 -0.39 -0.75 -0.41 -0.26 -0.26 
FBgn0016940 snRNP69D -0.49 -0.46 0.27 -0.40 -0.81 -0.64 
FBgn0035710 SP1173 -0.08 0.44 -0.03 0.56 0.44 0.74 
FBgn0024294 Spn43Aa -0.79 1.72 1.32 1.01 0.87 0.52 
FBgn0003495 spz 0.01 0.07 0.03 0.21 0.46 0.81 
FBgn0020377 Sr-CII -0.46 -1.12 -1.11 -0.56 -0.90 -0.65 
FBgn0024285 Srp54 -0.55 -0.60 -0.08 -0.45 -0.81 -0.60 
FBgn0051641 stai -0.16 0.05 0.06 0.68 0.61 0.73 
FBgn0003525 stg 0.09 0.09 0.36 -0.41 -0.78 -0.93 
FBgn0033782 sug -0.12 -0.08 0.02 -0.60 -0.95 -0.89 
FBgn0013343 Syx1A 0.13 -0.11 -0.70 0.06 0.37 0.09 
FBgn0011291 Taf11 -0.17 -0.42 -0.38 -0.49 -0.48 -0.69 
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FBgn Symbol 5-6 h 6-7 h 7-8 h 8-9 h 9-10 h 10-11 h 
FBgn0031506 Tdp1 -0.66 -1.04 -0.96 -0.98 -0.96 -1.01 
FBgn0043472 tef 0.13 -0.12 -0.12 -0.27 -0.65 -0.69 
FBgn0003701 thr -0.18 -0.58 -0.84 -0.60 -0.77 -0.49 
FBgn0025879 Timp -0.05 0.12 -0.08 0.07 0.28 0.74 
FBgn0003714 tko -0.76 0.12 0.10 -0.38 -0.56 -0.88 
FBgn0003720 tll 0.44 0.12 0.01 -0.25 -0.58 -0.68 
FBgn0026320 Tom -0.24 0.39 0.44 -0.29 -0.70 -0.61 
FBgn0003732 Top2 -0.08 -0.63 -0.75 -0.46 -0.56 -0.42 
FBgn0010423 TpnC47D -1.24 -1.23 -1.50 -0.23 -0.13 -0.38 
FBgn0026319 Traf1 -0.16 -0.39 0.07 -0.39 -0.66 -0.75 
FBgn0046687 Tre1 0.17 0.19 0.18 0.66 0.45 0.73 
FBgn0003748 Treh -0.36 -0.23 -0.58 -0.53 -0.74 -1.06 
FBgn0024361 Tsp2A -0.06 -0.05 -0.01 0.61 0.81 0.76 
FBgn0029506 Tsp42Ee 0.98 1.04 0.50 0.96 0.80 0.53 
FBgn0033127 Tsp42Ef -0.21 -0.14 -0.08 0.38 0.67 0.91 
FBgn0035936 Tsp66E -0.83 -0.34 -0.17 0.94 0.71 1.39 
FBgn0026076 UBL3 0.43 0.45 0.46 0.55 0.43 0.76 
FBgn0010288 Uch -1.16 -1.10 -0.76 -0.35 -0.30 -0.13 
FBgn0040260 Ugt36Bc 0.64 0.18 0.19 -0.09 -0.56 -0.92 
FBgn0040091 Ugt58Fa 0.28 0.68 0.26 1.01 0.86 1.36 
FBgn0013349 UTPase -0.59 -0.64 0.00 -0.54 -1.04 -0.90 
FBgn0027779 VhaSFD 0.43 0.09 -0.12 0.63 0.32 0.78 
FBgn0038134 Wnt8 -0.16 -1.27 -0.74 -0.50 -0.66 -0.22 
FBgn0030805 wus 0.01 0.12 0.25 0.45 0.29 0.91 
FBgn0021872 Xbp1 0.41 1.06 0.81 0.36 0.31 0.45 
FBgn0022959 yps -0.14 0.43 0.91 -0.04 -0.49 0.35 
 
 
8.3. Direct target genes of  lmd and Mef2 
Table V - Direct target genes list for lmd and Mef2, showing shared target genes. 
 
Symbol FBgn lmd target Mef2 target Common 
Act57B FBgn0000044 yes yes yes 
betaTub60D FBgn0003888 yes yes yes 
CG11825 FBgn0033519 yes yes yes 
CG30349 FBgn0050349 yes yes yes 
cnn FBgn0013765 yes yes* yes 
Dll FBgn0000157 yes no no 
Dp FBgn0011763 yes yes yes 
lmd FBgn0039039 yes yes yes 
m6 FBgn0002632 yes yes yes 
mam FBgn0002643 yes yes* yes 
mbl FBgn0053197 yes yes yes 
mir-1 FBgn0046834 yes yes yes 
pnr FBgn0003117 yes yes* yes 
prd FBgn0003145 yes no no 
Tina-1 FBgn0035083 yes yes yes 
Tm1 FBgn0003721 yes yes yes 
tou FBgn0033636 yes yes yes 
18w FBgn0004364 yes no no 
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Symbol FBgn lmd target Mef2 target Common 
ab FBgn0259750 yes yes yes 
Act87E FBgn0000046 yes yes yes 
aop FBgn0000097 yes yes yes 
asrij FBgn0034793 yes yes yes 
blow FBgn0004133 yes yes yes 
by FBgn0000244 yes no no 
CG1074 FBgn0037250 yes no no 
CG11033 FBgn0037659 yes yes yes 
CG12203 FBgn0031021 yes yes yes 
CG13838 FBgn0039041 yes yes yes 
CG14687 FBgn0037835 yes yes yes 
CG14757 FBgn0033274 yes yes yes 
CG17181 FBgn0035144 yes yes yes 
CG30035 FBgn0050035 yes yes yes 
CG31038 FBgn0051038 yes yes yes 
CG32982 FBgn0052982 yes yes yes 
CG4984 FBgn0034267 yes yes yes 
CG5080 FBgn0031313 yes yes yes 
CG9005 FBgn0033638 yes yes yes 
CG9416 FBgn0034438 yes yes yes 
chic FBgn0000308 yes yes yes 
CR18854 FBgn0042174 yes yes* yes 
csul FBgn0015925 yes no no 
dome FBgn0043903 yes yes yes 
Dsp1 FBgn0011764 yes yes yes 
Git FBgn0033539 yes yes yes 
Glycogenin FBgn0034603 yes yes yes 
gol FBgn0004919 yes yes yes 
HLHmgamma FBgn0002735 yes yes yes 
Hph FBgn0086689 yes yes yes 
hth FBgn0001235 yes yes yes 
jing FBgn0086655 yes yes yes 
jp FBgn0032129 yes yes yes 
lbl FBgn0008651 yes no no 
lola FBgn0005630 yes yes yes 
malpha FBgn0002732 yes yes yes 
Mef2 FBgn0011656 yes yes yes 
MESK2 FBgn0043070 yes no no 
mthl5 FBgn0037960 yes no no 
ninaD FBgn0002939 yes yes yes 
Pak FBgn0014001 yes yes yes 
Pax FBgn0041789 yes yes yes 
Pfrx FBgn0027621 yes yes yes 
rib FBgn0003254 yes no no 
Rya-r44F FBgn0011286 yes yes yes 
shot FBgn0013733 yes yes* yes 
sns FBgn0024189 yes yes yes 
Srp54 FBgn0024285 yes no no 
sug FBgn0033782 yes no no 
svp FBgn0003651 yes yes yes 
tal FBgn0087003 yes no no 
tsh FBgn0003866 yes yes yes 
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Symbol FBgn lmd target Mef2 target Common 
ttk FBgn0003870 yes yes* yes 
Uch FBgn0010288 yes yes yes 
Hsp70Ab FBgn0013276 yes no no 
RpS26 FBgn0004413 yes no no 
Ance-5 FBgn0035076 no yes no 
ball FBgn0027889 no yes no 
bap FBgn0004862 no yes no 
bib FBgn0000180 no yes no 
bowl FBgn0004893 no yes no 
C15 FBgn0004863 no yes no 
CG10641 FBgn0032731 no yes no 
CG11755 FBgn0037611 no yes no 
CG13011 FBgn0261245 no yes no 
CG13335 FBgn0033857 no yes no 
CG13784 FBgn0031897 no yes no 
CG14207 FBgn0031037 no yes no 
CG14612 FBgn0040670 no yes no 
CG15027 FBgn0030611 no yes no 
CG15105 FBgn0034412 no yes no 
CG15353 FBgn0040718 no yes no 
CG17124 FBgn0032297 no yes no 
CG17273 FBgn0027493 no yes no 
CG17836 FBgn0261113 no yes no 
CG18446 FBgn0033458 no yes no 
CG2010 FBgn0039667 no yes no 
CG2165 FBgn0259214 no yes no 
CG2246 FBgn0039790 no yes no 
CG2791 FBgn0037533 no yes no 
CG30015 FBgn0050015 no yes no 
CG30460 FBgn0050460 no yes no 
CG30492 FBgn0050492 no yes no 
CG31365 FBgn0051365 no yes no 
CG33108 FBgn0053108 no yes no 
CG33505 FBgn0053505 no yes no 
CG4239 FBgn0030745 no yes no 
CG4567 FBgn0243517 no yes no 
CG4572 FBgn0038738 no yes no 
CG4679 FBgn0033816 no yes no 
CG4829 FBgn0030796 no yes no 
CG5174 FBgn0034345 no yes no 
CG5177 FBgn0031908 no yes no 
CG6900 FBgn0030958 no yes no 
CG6904 FBgn0038293 no yes no 
CG6930 FBgn0086910 no yes no 
CG7655 FBgn0038536 no yes no 
CG8147 FBgn0043791 no yes no 
CG8173 FBgn0030864 no yes no 
CG8315 FBgn0034058 no yes no 
CG8557 FBgn0030842 no yes no 
CG8713 FBgn0033257 no yes no 
CG9296 FBgn0032059 no yes no 
CG9626 FBgn0037565 no yes no 
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Symbol FBgn lmd target Mef2 target Common 
CG9663 FBgn0031516 no yes no 
CG9752 FBgn0034614 no yes no 
CG9837 FBgn0037635 no yes no 
coro FBgn0033109 no yes no 
CycG FBgn0039858 no yes no 
Dl FBgn0000463 no yes no 
Doa FBgn0259220 no yes no 
Dph5 FBgn0024558 no yes no 
dpn FBgn0010109 no yes no 
dpp FBgn0000490 no yes no 
Drip FBgn0015872 no yes no 
drl FBgn0015380 no yes no 
Dys FBgn0260003 no yes no 
E(spl) FBgn0000591 no yes no 
E2f FBgn0011766 no yes no 
EcR FBgn0000546 no yes no 
esn FBgn0028642 no yes no 
eve FBgn0000606 no yes no 
eya FBgn0000320 no yes no 
Fas3 FBgn0000636 no yes no 
fd64A FBgn0004895 no yes no 
fray FBgn0023083 no yes no 
gcl FBgn0005695 no yes no 
Gpdh FBgn0001128 no yes no 
gukh FBgn0026239 no yes no 
Him FBgn0030900 no yes no 
HLH54F FBgn0022740 no yes no 
HLHm3 FBgn0002609 no yes no 
HLHm7 FBgn0002633 no yes no 
HLHMbeta FBgn0002733 no yes no 
hoip FBgn0015393 no yes no 
htl FBgn0010389 no yes no 
hts FBgn0004873 no yes no 
Hus1-like FBgn0026417 no yes no 
if FBgn0001250 no yes no 
insc FBgn0011674 no yes no 
Keap1 FBgn0038475 no yes no 
kn FBgn0001319 no yes no 
Kr FBgn0001325 no yes no 
KrT95D FBgn0020647 no yes no 
l(1)G0084 FBgn0087008 no yes no 
l(2)k01209 FBgn0022029 no yes no 
LanB1 FBgn0002527 no yes no 
m4 FBgn0002629 no yes no 
Mhc FBgn0086783 no yes no 
mib2 FBgn0086442 no yes no 
Mlc2 FBgn0002773 no yes no 
Mlp60A FBgn0259209 no yes no 
Mlp84B FBgn0014863 no yes no 
Mp20 FBgn0002789 no yes no 
mtSSB FBgn0010438 no yes no 
NaCP60E FBgn0085434 no yes no 
APPENDIX 123 
 
Symbol FBgn lmd target Mef2 target Common 
nau FBgn0002922 no yes no 
NetA FBgn0015773 no yes no 
NetB FBgn0015774 no yes no 
neur FBgn0002932 no yes no 
Oda FBgn0014184 no yes no 
Odd FBgn0002985 no yes no 
Orc1 FBgn0022772 no yes no 
osa FBgn0003013 no yes no 
pnt FBgn0003118 no yes no 
pont FBgn0040078 no yes no 
ps FBgn0026188 no yes no 
Ptx1 FBgn0020912 no yes no 
rdo FBgn0243486 no yes no 
RfaBp FBgn0087002 no yes no 
rgr FBgn0033310 no yes no 
robo FBgn0005631 no yes no 
RpS5a FBgn0002590 no yes no 
run FBgn0003300 no yes no 
SdhB FBgn0014028 no yes no 
sli FBgn0003425 no yes no 
slp1 FBgn0003430 no yes no 
Snr1 FBgn0011715 no yes no 
so FBgn0003460 no yes no 
sog FBgn0003463 no yes no 
Sox14 FBgn0005612 no yes no 
spi FBgn0005672 no yes no 
sqz FBgn0010768 no yes no 
Src42A FBgn0004603 no yes no 
Stat92E FBgn0016917 no yes no 
stg FBgn0003525 no yes no 
stumps FBgn0020299 no yes no 
tara FBgn0040071 no yes no 
Tig FBgn0011722 no yes no 
tkv FBgn0003716 no yes no 
tok FBgn0004885 no yes no 
trx FBgn0003862 no yes no 
twi FBgn0003900 no yes no 
Ubx FBgn0003944 no yes no 
up FBgn0004169 no yes no 
vkg FBgn0016075 no yes no 
wfs1 FBgn0039003 no yes no 
wgn FBgn0030941 no yes no 
wupA FBgn0004028 no yes no 
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